ExtraVascular Implantable Cardioverter Defibrillator (EV ICD) P ivotal Study  
[STUDY_ID_REMOVED]  
Clinical Investigation Plan, 02 -JUL-2019  
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL-2019 Page 1 of 165 
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
    
Clinical Investigation Plan  
Clinical Investigation Plan/Study Title  ExtraVascular Implantable Cardioverter Defibrillator 
(EV ICD) Pi[INVESTIGATOR_905341]1 [ADDRESS_1270780] Name  [CONTACT_905549]/Local Sponsor  Sponsor:  
Medtronic , Inc.  
[ADDRESS_1270781] NE  
Mounds View, MN [LOCATION_003]  
[ZIP_CODE] 
+[PHONE_2905] 
 
Local Sponsors:  
Australia 
Medtronic Australasia Pty Ltd  
[ADDRESS_1270782]  
Macquarie Park NSW, 2113  
Australia  
[PHONE_18768]  
 
Canada 
Medtronic of Canada, Ltd.  
[ADDRESS_1270783] Brampton  
Ontario, L6Y 0R3 Canada  
+[PHONE_2906] 
 
Europe, Middle East, Africa  
Medtronic, Bakken Research Center B.V.  
Endepolsdomein 5  
6229 GW Maastricht  
The Netherlands  
[PHONE_2909]-566 
 
Hong Kong  
Medtronic Hong Kong Medical Ltd.  
1104- 11, 11/F, Tower 1,  
The Gateway, Harbour City, Kowloon  
Hong Kong SAR, China  
+852 -2919 -1300 
 
 

EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL-2019 Page 2 of 165 
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
     Japan  
Medtronic Japan Co ., Ltd. 
1-2-70 Konan, Minato-ku, 
Tokyo Japan 108 -0075  
Shinagawa Season Terrace 22F 
Phone: (+81) 3 -6774- 4611  
Fax: (+81) 3-[ADDRESS_1270784]  
Penrose  
Auckland 1051 New Zealand  
[PHONE_18769]- 1049 
 
Document Version  1.0, 02-JUL-2019  
Lead  Principal Investigator /Coordinating Investigator  [INVESTIGATOR_124]. Paul Friedman   
Mayo Clinic [COMPANY_002]ster  
  
 
 
 
Confidentiality Statement  
The information contained in this document  is confidential and the proprietary  property  of Medtronic.  Any 
distribution,  copying,  or disclosure  without  the prior written  authorization of Medtronic  is strictly  prohibited.  
Persons to whom  the information is disclosed  must  know that it is confidential and that it may  not be further  
disclosed  by [CONTACT_476].  

EV ICD Pi[INVESTIGATOR_905340]1 [ADDRESS_1270785] Information  ................................................................................................  10 
1.3. CROs and Core Labs  ............................................................................................................ 11 
1.4. Glossary  .............................................................................................................................. 12 
2. Synopsis  ...........................................................................................................................  14 
3. Introduction  .....................................................................................................................  22 
3.1. Background  ......................................................................................................................... 22 
3.2. Purpose  .............................................................................................................................. 24 
4. Objectives and/or Endpoints  ...........................................................................................  [ADDRESS_1270786] Description ..........................................................................................................  30 
6.1. General  ...............................................................................................................................  30 
 EV ICD (Model  DVEX3E4)  .......................................................................................................... 31 
 EV ICD Lead (Model EV2401)  .................................................................................................... 32 
 Sternal Tunneling tool (Model EAZ101)  .................................................................................... 33 
 Transverse Tunneling tool (Model EAZ201)  .............................................................................. 34 
 Oscor SafeSheath® II Model SSCL9  ............................................................................................ 34 
 EV ICD Programmer Software (Model SW041), Medtronic CareLink 2090 Programmer with 
Analyzer and Medtronic CareLink Encore [ZIP_CODE] Programmer  .......................................................... 35 
 MyCareLink Patient Monitor (Model [ZIP_CODE])  ............................................................................ [ADDRESS_1270787] Consent  ..................................................................................................................  46 
8.4. Enrollment / Baseline  ...........................................................................................................  [ADDRESS_1270788] Pre-implant Anatomy Evaluation  ................................................................................. 49 
8.5. Implant Visit  ........................................................................................................................  49 
 Antibiotic and Infection Control Strategies  .............................................................................. 49 
 Anticoagulation  ......................................................................................................................... 50 
 Dual antiplatelet therapy .......................................................................................................... 50 
 Fluoroscopy and Photography  .................................................................................................. 50 
 Implant Procedure Steps  ........................................................................................................... 51 
 Implant Testing – EV ICD System  .............................................................................................. [ADDRESS_1270789] Complaint Reporting  .............................................................................................  100 
11. Data Review Committees  ............................................................................................ 100  
11.1. Clinical Events Committee  ................................................................................................ . 100 
11.2. Data Monitoring Committee  .............................................................................................. 101 
11.3. Epi[INVESTIGATOR_905342]  ...............................................................................................  102 
12. Statistical Design and Methods  ...................................................................................  102  
12.1. General Considerations  .....................................................................................................  102 
12.2. Analysis for market approval outside the US  ....................................................................... 102 
12.3. Sample Size  .....................................................................................................................  103 
 Primary Objective #1: Safety  ................................................................................................. 103 
 Primary Objective #2: Efficacy  .............................................................................................. 104 
12.4. Primary Objective #1: Safety  ............................................................................................  104 
 Hypothesis ............................................................................................................................. 105 
 Performance Requirements  .................................................................................................. 105 
 Rationale for Performance Criteria ....................................................................................... 105 
 Analysis Methods  .................................................................................................................. 108 
 Determination of Subjects/Data for Analysis ....................................................................... 108 
12.5. Primary Objective #2: Efficacy  ..........................................................................................  108 
 Hypothesis ............................................................................................................................. 108 
 Performance Requirements  .................................................................................................. 109 
 Rationale for Performance Criteria ....................................................................................... 109 
 Analysis Methods  .................................................................................................................. 111 
 Determination of Subjects/Data for Analysis ....................................................................... 111 
12.6. Ancillary Objective #1 ......................................................................................................  112 
 Hypothesis ............................................................................................................................. 112 
 Performance Requirements  .................................................................................................. 112 
 Rationale for Performance Criteria ....................................................................................... 112 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL-2019 Page 7 of 165 
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   
 Analysis Methods  .................................................................................................................. 112 
 Determination of Subjects/Data for Analysis ....................................................................... 112 
12.7. Ancillary Objective #2 ......................................................................................................  113 
 Hypothesis ............................................................................................................................. 113 
 Performance Requirements  .................................................................................................. 113 
 Rationale for Performance Criteria ....................................................................................... 113 
 Analysis Methods  .................................................................................................................. 113 
 Determination of Subjects/Data for Analysis ....................................................................... 113 
12.8. Ancillary Objective #3 ......................................................................................................  113 
 Hypothesis ............................................................................................................................. 114 
 Performance Requirements  .................................................................................................. 114 
 Rationale for Performance Criteria ....................................................................................... 114 
 Analysis Methods  .................................................................................................................. 114 
 Determination of Subjects/Data for Analysis ....................................................................... 114 
12.9. Ancillary Objective #4 ......................................................................................................  114 
 Hypothesis ............................................................................................................................. 114 
 Performance Requirements  .................................................................................................. 114 
 Rationale for Performance Criteria ....................................................................................... 115 
 Analysis Methods  .................................................................................................................. 115 
 Determination of Subjects/Data for Analysis ....................................................................... 115 
12.10. Ancillary Objective #5 .....................................................................................................  115 
 Hypothesis ........................................................................................................................... 115 
 Performance Requirements  ................................................................................................ 115 
 Rationale for Performance Criteria  ..................................................................................... 115 
 Analysis Methods  ................................................................................................................ 116 
 Determination of Subjects/Data for Analysis ..................................................................... 116 
12.11. Ancillary Objective #6 .....................................................................................................  116 
 Hypothesis ........................................................................................................................... 116 
 Performance Requirements  ................................................................................................ 116 
 Rationale for Performance Criteria  ..................................................................................... 116 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL-2019 Page 8 of 165 
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   
 Analysis Methods  ................................................................................................................ 117 
 Determination of Subjects/Data for Analysis ..................................................................... 117 
12.12. Ancillary Objective #7 .....................................................................................................  117 
 Hypothesis ........................................................................................................................... 117 
 Performance Requirements  ................................................................................................ 117 
 Sample Size  ......................................................................................................................... 117 
 Rationale for Performance Criteria  ..................................................................................... 118 
 Analysis Methods  ................................................................................................................ 118 
 Determination of Subjects/Data for Analysis ..................................................................... 118 
12.13. Supplemental Analysis  .................................................................................................... 118 
13. Ethics  ...........................................................................................................................  118  
13.1. Statement(s) of Compliance  .............................................................................................. [ADDRESS_1270790] Access to Source Data/Documents  ...........................................................................  123 
14.4. Confidentiality  ..................................................................................................................  123 
14.5. Liability ........................................................................................................................... 123 
14.6. CIP Amendments  .............................................................................................................  124 
14.7. Required Records and Reports  ..........................................................................................  124 
 Investigator Records  ............................................................................................................. 124 
 Investigator Reports  .............................................................................................................. 125 
 Sponsor Records  ................................................................................................................... 129 
 Sponsor Reports  .................................................................................................................... 130 
14.8. Suspension or Early Termination  .......................................................................................  134 
 Study -wide Suspension or Early Termination  ....................................................................... 135 
 Investigator/Site Suspension or Early Termination .............................................................. 135 
 Procedures for Suspension or Early Termination  ................................................................. 135 
15. References  ...................................................................................................................  138  
16. Appendices  .................................................................................................................. 140  
Appendix A: Draft Data Collection Elements (Case Report Forms)  ...........................................  141  
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL-2019 Page 9 of 165 
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Appendix B: Preliminary Publication Plan  ............................................................................... 142  
Appendix C: Instructions for Use  ............................................................................................ 145  
Appendix D: Informed Consent Templates ............................................................................... 146  
Appendix E: Foreseeable Adverse Event List  .......................................................................... 147  
Appendix F: Participating Investigators and Institutions  .......................................................... 157  
Appendix G: Ethics Committee and Competent Authority List .................................................  158  
Appendix H: Previous Clinical Investigations  .......................................................................... 159  
Appendix I: Chronic Defibrillation Testing Protocol  ................................................................ . 160 
Appendix J: Applicability to CMS Beneficiaries  ....................................................................... 162  
Appendix K: Investigator Statement (where applicable)  ...........................................................  [ADDRESS_1270791] Information and Glossary 
1.1. Steering  Committee  
The Steering Committee (SC) is responsible for the scientific content of the study and provides input for 
its execution.  The SC will also serve as the sponsor’s Medical Experts for the trial.  The members and 
contact [CONTACT_905472].  
1.2. Sponsor Contact [CONTACT_905473]. This information is subject to change during the 
course of the clinical study. Periodic updates to study contact [CONTACT_905474]. Other sponsor contact [CONTACT_3031], such as name [CONTACT_905550], etc. will be 
provided under a separate cover to the sites as needed.  
Table 1 : Study sponsor contact [CONTACT_905475] , Program Manager   
Direct Phone: +[PHONE_18759] Email: [EMAIL_17242]    Worldwide Clinical Study Leader  
Jo Krueger, Prin. Clinical Research Specialist Direct Phone: +[PHONE_18760] Email: [EMAIL_17243]  
Australia and New Zealand   
Samuel Liang, Sr. Clinical Research Specialist  
Direct Phone: +61 -2 9857 9391 
Email: [EMAIL_17244]   Canada 
Aarthi Kamath , Sr. Clinical Research Specialist  
Direct Phone: +[PHONE_18761] 
Email: [EMAIL_17245]   
Europe, Middle East, and Africa ( EMEA ) 
Katrien Vandersteegen, Sr. Clinical Research 
Specialist 
Direct Phone: [PHONE_18770] 
Email: [EMAIL_17246]  Hong Kong  
Tina Ling, Clinical Research Specialist  
Direct Phone: +85  229191300 
Email: [EMAIL_17247]  
Japan 
Naohiro Masumoto, PhD, Pr. Clinical Research 
Specialist  Direct Phone: +81  367760056 
Email: [EMAIL_17248]  United S tates of America (US)  
Diedre Ribbens , Sr. Clinical Research Specialist  
Direct Phone: +[PHONE_18762] Email: [EMAIL_17249]  
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL-2019 Page 11 of 165  
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Monitoring contacts 
US/Canada 
Taryn Randall, Sr. Clinical Monitoring Manager  
Direct Phone: +[PHONE_18763] 
Email: [EMAIL_8542]  EMEA/ Asia Pacific/Hong Kong/Japan  
Anja Hesse, Monitoring Portfolio Specialist CRHF  
Direct Phone: +49 [PHONE_18764] 
Email: anja.hesse @medtronic.com  
1.3. CROs and Core Labs  
No core labs will be used in this study. At the time of finalization of this clinical investigation plan (CIP), 
there is only one contract research organization (CRO ) planned:  
Cognizant Technology Solutions  
[ADDRESS_1270792] Phone: [PHONE_18771]  [ADDRESS_1270793] F ax: +[PHONE_18765] 
Duties performed:  
• Development of study electronic case report forms, edit  checks, and study management reports  
• Review of electronic case report forms and  management of  discrepancies . 
  
EV ICD Pi[INVESTIGATOR_905340]1 [ADDRESS_1270794]  
ALARA  As Low as Reasonably Achievable  
ANZ Australia and New Zealand  
AP Anterior -Posterior  
ATP Antitachycardia Pacing  
BMI Body Mass Index  
“can”  Used to indicate that something is possible, for example, that an organization or individual is able to 
do something  
CEC Clinical Event s Committee  
CIP Clinical Investigation Plan  
CMS  Centers for Medicare & Medicaid Services  
CFR (US) Code of Federal Regulations  
DD Device Deficiency  
DMC  Data Monitoring Committee  
EC Ethics Committee  
ECG Electrocardiogram  
Ethics 
Committee  Term that will be used collectively in reference to an Institutional Review Board (IRB)/Medical Ethics 
Committee (MEC)/Human Research Ethics Committee (HREC)/Research Ethics Board (REB)/Head of 
Medical Institution (HOMI ) unless otherwise  stated 
eCRF Electronic Case Report Form  
EDC Electronic Data Capture  
EGM  Electrogram  
EMEA  Europe, Middle East, and Africa  
EP Electrophysiologist /Electro physiology  
ERC Epi[INVESTIGATOR_905343] (US) Food and Drug Administration  
FDAAA Food and Drug Administration Amendments Act  
FPAS  [LOCATION_012] Patient Acceptance Survey  
GCP Good Clinical Practice  
HCU  Health  Care Utilization  
HIPAA  Health Insurance Portability and Accountability Act of 1996  
HOM I Head of Medical Institution  
IB Investigator’s Brochure  
IC Informed Consent  
ICD Implantable Cardioverter Defibrillator  
ICF Informed Consent Form  
ID Identification  
IFU Instructions for Use  
EV ICD Pi[INVESTIGATOR_905340]1 [ADDRESS_1270795]  
ISF Investigator Site File  
LA Left A trium  
LAT Lateral  
LV Left Ventricular  
LVEF  Left Ventricular Ejection Fraction  
LVEDD  Left Ventricular End Diastolic Diameter  
“may”  Used to indicate that something is permitted  
MedDRA  Medical Dictionary for Regulatory Activities  
NHMRC  The National Health and Medical Research Council  
NOAC  Novel Oral Anticoagulant  
PA Posterior -Anterior  
PHD  Pre-Hospi[INVESTIGATOR_905344]  
“shall”  Indicates a requirement  
“should”  Indicates a recommendation  
SF-12 Short Form, 12 -question (Quality of Life Survey)  
SSI Significant Safety Issue  
SSVA  Sustained Shockable Ventricular Arrhythmia  
TEE Transesophageal Echocardiogram  
TV Transvenous  
US [LOCATION_002]  of America  
USM  Urgent Safety Measure  
UADE  Unanticipated Adverse Device Effect  
[LOCATION_003]DE  Unanticipated Serious Adverse Device Effect  
VF Ventricular Fibrillation  
VT Ventricular Tachycardia  
Zone 1  Tunnel ling and deployment of the lead in the substernal space  
Zone 2  Tunnel ling of the lead from the sternum to the device pocket  
 
  
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL-2019 Page 14 of 165  
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   2. Synopsis  
Title  Extravascular Implantable Cardioverter Defibrillator (EV ICD)  
Pi[INVESTIGATOR_905345], multi -center, single -arm, non -randomized , pre-
market clinical study   
Product Name  [CONTACT_905551] : 
• Medtronic Model DVEX3E4  EV ICD  
• Medtronic Model EV2401 EV ICD Lead  
 
Investigational Accessory Components : 
• Medtronic Model EAZ101 Sternal Tunneling Tool  
• Medtronic Model EAZ201 Transverse  Tunneling Tool  
• Oscor SafeSheath® II, model number SSCL9  introducer  
(market -released in US)  
• EV ICD  SW041 Programmer Software Version 8.1 (or 
greater) 
• MyCareLink Patient Monitor Model [ZIP_CODE] (may become 
available during the course of the study)  
 
Market Released Components:  
• Medtronic  2090 CareLink Programmer  with analyzer (or 
CareLink Encore [ZIP_CODE] Programmer)  
Sponsor  Medtronic , Inc. 
[ADDRESS_1270796] NE  
Mounds View, MN [ZIP_CODE] 
[LOCATION_002] of America  
+[PHONE_4970] 
Local Sponsor  Local Sponsors:  
Australia 
Medtronic Australasia Pty Ltd  
[ADDRESS_1270797]  
Macquarie Park  
NSW, 2113  
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL-2019 Page 15 of 165  
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Australia  
[PHONE_18768] 
 
Canada  
Medtronic of Canada, Ltd.  
[ADDRESS_1270798] Brampton  
Ontario, L6Y 0R3  
Canada +[PHONE_18766] 
 
Europe, Middle East, Africa  
Medtronic, Bakken Research Center B.V. Endepolsdomein 5  
6229 GW Maastricht  
Netherlands  
[PHONE_18772] 
 
Hong Kong  
Medtronic Hong Kong Medical Ltd.  
1104-11, 11/F, Tower 1,  
The Gateway, Harbour City, Kowloon Hong Kong SAR, China  
[PHONE_18773] 
 
Japan  
Medtronic J apan Co ., Ltd. 
1-2-70 Konan, Minato -ku, 
Tokyo Japan 108 -0075 
Shinagawa Season Terrace 22F  
Phone: +[ADDRESS_1270799]  
Penrose  Auckland 1051  
New Zealand  
[PHONE_18769]  1049  
Indication under investigation  The Medtronic EV ICD System (defibrillator and lead) is 
indicated for the automated treatment of patients who have 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL-2019 Page 16 of 165  
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   experienced, or are at significant risk of developi[INVESTIGATOR_007], life -
threatening ventricular tachyarrhythmias.   
Investigation Purpose  The main purpose of the EV ICD Pi[INVESTIGATOR_905346].  
Primary Objective(s)  Primary Safety Objective:  Demonstrate  the freedom from 
major complications related to the EV  ICD System and/or 
procedure at [ADDRESS_1270800] -implant  exceeds 79% O bjective 
Performance Criterion (OPC). 
 
The endpoint is defined as a subject’s first occurrence of a 
major complication related to the EV ICD System and/or procedure, as determined by [CONTACT_249005] (CEC), that occurs on or prior to 6 months (182 
days) post -imp lant.  
 
Primary Efficacy Objective: Demonstrate  the EV ICD 
defibrillation testing success rate at implant is greater than 
88% OPC . 
 The endpoint , defibrillation testing success , is defined as:  
• Single SSVA  conversion at 20J, or  
• Conversion of two successive epi[INVESTIGATOR_905347] 30J in final system configuration.  
Ancillary  Objective(s)  • Characterize appropriate and inappropriate shocks  
• Characterize electrical performance (pacing capture 
thresholds, pacing impedance, sensing amplitudes) over 
time  
• Characterize  extracardiac pacing sensation  
• Characterize asystole pacing  
• Summarize ATP performance with spontaneous arrhythmias
 
• Summarize adverse events  
• Characterize the EV ICD defibrillation testing success rate at [ADDRESS_1270801] 292 subjects to, in the case of the safety objective, 
undergo an  implant attempt of the EV ICD System, and in the 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL-2019 Page 17 of 165  
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   case of the efficacy objective, complete the pre -specified 
defibrillation testing  protocol .  
 
Maximum number of subjects enrolled at each site will be 
capped at 35, which is approximately  10% of the total number 
of subjects enrolled.  
Inclusion/Exclusion Criteria  Inclusion Criteria  
1. Patient has a Class I or IIa indication for implantation of an 
ICD according to the ACC/AHA/HRS Guidelinesi, or ESC 
guidelinesii. 
2. Patient is at least 18 years of age and meets age 
requirements per local law . 
3. Patient is geographically stable and willing and able to 
complete the study procedures and visits for the duration 
of the follow -up. 
Exclusion Criteria  
1. Patient is unwilling or unable to personally provide 
Informed Consent.  
2. Patient has indications for bradycardia pacing iii or Cardiac 
Resynchronization Therapy (CRT) iv (Class I, IIa, or IIb 
indication).  
3. Patient with  an existing pacemaker, ICD, or  CRT device 
implant or leads . 
4. Patients with these medical interventions are excluded 
from participation in the study:  
• Prior sternotomy  
                                                            
i Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis 
AM, Hlatky MA, Granger CB, Hammill SC, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS guideline 
for management of patients with ventricular arrhythmias . 
ii Priori SG, Blomstrom -Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliot PM, Fitzsimons D, Hatala R, Hindricks G, 
Kirchhof P, Kjeldsen K, Kuck KH, Hernandez -Madrid A, Nikolaou N, Norekval TM, Spaulding C, Van Veldhuisen DJ. 2015 ESC 
guidelines fo r the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. European 
Heart Journal 2015 36:41 (2793- 2867). https://doi.org/10.1093/eurheartj/ehv316 
iii 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter -defibrillator 
programming and testing). 
iv ACC/AHA/HRS guidelines for Cardiac Resynchronization Therapy  
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL-2019 Page 18 of 165  
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   • Any prior medical condition or procedure that leads to 
adhesions in the anterior mediastinal space (i.e., prior 
mediastinal instrumentation, mediastinitis)  
• Prior abdominal surgery in the epi[INVESTIGATOR_905348]  
• Planned sternotomy  
• Prior chest radiotherapy  
Or any other prior/planned medical intervention not listed 
that precludes their participation in the opi[INVESTIGATOR_684].  
5. Patient has previous pericarditis that:  
• Was chronic and recurrent, or  
• Resulted in pericardial effusion v, or 
• Resulted in pericardial thickening or calcification. vi 
6. Patients with these medical conditions or  anatomies are 
excluded from participation in the study:  
• Hiatal hernia that distorts mediastinal anatomy  
• Marked sternal abnormality (e.g., pectus excavatum)  
• Decompensated heart failure 
• COPD with oxygen dependence  
• Gross hepatosplenomegaly  
Or any other known  medical condition or anatomy type 
not listed that precludes their participation in the opi[INVESTIGATOR_18959]. 
7. Patients with a medical condition that precludes them 
from undergoing defibrillation testing:  
• Severe aortic stenosis  
• Intracardiac LA or LV thrombus  
• Severe proximal three -vessel or left main coronary 
artery disease without revascularization 
• Hemodynamic instability  
• Unstable angina  
                                                            
v As documented on echo or MRI  
vi As documented on CT scan or MRI   
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL-2019 Page 19 of 165  
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   • Recent stroke or transient ischemic attack  (within the 
last 6 months)  
• Known inadequate external defibrillation 
• LVEF <20% 
• LVEDD >70 mm  
Or any other known medical condition not listed that 
precludes their participation in the opi[INVESTIGATOR_684].  
8. Patient with any evidence of active infection or undergoing treatment for an infection.  
9. Patient is contraindicated from temporary suspension of 
oral/systemic anticoagulation   
10. Patient with current implantation of neurostimulator or any other chronically implanted device that delivers 
current in the body.  
11. Patient meets  ACC/AHA/HRS  or ESC clinical guideline Class 
III criteria for an ICD  (e.g., life expectancy of less than 12 
months ). 
12. Patient is enrolled or planning to enroll in a concurrent clinical study that may confound the results of this study, 
without documented pre-approval from a Medtron ic 
study manager. 
13. Patient with any exclusion criteria as required by [CONTACT_1769] (e.g., age or other).  
14. Pregnant women or breastfeeding women, or women of 
child bearing potential and who are not on a reliable form 
of birth regulation method or abstinence. 
vii 
Study Procedures and Assessments  Subjects indicated for single -chamber ICD therapy will be 
recruited and implanted with the Medtronic EV ICD S ystem . 
Once  enrolled, a subject will be assessed at the following 
visits:  
• Baseline   
                                                            
vii if required by [CONTACT_1769], women of child -bearing potential  must undergo a pregnancy test within seven days 
prior to EV ICD Pi[INVESTIGATOR_905349]1 6028 Version  1.0, 02- JUL-2019 Page 20 of 165  
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   • Implant   
• Pre-Hospi[INVESTIGATOR_3849]  (PHD)  
• 2 Weeks  (2WK)  
• 3 Months  (3M)  
• 6 Months  (6M)  
• Long-term: Every 6 months thereafter until study closure 
(12, 18, 24… Months ) 
• Unscheduled (as they occur)  
• System Modifications (as they occur)  
• Exit 
 Study procedures are outlined in the table below.  
 
Study procedure  Baseline  Implant  PHD  2WK 3M 6M Long 
Term  Unscheduled  Sys 
Mod  Exit 
Informed Consent  X          
Inclusion/Exclusion Assessment  X          
Physical Exam, Demographics, 
Cardiovascular Medical History, 
Surgical History  X          
SF-12 quality of life survey  X     X     
[LOCATION_012] Patient Acceptance 
Survey (FPAS)1      X     
System and procedure 
information   X       X  
Pre-procedure Transesophageal 
Echocardiogram (TEE)[ADDRESS_1270802]-Scan  or MRI  X3          
Fluoroscopy recordings during 
tunneling procedure   X       X6  
Fluoroscopy (AP and Lateral 
cine) of final ICD generator and 
lead position   X       X6  
Sensing, Impedance, & Pacing 
tests   X X X X X X X5 X6  
Defibrillation testing   X    X4   X6  
Chest Radiographs (PA/Lateral)  X  X   X     
Echocardiogra phic data  within 
the last [ADDRESS_1270803] -to-media files   X X X X X X X X X 
Medications (for subjects 
implanted with any device)  X X X X X X X X X X 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL-2019 Page 21 of 165  
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Adverse Events7 (including AEs 
with fatal outcome), Device 
Deficiencies, HCUs, Study Deviations, and Other cardiac 
imaging  As they occur  
[ADDRESS_1270804] 3 subjects at minimum, for each implanter. If collected/reviewed, send CT -scan and/or 
MRI to Medtronic.  
[ADDRESS_1270805] incision photographs if an infection related to the EV ICD System is suspected.  
Safety Assessments  All Adverse Events that occur from the time of enrollment 
through study exit will be collected and reported to Medtronic 
and regulatory agencies (per local requirement) during the study. Additionally, any device deficiency related to the EV ICD 
System or accessory will be co llected.   
 Statistics  The efficacy primary objective will be evaluated using a 
binomial confidence interval compared against a pre-specified threshold. To evaluate the safety primary objective, the 95% 
confidence interval for the 6-month system/procedure major 
complication -free rate will be generated and compared 
against a pre -specified threshold. A Kaplan -Meier survival 
curve will also be generated to provide incidence of EV ICD 
System/procedure-related major complications over time . 
Descriptive statistics will be used to summarize remaining 
endpoints . For some endpoints such as pacing testing, 
multiple measurements per subject will be assessed and compared.   
 
  
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL-2019 Page 22 of 165  
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   3. Introduction  
3.1. Background  
Today,  implantable cardioverter defibrillator  (ICD)  therapy is the treatment of choice for patients who 
are at risk for sudden cardiac death due to life-threatening ventricular arrhythmias. Traditional ICD 
systems with transvenous leads are considered standard of care for primary or secondary prevent ion of 
tachy arrhythmic death. However, these systems have limitations.  Short- and long-term complications 
arising from ICD systems with transvenous leads, such as infection, pneumothorax, venous thrombosis, lead dislodgement, lead malfunction, and lead perforation, have persisted for decades as impediments 
to ICD usage
1,2,3,4,5. As a result, there is demand for novel ICD systems that circumvent the potential 
disadvantages of transvenous ICD systems by [CONTACT_905476]6,7. 
Non-transvenous ICD systems may represent a means of providing life-saving therapy to patients in 
whom it is not possible or desired to enter the venous system or heart chambers; for example, patients with anatomical anomalies, high infection risk, limited vascular access, or juvenile patients where the 
venous anatomy is preferably avoided
8,9,10,11.  
Currently , there are non -transvenous subcutaneous and epi[INVESTIGATOR_905350]. Cameron Health developed the SQ -RX Sub Q ICD system , which  was market released in 2009. 
[LOCATION_011] Scientific acquired the Cameron Health device, and market released their Emblem Subcutaneous (SubQ) ICD system in 2015. During clinical studies for both of these devices, patients were implanted 
with  a non-transvenous ICD system and a subcutaneous lead . Perioperative results from the S-ICD post 
approval  study indicate acceptable short -term complication rates
12, and first year post -implant results 
from the EFFORTLESS study confirm the safety demonstrated in the IDE S -ICD trial, and indicate 
performance rates for S -ICD complications, inappropriate shocks, and conversion efficacy similar to 
those observed in transvenous systems13. 
Medtronic has developed an extravascular ICD system which uses a substernal lead rather than  a 
transvenous or a subcutaneous lead. The EV ICD System has  similar capabilities to a single -chamber 
transvenous system  while avoiding leads in the heart or vasculature . Compared to current market-
released non- transvenous subcutaneous ICDs, the EV ICD Sys tem includes a smaller device that uses less 
defibrillation energy which may result in longer battery life and has the add itional capabilities to deliver 
pacing therapi[INVESTIGATOR_905351] a single device . 
Previously published case studies indicate defibrillation from non-endocardial locations  is possible and 
shock energies similar to those of transvenous devices can successfully defibrillate if the defibrillation 
coil is placed in an epi[INVESTIGATOR_905352]8,9,10,14,15,16,17,18,19,20. The EV ICD System is of similar 
size and energy outputs as current transvenous systems  (e.g., approximately 33cc  and 40 Joules ).  
EV ICD Pi[INVESTIGATOR_905340]1 [ADDRESS_1270806] human experience of acute and chronic defibrillation lead placement in the substernal extra -
cardiac space was reported by [CONTACT_905477]. in 2007 using a minimally invasive approach  via the 
manubrium10. In three  patients (two  patients having ipsilateral venous occlusion and one  patient 
wishing to avoid additional transvenous hardware placement), either a Medtronic Model 6996SQ or 
Model 6937 coil was tunneled to the substernal extra -cardiac space anterior to the right ventricle (RV). 
All implants were successful without complication. Ventricular Fibrillation (VF) was induced with T -wave 
shock. In each patient, the safety margin was determined to be at least 10 Joules (J) by [CONTACT_905478].  
Later, Guenther et al. reported the results of failed subcutaneous defibrillation lead implantation in one 
human patient for whom defibrillation threshold testing (DFT) at [ADDRESS_1270807] insertion sheath and the tunneling tool of the manufacturer. 
After making a small incision at the xiphoid process, fluoroscopy and “direct bone contact” were used to guide lead placement. Substernal DFT was successful and substernal sensing quality was acceptable. 
There were no complications, including no damage to the pericardium. The patient reported no chronic 
pain and there were no other findings at follow -up of four weeks. Guenther et al. concluded that 
“substernal lead positioning is easy to achieve” and provides an effective means of extravascular lead implantation
17. 
In order to develop and evaluate a newly desig ned system for the substernal space,  Medtronic 
completed pre-clinical research evaluations of substernal defibrillation, pacing , and sensing, and 
subsequently initiated three acute human clinical research feasibility studies  with combined 121 
implants  to explore the potential development of a future chronic implantable extravascular 
defibrillation system with a lead implanted in the substernal space. Both pre -clinical and clinical data  are 
described in further detail within the Investigator’s Brochure.  
The first human clinical feasibility study, Acute Substernal Defibrillation (ASD) , showed substernal 
defibrillation is feasible with energy available in current transvenous ICDs, with defibrillation successful 
in 13 of 14 subjects (93%) at 35J (95% CI: 74.7% - 99.8%). One failure was associated with high and 
lateral shock coil placement21. The second human clinical feasibility study, Substernal Pacing Acu te 
Clinical Evaluation (SPACE) , in which [ADDRESS_1270808] human clinical 
feasibility study, Acute Extravascular Defibrillation, Pacing and Electrogram (ASD2), was designed to further  assess study pacing thresholds and defibrillation efficacy via substernal therapy deliv ery in a 
larger cohort as well as collect additional data, mainly multi -vector substernal electrograms during 
induced VF/VT and intrinsic rhythms directly from an investigational lead placed in the substernal space. The substernal lead was implanted in 79 patients, with a median implantation time of 12.0 ± 9.[ADDRESS_1270809] 1 vector in 76 of 78 patients (97.4%), and 72 of 78 (92.3%) patients  had capture in ≥1 vector with no extracardiac stimulation. A 30 -J shock successf ully terminated 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL-2019 Page 24 of 165  
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   104 of 128 epi[INVESTIGATOR_1841]  (81.3%) of ventricular fibrillation in [ADDRESS_1270810] -in-human 
chronic device implant  of the EV ICD System . The main benefits of conducting  a pi[INVESTIGATOR_27975]  (1) 
facilitating optimization of device settings, (2) provid ing additional recommendations and best practices 
during the implant procedure, and (3) provid ing an avenue for more robust data collection leading up to 
a pi[INVESTIGATOR_16076].  A pi[INVESTIGATOR_905353] a limited 
number of subjects before launching into this large-scale, global, pi[INVESTIGATOR_2397].  
The EV ICD Pi[INVESTIGATOR_372210] a prospective, non -randomized, chronic first-in-human study conducted in four 
sites in Australia and New Zealand.  In this pi[INVESTIGATOR_799], 21 patients underwent the EV ICD implant 
procedure. Patients were evaluated at implant, two weeks, four to six weeks, and three months after 
device implant, and continue to be followed . Study investigators characterized the safety of the system 
and implant procedure, defibrillation effectiveness, and sensing and pacing . At the time of implant, 
defibrillation testing was completed on 20 patients. The system successfully terminated induced 
ventricular arrhythmias in 1 8 patients ( 90.0% ), which is consis tent with prior clinical studies of existing 
ICDs24,25. Pacing capture was achieved in more than 95 % of study patients. One patient experienced 
ventricular tachycardia outside the hospi[INVESTIGATOR_6885], which was successfully detected and treated by [CONTACT_905479] . This first-in -human chronic study demonstrated that the EV ICD system can be implanted 
with no major complications, and can sense, pace and defibrillate the heart26.   
In summary, the acute feasibility and pi[INVESTIGATOR_905354], including refinement of the device , algorithm and implant procedure.  
3.2. Purpose  
The purpose of the clinical study is to demonstr ate the safety and efficacy of the EV ICD System: a 
complete single-chamber extravascular ICD system with the lead implanted substernally .    
4. Objectives and /or Endpoints  
4.1. Objectives  
 Primary Objectives   
The first primary objective is to demonstrate the freedom from major complications related to the EV  
ICD System and/or procedure at [ADDRESS_1270811] -implant exceeds 79%  Objective Performance Criterion  
(OPC) . The endpoint is defined as a subject’s first occurrence of a major complication related to the EV 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL-2019 Page 25 of 165  
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   ICD System and/or procedure, as determined by [CONTACT_905480] s Committee (CEC) , that 
occurs on or prior to 6 months ( 182 days) post -implant.  
For an adverse event to meet the endpoint , the event must have occurred within 182 days (inclusive) of 
the EV ICD System implant and be adjudicated by [CONTACT_905481] a major complication rela ted (causal 
relationship) to the EV ICD System and/or procedure. Major complications are those complications  
resulting in:  
• Death  
• Permanent loss of defibrillation function (specifically shock)  due to mechanical or electrical 
dysfunction of the device  
• Hospi [INVESTIGATOR_059]  
• Prolong ation of an existing  hospi[INVESTIGATOR_905355] 48 hours  
• System revision (reposition, replacement, explant)  
The second primary objective is to demonstrate  the defibrillation efficacy at implant of the EV ICD 
System  exceeds 88%  (OPC). The endpoint , defibrillation testing success , is defined as:  
• Single sustained shockable ventricular arrhythmia ( SSVA) conversion at 20J, or  
• Conversion of two consecutive  epi[INVESTIGATOR_905347] 30J in final system configuration.  
Notes:  
• In one of the two consecutive  SSVA epi[INVESTIGATOR_1841], up to two 30J shocks are permitted . 
• To achieve final system configuration, changing the position of the  ICD generator and/or the 
lead, or changing shock polarity is permitted . 
• Subjects can return for testing on another day if tes ting is not fully completed on  the day of 
implant.  
• If SSVA cannot be induced, the EV ICD System must be removed (refer to section 8.5.8 ). 
• For more information on the rationale behind these objectives, refer to section 12. 
 Ancillary  Objectives   
• Characterize appropriate and inapprop riate  shocks  
• Characterize electrical performance (pacing capture thresholds, pacing impedance, sensing 
amplitudes)  over time  
• Characterize extracardiac pacing sensation  
• Characterize asystole pacing  
• Summarize ATP performance with spontaneous arrhythmias  
• Summari ze adverse events  
• Characterize the EV ICD defibrillation testing success rate at [ADDRESS_1270812] -implant.  
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL-2019 Page 26 of 165  
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   5. Study Design  
The EV  ICD Pi[INVESTIGATOR_905356] y is a prospective, multi -cent er, single-arm, non-randomized , pre-market clinical  
study. Enrollment  will include up to 400 subjects  at up to 60 sites worldwide .  
Participating geographies are expected to include but are not limited to: ANZ  (Australia and New 
Zealand), Canada, EMEA (Europe, Middle East, and Africa), Hong Kong, Japan, and the [LOCATION_002].  
Participating sites that enroll faster than others will be allowed to do so to maintain an adequate 
enrollment rate. However, to ensure a reasonable distribution of experience and minimize site  bias in 
study results, the maximum number of subjects enrolled at each site will be capped at 35 
(approximately  10% of total enrollments).  
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL-2019 Page 27 of 165  
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
      
Figure 1 : Overview of the EV ICD Pi[INVESTIGATOR_905357]1 6028 Version  1.0, 02- JUL-2019 Page 28 of 165  
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
    
5.1. Duration  
The expected study duration is approximately 3 years from the study’s first enrollment. The enrollment 
period is expected to take approximately [ADDRESS_1270813] 
participation will vary based on timing of site activation , timing of enrollment and enrollment rate . 
Subjects will undergo assessments at Baseline, Pre-Hospi[INVESTIGATOR_3849], 2 Weeks, 3 Month s, 6 Months, 
and every 6 months thereafter until official study closure . Official study closure is defined as when 
Medtronic and/or applicable regulatory authority agency or governing body  requirements have been 
satisfied per the CIP  and/or by a decision by [CONTACT_905482]. Official s tudy closure is expected to occur after the EV ICD S ystem is approved by [CONTACT_1622] , 
anticipated in 2022.  
5.2. Rationale  
The main purpose of the EV ICD Pi[INVESTIGATOR_905358].   
Prior to this study, three acute human feasibility studies were  performed:  
• The ASD study demonstrated that s ubsternal defibrillation is feasible with energy available in 
current transvenous ( TV)-ICDs21 
• The SPACE study demonstrated that pacing is possible in nearly all patients  with  detection 
comparable to TV -ICD22 
• The ASD2 study demonstrated that p acing, sensing, and defibrillation is feasible with a  lead designed 
specifically for the substernal spac e23 
EV ICD device f eatures were  designed and developed using data  collected from these studies and 
supplemented with animal and bench evaluations .  
In addition to the acute feasibility studies, the EV ICD Pi[INVESTIGATOR_905359] n of the EV ICD System in a limited number of subjects before launching into a large-
scale, global, pi[INVESTIGATOR_2397]. At this time, the EV ICD Pi[INVESTIGATOR_905360] -term follow -up is ongoing, and  will 
continue through the duration of the EV ICD Pi[INVESTIGATOR_905361]-term 
follow-up data.   
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL-2019 Page 29 of 165  
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
    
5.3. Minimization of Bias  
Selection of subjects, treatment of subjects, and evaluation of study data are potential sources of bias. 
Methods incorporated in the study design to minimize potential bias include (but are not limited to):  
• Subject demographics and comorbidities  will be collected at baseline to  later assess possible 
characteristics that may influence endpoints  
• Data collection requirements and study procedures will be standardized across all geographies  
• To ensure a reasonable distribution of data among sites, the maximum number of enrollments per site will be [ADDRESS_1270814] 3 subjects.  
• A statistical analysis plan will be developed prior to analyzing data which will document all pre-
specified analyses and analysis methods  
• All study clinicians will be trained on and required to follow the CIP 
• All study clinicians and Medtronic personnel will be trained on their respective aspects of the 
study using standardized training materials  
• An independent Clinical Events  Committee (CE C) will be utilized to regularly review and 
adjudicate reported adverse events  
• An Epi[INVESTIGATOR_905342] (ERC) containing independent reviewers  will be utilized to 
revie w and adjudicate device-treated epi[INVESTIGATOR_905362] 
(shocks and ATP) delivered to subjects  
• An independent D ata Monitoring Committee (DMC) will be utilized to review accumulating 
data and interim analyses, help safeguard the interests of study subjects, and monitor the 
overall conduct of the study  
• All sites will use the same version of the CIP and standardized case report forms when possible 
• All study investigators will be required to meet 21 CFR Part 54, Financial Disclosure by [CONTACT_6230]   
• Monitoring visits will be conducted to verify adherence to the CIP  and source data.  
In summary, potential sources of bias that may be encountered in this clinical study have been 
considered and minimized by [CONTACT_54415].  
  
EV ICD Pi[INVESTIGATOR_905340]1 [ADDRESS_1270815] Description  
6.1. General  
The EV ICD System consists of market-released and investigational components . 
 Table 2: EV ICD System Components  
Model Number  Component  Investigational or Commercially 
Available at study start  
System Components  
DVEX3E4  Extravascular Implantable Cardioverter 
Defibrillator (EV ICD)  Investigational in all geographies  
EV2401  Extravascular quadripolar lead with shaped 
passive fixation  Investigational in all geographies  
Accessory Components  
EAZ101  Sternal Tunneling Tool  Investigational in all geographies  
EAZ201  Transverse Tunneling Tool  Investigational in all geographies  
SSCL9  Oscor SafeSheath ® II Hemostatic Tear -away 
Introducer System with Infusion Side Port  Investigational in all geographies  
SW041  Medtronic EV ICD SW041 Programmer 
Software Version 8.1 or greater  Investigational in all geographies  
2090  
 
or 
[ZIP_CODE] Medtronic CareLink Programmer with 
analyzer  
or Medtronic CareLink Encore Programmer  Commercially available in all 
geographies  
Investigational EV ICD SW041 
software is downloaded onto 
programmer, and programmer is 
subsequently labeled as containing 
investigational software  
[ZIP_CODE]  Medtronic MyCareLink  Patient Monitor (may 
become available during the course of the 
study)  Commercial ly available in all 
geographies , but investigational 
when used with EV ICD  
 
The CIP  permits up to [ADDRESS_1270816], as well as a 15% increase to account for system revisions, dropped product, etc., it is expected 
that up to approximately 460 of the following investigational devices  may be used during the trial: EV 
ICD, lead, sternal tunneling tool, transverse tunneling tool, introducer, and MyCareLink monitor. Each 
site (up to 60 sites) will have access to at least one programmer with software.  
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL-2019 Page 31 of 165  
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   
  EV ICD  (Model DVEX3E4) 
The Medtronic Model DVEX3E4  is an investigational single- chamber , MR -conditional,  extravascular 
implantable cardioverter defibrillator ( EV ICD). It consists of a titanium generator and a connector port 
housing made from polyurethane and silicone rubber. This multiprogrammable cardiac device monitors 
and r egulates the subject’s  heart rate. It provides asystole detection and therapy (Pause Prevention) , 
ventricular tachyarrhythmia detection and therapy  including ATP , and post -shock pacing. The EV  ICD 
also provides diagnostic and monitoring features to assist with system evaluation and patient care.  
 
Figure 2 : The Medtronic EV ICD Model DVEX3E4  
The DVEX3E4  EV ICD contains an EV4 connector, which is compatible with an EV4 -LLHH quadr ipolar lead.   

EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL-2019 Page 32 of 165  
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   
  EV ICD Lead (Model EV2401)  
The Medtronic Model EV2401 extravascular lead  is an investigational , pre-shaped , MR-conditional  lead 
with passive fixation, designed for sensing, cardioversion, defibrillation and pacing therapi[INVESTIGATOR_014]. The lead is 
8.7 Fr and available in both 52 cm or 63 cm lengths. The body of the lead is made from polyurethane, 
with ring electrodes made from titanium nitride coated platinum iridium, and coil electrodes from platinum iridium and tantalum.  The lead has  two ring electrodes and two  coil electrodes: Ring  2 
(proximal  ring) , Coil 2 ( proximal  coil), Ring 1 ( distal  ring) , Coil 1 ( distal  coil). The configuration of these 
electrodes is shown in Figure 3 . The lead h as the ability to pace and sense between the ring and coil 
electrodes. In addition, the Coil 1 and Coil 2 electrodes deliver cardioversion and defibrillation therapy.  
Figure 3 : The EV2401 lead  
The proximal end of the lead features an EV4-LLHH quadripolar connector, which is compatible with an 
EV4 connector on an EV ICD .  
 

EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL-2019 Page 33 of 165  
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   
  Sternal  Tunneling tool (Model EAZ101)   
The Medtronic Model EAZ101 sternal tunneling tool is  an investigational tool  designed to deliver an 
introducer and  an extravascular  lead into the anterior mediastinum during implant of an extravascular 
implantable device system.  This is referred to  as Zone 1 in Table 5: Outline of the  proposed  implant 
procedure steps . 
The sternal tunneling tool, shown in Figure 4   below, consists of the following components:  
• Handle  
•  tunneling rod that delivers a  introducer to the anterior mediastinum. The 
tunneling rod  is malleable to accommodate pat ient anatomy  
• External guide that remains above the skin and indicates the distance and direction of the 
tunneling rod. The external guide is hinged and removable to accommodate physician preference 
and patient anatomy  
• Thumb tab used to raise and lower the external guide  
 
 
Figure 4 : EAZ101 sternal tunneling tool  
 
 
 The
 Oscor 
SafeSheath® II (Model SSCL9) introducer  (section 6.1.5 )  is to be used with the sternal tunneling tool.   
 
 

EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL-2019 Page 34 of 165  
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   
  Transverse Tunneling tool (Model EAZ201)  
The Medtronic Model EAZ201 transverse tunneling tool , shown in Figure 5 , is an investigational tool  
designed to deliver the proximal portion  of an extravascular lead to the device pocket during implant of 
an extravascular implantable device system.  This is referred to as Zone 2 in Table 5: Outline of the 
proposed  implant procedure steps . 
 
Figure 5 : EAZ201 transverse tunneling tool  
 
 
 
 
   
If a
dditional tunneling tools are used to tunnel the lead subcutaneously, this shall be discussed with 
Medtronic clinical study personnel prior to use and the tools used will be documented. Use of additional 
tools  will be considered a study deviation.   
  Oscor SafeSheath® II Model SSCL9  
The Oscor (Palm Harbor, FL) SafeSheath® II Model SSCL9 introducer is a hemostatic tear -away 
introducer.   A 10cc 
plastic syringe will be packaged with the introducer sheath. T he introducer  sheath and hemostatic valve  
are indicated for the introduction of various types of pacing leads and catheters. The infusion side  port is 
used to inject  or aspi[INVESTIGATOR_905363].  

EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL-2019 Page 35 of 165  
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   In this study, the SSCL9 introducer is used over the tunneling rod of the EAZ101 sternal tunneling tool to 
create a tunnel  and facilitate insertion of the EV2401 extravascular lead into the mediastinum  with a 
saline-filled syringe connected to the infusion sideport .  
 
Figure 6 : The Oscor SafeSheath ® II Model SSCL9  
The Oscor SafeSheath® II Model SSCL9 introducer is considered investigational in all geographies but 
may become commercially available during the course of the study . 
 EV ICD Programmer Software  (Model SW041) , Medtronic CareLink  
2090 Programmer  with Analyzer  and Medtronic CareLink 
Encore [ZIP_CODE] Programmer  
The investigational Medtronic Model SW041 programmer software , Version 8. 1 (or greater)  runs on the 
commercially available Medtronic CareLink 2090 P rogrammer or the commercially available Medtronic 
CareLink Encore [ZIP_CODE] Programmer, both with Conexus telemetry,  and communicates with an 
implanted EV ICD Model DVEX3E4 . Following software download, the Medtronic Programmer 2090 or 
[ZIP_CODE] will be labeled per local requirements to indicate that it contains investigational software.  
Within its intended use, the programmer and programmer software will be used to provide a user 
interface with which the user can interrogate the device, control induction, shocking, sensing and pacing features and their parameters, and display diagnostic information. At implant, t he 2090 analyzer (which 
is part of the 2090 programmer) will be used to test the lead electrical signals before the device is 
implanted.  
 MyCareLink Patient  Monitor  (Model [ZIP_CODE])  
The commercially available Model [ADDRESS_1270817]’s clinic using the CareLink network. In this study, the CareLink monitor will be 
used within its intended use, but will be considered investigational when used with EV ICD until the firmware is approved for use with the EV ICD system .  
6.2. Manufacturer  
All of the EV ICD System and accessory components are  manufactured by [CONTACT_13735] , with the exception 
of the SSCL9 introducer sheath , manufactured by [CONTACT_905483], Inc . 
Manufacturer Name  [CONTACT_905552]  [ADDRESS_1270818]  
Minneapolis, MN [ZIP_CODE]  
[LOCATION_003] 
www.medtro nic.com  
+[PHONE_18767]  
6.3. Packaging  
For investigational products , the device labeling and clinical manuals will be translated into the local 
language. The Clinical Manuals or Instructions for Use (IFU)  will accompany each investigational 
component. Investigational products will be clearly labeled, e.g., “ Exclusively for clinical investigations” 
and with the study identifier “Protocol #: MDT1 6028” per local requirements . In some geographies, the 
IFUs may be delivered via an alternate format (e.g., CD-ROM format, USB, or electronic format)  if 
allowed within local requirements . 
The investigational Medtronic Model SW041 programmer software application  may be installed onto 
the Medtronic Care Link 2090 or Medtronic CareLink Encore [ZIP_CODE] programmer s using US B drives with 
SW041 or Software Distribution Network  (SDN)  (if available) ; media packaging requirements are not 
applicable for distribution via the SDN. USB drives containing SW041, will be clearly labeled wit h 
identifier, version, and marked as “ Exclusive ly for clinical investigations ”. 
When investigational Medtronic Model SW041 software is installed on the 2090 or [ZIP_CODE] Medtronic 
Programmer s, the Medtronic Programmer s will be labeled to indicate they contain investigational 
software  per local requirements . 
Packaging and labeling for all other market approved system components can be found with each 
package insert. Manuals for market approved Medtronic devices can be found on  
http://manuals.medtronic.com . For CE marked devices and market devices in Japan, the labeling is in 
the appropriate local language.  
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL-2019 Page 37 of 165  
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   The l abeling for all components may include but is not limited to the following: 
• Device Name  
• Model number  
• Serial or Lot number, as applicable  
• Date of manufactur e  
• Expi[INVESTIGATOR_320]  
6.4.  Intended Population  
The Medtronic EV ICD System is indicated for the automated treatment of patients who have 
experienced, or are at significant risk of developi[INVESTIGATOR_007], life-threatening ventricular tachyarrhythmias. The 
intended population to receive the EV ICD System includes  patients who  are indicated for implantation 
of a single chamber ICD ac cording to current ACC/AHA/HRS  or ESC guidelines, and who do not have a 
bradycardia pacing or cardiac resynchronization therapy indication.  
6.5.  Equipment  
Sites are responsible for maintaining and calibrating site equipment used in the course of this study 
(e.g., radiograph  machine and fluoroscope) as applicable in accordance with established site practice 
and local regulation. Records shall  be kept and available  to be provided during monitoring visits and 
upon request by [CONTACT_446152].  
6.6. Product Use  
Instructions for installation and use for the components of the EV ICD System and accessories are 
located in the accompanying IFU for each component. Additionally, trained and experienced Medtronic 
personnel  will provide support at implant .  
6.7.  Product Training Requirements  
The EV ICD implant procedure is to be performed by [CONTACT_1629] i nvestigator who  has received training on all 
aspects of the implant  procedure, including but not limited to :  
• Access into the anterior mediastinum , 
• Substernal tunneling (Zone 1),  
• Lead anchoring technique  
• Transverse  tunneling to the device pocket (Zone 2),  
• Device pocket creation, and  
• Implant device testing  
All implant  training will be documented in the Investigator Site File (ISF).  
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL-2019 Page 38 of 165  
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   During the implant procedure, the investigator will be placing the lead utilizing a tunneling procedure. It 
is imperative that methods are utilized to ensure safe access to the anterior medi astinum via a sub -
xiphoid approach. As c ardiothoracic surgeons routinely perform midline sternotomy procedures , 
Medtronic intends to use a team approach  during the EV ICD implant to ensure the knowledge and skills 
are transferred to a non -surgical physician specialty (EP/Cardiologist).  A Cardiac Surgeon /Cardiothoracic 
Surgeon  trained on relevant components of the study procedure will attend , at minimum,  the first five 
implant procedures  attempted by [CONTACT_905484] . The Cardiac 
Surgeon/Cardiothoracic Surgeon can also add context to specific subject anatomy. It is required that the 
Cardiac Surgeon /Cardiothoracic Surgeon  will also provide emergency support during all clinical study  
implant procedures.  
For sites that participated in the EV ICD Pi[INVESTIGATOR_799], implanting physicians with previous proctored 
implant procedures from the EV ICD Pi[INVESTIGATOR_905364]/Cardiothoracic Surgeon to attend the first five EV ICD Pi[INVESTIGATOR_905365].  
If the implanting physician is also trained and currently performing activities similar to a cardiothoracic 
surgeon, there may be instances where a separate CT surgeon is not required. If this occurs, this shall be 
discussed ahead of time with the Medtronic clinical study team, and  Medtronic approval must be 
documented prior to the procedure taking place.  
6.8.  Prod uct Receipt , Tracking , and Accountability  
The EV ICD System components ( EV ICD, lead ) and accessory components ( sternal tunneling tool, 
transverse tunneling tool, SafeSheath introducer , software , and MyCareLink Patient Monitor ), will be 
considered investigational in geographies in which  the product is not available commercially and will be 
labeled for exclusive use in clinical investigations . Investigational system components will be distributed 
to a site only when Medtronic has received all required documentation (not limited to , Ethics 
Committee or Competent Authority approval, a signed Clinical Trial Agreement, and documentation of 
training) and has notified the site of site readiness.  
Distribution of the investigational product to study sites will be managed by [CONTACT_905485]. Sites with these clinically labeled 
EV ICD System components will track disposition upon receipt or return of the components , as well as 
upon implant or explant of the components.  
Product accountability will be documented o n the Device Accountability  electronic Case Report Form 
(eCRF), which will be maintained in the Electronic Data Capture (EDC) system.  
This eCRF will track, at a minimum, the following information:  
• Date of receipt  
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL-2019 Page 39 of 165  
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   • Identification of the investigational components , if applicable  (Lot or serial number or 
unique code)  
• Expi[INVESTIGATOR_320], if applicable 
• Date used or installed  
• Subject identification (ID ) Number , if applicable  
• Date and reason for return  or disposal , if applicable  
• Name [CONTACT_905553], return or destruction/disposal , if applicable 
• Uninstallation or explant date of the investigational components and software , if applicab le 
Medtronic will perform internal final study product reconciliation per the applicable study -specific 
document or per local requirements, to ensure all study product has been accounted for either by 
[CONTACT_905486] (including method of 
disposal).  Periodic reconciliation of investigational product will be performed to ensure traceability.   
6.9.  Product Storage  
All investigational products must be stored in accordance with their labelling in a secure loc ation at the 
site with access limited only to authorized personnel. It is the responsibility of the investigator to 
correctly handle, store, and track the investigational products. If allowed per local regulations, the 
programmer installed with the investi gational software may  be used for commercial use as the software 
can only communicate with investigational EV ICD devices. 
6.10.   Product Return  
All explanted, open but unused and potentially defective products (device, leads, tools, etc.) should be 
returned to Medtronic for analysis whenever possible and when permissible by [CONTACT_83344]. If the products are explanted but not returned, a justification is required to be reported on the appropriate eCRF(s)  (note that this is not considered a study deviation). T he Device Accountability  
eCRF must be updated in the event of an explant. L ocal Medtronic field personnel or representative  can 
be contact[CONTACT_502971] a Return Mailer Kit . All unused investigational products must be returned to 
Medtronic upon  study closure at the site.  
The SW041 software may remain installed on specific [ADDRESS_1270819]’s EV ICD System after the study is closed. If SW041 software is no longer required 
(e.g. , replaced by [CONTACT_905487] -released software), the SW041 software will be removed from the 
[ADDRESS_1270820] class I or I Ia indication  for implantation of a single 
chamber Implantable Cardioverter Defibrillator (ICD) according to current ACC/AHA/HRS  or ESC 
guidelines,  and who do not have a bradycardia pacing or cardiac resynchronization therapy indication.   
7.2. Subject Enrollment  
Patient s will be screened to ensure they meet all th e inclusion and none of the exclusion criteria.  
Subjects are considered enrolled in the study upon signing the Informed Consent Form. Informed 
Consent must be obtained prior to performing any study -related procedures.  
7.3. Inclusion Criteria  
 Inclusion Criteria  Rationale 
1. Patient has a Class I or I Ia indication for implantation of 
an ICD according to the ACC/AHA/HRS Guidelinesviii, or 
ESC guidelinesix. Study will be evaluated in the standard patient 
population that is indicated for the device under evaluation . 
2. Patient is at least 18 years of age and meets age 
requirements per local law . Ensure age is appropriate to provide Informed 
Consent . 
3. Patient is geographically stable and willing and able to 
complete  the study procedures and visits for the 
duration of the follow -up. Ensure ascertainment of data required for clinical evaluation . 
 
                                                            
viii Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, 
Gillis AM, Hlatky MA, Granger CB, Hammill SC, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS 
guideline for management of patients with ventricular arrhythmias . 
ix Priori SG, Blomstrom -Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliot PM, Fitzsimons D, Hatala R, Hindric ks G, 
Kirchhof P, Kjeldsen K, Kuck KH, Hernandez -Madrid A, Nikolaou N, Norekval TM, Spaulding C, Van Veldhuisen DJ. 2015 ESC 
guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. European 
Heart J ournal 2015 36:41 (2793- 2867). https://doi.org/10.1093/eurheartj/ehv316 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL-2019 Page 41 of 165  
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   7.4. Exclusion Criteria  
 Exclusion Criteria  Rationale 
1. Patient is unwilling or unable to personally provide 
Informed Consent. Not allowing legally authorized 
representatives . 
2. Patient has indications for bradycardia pacing x or 
Cardiac Resynchronization Therapy (CRT) xi (Class I, I Ia, 
or IIb indication).  First generation of system does not include chronic bradycardia pacing support and does not include a left ventricular lead . 
3. Patient s with  an existing pacemaker, ICD, or CRT device 
or leads . Avoid possible confounding factors (e.g., complications due to changeout  procedure ). 
Subjects who have recently had a system removal may be considered if the physician 
feels procedure  complications and/or 
infections are resolved.  
4. Patient s with  these  medical intervention s are excluded 
from participation in the study:  
• Prior sternotomy  
• Any prior medical condition or procedure that leads to adhesions in the anterior mediastinal space (i.e., prior mediastinal instrumentation, mediastinitis)  
• Prior abdominal surgery in the epi[INVESTIGATOR_905348]  
• Planned sternotomy  
• Prior chest radiotherapy  
Or any  other prior/planned medical intervention not 
listed that precludes their participation in the opi[INVESTIGATOR_689].  Avoid possible surgical risks during the 
tunneling procedure  due to fibrosis or 
scarring in the mediastinal tissue . 
5. Patient has previous pericarditis that:  
• Was chronic and recurrent, or  
• Resulted in pericardial effusion xii, or 
• Resulted in pericardial thickening or 
calcification. xiii Avoid possible surgical risks related to the 
tunneling procedure  arising from clinically 
significant pericarditis.  
                                                            
x 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter -defibrillator programming 
and testing).  
xi ACC/AHA/HRS guidelines for Cardiac Resynchronization Therapy  
xii As documented on echo or MRI 
xiii As documented on CT scan or MRI  
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL-2019 Page 42 of 165  
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
    Exclusion Criteria  Rationale 
6. Patients with these medical conditions or anatomies 
are excluded from participation in the study:  
• Hiatal hernia that distorts mediastinal anatomy  
• Marked sternal abnormality  (e.g., pectus 
excavatum) 
• Decompensated heart failure  
• COPD with oxygen dependence  
• Gross hepatosplenomegaly  
Or any other known medical condition or anatomy type not listed that precludes their participation in the opi[INVESTIGATOR_689].  Excluded due to anatomical abnormalities  
that increase procedure risk, increased risk of infection, or risk of potential comorbidities that impact evaluation of the system during a clinical study . 
7. Patients with a medical condition that precludes them from undergoing defibrillation testing:  
• Severe aortic stenosis  
• Current Intracardiac LA or LV thrombus  
• Severe proximal three- vessel or left main coronary 
artery disease without revascularization  
• Hemodynamic instability  
• Unstable angina  
• Recent stroke or transient ischemic attack  (within 
the last 6 months)  
• Known inadequate external defibrillation  
• LVEF <  20%  
• LVEDD >[ADDRESS_1270821] exclusion criterion for device 
implant, emphasized due to importance. 
9. Patient is contraindicated from temporary suspension 
of oral/systemic anticoagulation   To reduce risk of bleeding/hematoma intraprocedurally or in the event that an 
urgent sternotomy/thoracotomy is required  
10. Patient with current implantation of neurostimulator or any other chronically implanted device that delivers 
current in the body. For the purposes of clinical data collection and interpretation it is preferable to avoid any possible electrical interference with the EV ICD System.  
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL-2019 Page 43 of 165  
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
    Exclusion Criteria  Rationale 
11. Patient meets  ACC/AHA/HRS or ESC clinical guideline 
Class III criteria for an ICD  (e.g., life expectancy of less 
than 12 months).  
 Standard exclusion criterion  to ensure study 
cohort is expected to survive to the time of 
endpoint evaluation  and to ensure the study 
only includes patients with current clinical indications for an ICD. 
12. Patient is enrolled or planning to enroll in a concurrent clinical study that may confound the results of this 
study, without documented pre -approval from a 
Medtronic study manager . Standard exclusion criterion  to avoid 
confounding procedural requirements due to multiple experimental studies.  
13. Patient with any exclusion criteria as required by [CONTACT_49762] (e.g., age or other ).  Standard exclusion criterion  to comply with 
any additional local requirements which may 
apply.  
14. Pregnant women or breastfeeding women, or women of child bearing potential and who are not on a reliable form of birth regulation method or abstinence . 
xiv  Pregnant women are excluded to  avoid harm 
to the fetus caused by [CONTACT_905488].  
 
 
8. Study Procedures  
The following criteria were considered when selecting sites for the EV ICD Pi[INVESTIGATOR_112688]: 
• Investigator/site is qualified by [CONTACT_45437], education, and relevant experience appropriate to the 
use of the product and associated procedures  
• Investigator/site expects to have adequate time and resources to conduct the study throughout the duration of the study  
• Investigator/site has access to an adequate number of eligible subjects  
• Ability to comply with applicable Ethics Committee and regulatory requirements  
• Investigator is not debarred, disqualified, or working under sanctions in applicable regions  
• Site ha s demonstrated experience working (well) with Medtronic clinical research in the last 3 
years  
• Site can support timely data entry (e.g., coordinator)  
• Site has the ability to do full (90°) lateral fluoroscopy (biplane preferred), anesthesia, and the 
ability to treat AEs that require surgical intervention in the location where they plan to perform the procedure 
                                                            
xiv If required by [CONTACT_1769], women of child -bearing potential must undergo a pregnancy test within seven days prior to EV ICD 
Pi[INVESTIGATOR_905349]1 6028 Version  1.0, 02- JUL-2019 Page 44 of 165  
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   • Investigator(s) is willing and able to attend hands on implant training as outlined in section 6.7  
(1-2 implanting investigators per site ) 
• Site has a robust emergency protocol  - site can react to  need for major cardiac surgery within 
10 minutes  
Medtronic contracts with participating institutions/investigators through a Clinical Trial Agreement that 
defines the scope and responsibilities and associated compensation related to carrying out the 
obligations under a clinical study sponsored by [CONTACT_13735].  
During the activation process (prior to subject enrollment), Medtronic will train site personnel on, but not limited to, the current version of  the CIP, relevant standards and regulations, Informed Consent  
process , data collection and reporting tools. In addition, site personnel must be delegated by [CONTACT_227559] I nvestigator to perform study -related activities. If new members join the site team,  required 
documentation will be obtained and they will receive training on the applicable clinical investigation 
requirements relevant to their role before contributing to the clinical investigation.  Medtronic will 
provide each study site with written docu mentation of study site/investigator readiness.  In order to 
receive written documentation of study site/investigator readiness, the following documentation must be available:  
• Regulatory authority approval  
• Ethics Committee  approval and voting list 
• Signed Clinical Trial Agreement  
• Current CVs for investigators and authorized designees, signed and dated  
• Confirmation of receipt of IB, if available  
• Financial disclosure for investigators  
Prior to performing study -related procedures, all sites must have Ethics Committee and associated 
regulatory authority approval if applicable (e.g., Competent Authority approval) as well as documentation from Medtronic of site readiness.  
8.1. Schedule of Events  
Visit schedule and data collection requirements are summarized below  in Table 3.  
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL-2019 Page 45 of 165  
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Table 3:  EV ICD Pi[INVESTIGATOR_905366]  2 Weeks  3 Months  6 Months  Long -Term (12, 18, 
24…months)  Unsched.  Sys. Mod.  Exit 
Informed Consent  X          
Inclusion/Exclusion Assessment  X          
Physical Exam, Demographics, Cardiovascular Medical 
History , Surgical History  X          
SF-12 quality of life survey  X     X     
[LOCATION_012] Patient Acceptance Survey  (FPAS)1      X     
System and procedure information   X       X  
Pre-procedure Transesophageal Echocardiogram (TEE)[ADDRESS_1270822] or MRI  scan  X3          
Fluoroscopy recordings during tunne ling procedure   X       X6  
Fluoroscopy (AP and Lateral  cine) of final ICD generator and 
lead position   X       X6  
Sensing, Impedance & Pacing Tests   X X X X X X X5 X6  
Defibrillation Testing   X    Subset4   X6  
Chest Radiographs – (PA/Lateral)  X  X   X     
Echocardiogra phic data within the last [ADDRESS_1270823] -to-media  files   X X X X X X X X X 
Medications  (for subjects implanted with any device)  X X X X X X X X X X 
Adverse Events7 (including AE s with fatal outcome) , Device 
Deficiencies, HCUs, Study Deviations, and Other Cardiac 
Imaging  As they occur  
[ADDRESS_1270824] 3 subjects at minimum, for each implanter. If collected/reviewed, send CT -scan and/or MRI to Medtronic . 
[ADDRESS_1270825]  incision photographs if an infection related to the EV ICD System is suspected.   
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 46 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   8.2. Medications  
Medication  detail s will be collected via electronic case report forms (eCRFs) on a rolling basis 
throughout the study. Document all  oral and intravenous  medications prescribed to the subject at the time 
of the  Baseline  visit on the  eCRFs  and continue to document medication  changes (when medications are 
stopped or started)  throughout the subject’s participation in the study . In addition, medications administered or 
adjusted to treat a reported adverse event shall be reported. If the subject is not implanted or attempted to b e 
implanted, medication collection is not required. 
 Prior and Concomitant Medications  
There are no restrictions regarding prior or concomitant medications , with the exception of 
oral/systemic anticoagulants per study exclusion  criteria (section 7.4).  
8.3. Subject Consent  
Informed Consent (IC) is defined as a legally effective documented confirmation of a subject’s voluntary 
agreement to participate in a particular clinical study. This confirmation occurs  after information has 
been given to the subject on all aspects of the clinical study that are relevant to the subject’s decision 
to participate  (ISO [ZIP_CODE]:2011) . This process includes obtaining an Informed Consen t Form ( ICF) and an 
Authorization to Use and Disclose Personal Health Information/Research Authorization/other privacy language as required by [CONTACT_2371]. The ICF and Authorization to Use and Disclose Personal Health 
Information/Research Authorization/other priva cy language  as required by [CONTACT_905489]’s Ethics Committee (EC) prior to enrolling subjects. These shall be signed 
and personally dated by [CONTACT_905490]  [INVESTIGATOR_905367] .  
Subjects of centers that agree with  and obtain approval from their EC  and associated regulatory 
authority , if applicable , will be invited to participate in the optional 6 -month defibrillation testing. 
Subjects are free to decline this testing with no penalty.  
An ICF, either part of the initial ICF or a stand -alone document, will be provided to potential 
participants, outlining the procedure, potential risks, and benefits. Subjects will be considered enrolled for the 6- month defibr illation testing at the time they sign the ICF.  
The document(s) must be controlled (i.e. , versioned and dated) to ensure it is clear which version(s) 
was/were approved by [CONTACT_905491] . Any adaptation of the previously approved ICF must be 
reviewed and approved by [CONTACT_905492]-consent a study  
subject.  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 [ADDRESS_1270826]’s willingness to participate in the study. If relevant, subjects must be 
requested to confirm their continued participation  in writing .  
Prior to initiation of any study -spec ific procedures, IC must be obtained from the subject. Subjects in 
the US will be required to sign a HIPAA authorization form before participating sites can collect, use and submit subject information to the study sponsor.   
The process of obtaining Inform ed Consent shall:  
• Ensure that the Principal I nvestigator or an authorized designee conducts the IC process.  
• Include all aspects of the EV ICD Pi[INVESTIGATOR_905368]'s decision to 
participate throughout the clinical study. 
• Avoid any coercion or undue improper influence on, or inducement of the subject to 
participate.  
• Not waive or appear to waive the subject’s legal rights.  
• Ensure the ICF and  Authorization to Use and Disclose Personal Health I nformation/Research 
Authorization/HIPAA/oth er privacy language, as required by [CONTACT_2371], are given to the subject in a 
non-technical language the subject is able to read and understand.  
• Provide ample time and opportunity for the subject to read and understand the ICF to inquire about details of the stud y, and to consider participation. All questions about the study should 
be answered to the satisfaction of the subject.  
• Include a personally dated signature [CONTACT_905554].  
• Include a personally dated signature [CONTACT_523736] I nvestigator or authorized designee 
responsible for conducting the IC process, as required by [CONTACT_1769]. 
• Include any other locally required signatories, such as witnesses, as indicated by [CONTACT_1606] -
specific legislations.  
• Provide the subject with a copy of the ICF and Authorization to Use and Disclose Personal 
Health Information/Research Authorization/HIPAA/other privacy language as required by [CONTACT_2371], 
and any other written information, signed and dated if required by [CONTACT_1769].    
• Ensure subject  is notified of any significant new findings about the study that become available 
during the course of the study which are pertinent to the safety and well -being of the subject, 
as this could impact a subject’s willingness to participate in the study.  
If the IC is obtained the same day the subject begins participating in study -related procedures, it must 
be documented in the subject’s case history that consent was obtained prior to participation in any 
study -related procedures. The IC process s hall be documented in the subject’s case history, regardless 
of circumstance.  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 [ADDRESS_1270827] cannot read and/or write, and if allowed by [CONTACT_1769] , the IC shall be obtained 
through a supervised oral process. An independent witness (if applicable as per local regulation) must 
be present during this process. The ICF and any other information must be read aloud and explained to the prospective subject, and whenever possible, either the witness or prospective subject shall sign and 
personally dat e the ICF attesting that the information was accurately explained , and that IC was freely 
given. The source documentation sh all provide the method used for communication with the 
prospective subject and the specific means by [CONTACT_905493] c ommunicated agreement 
to participate in the study.  
The original signed IC F must be filed in the hospi[INVESTIGATOR_307]/clinical chart and/or with the subject’s study 
documents.  
The ICF and Authorization to Use and Disclose Personal Health Information/Research 
Authorization/HIPAA/other privacy language shall  be available for monitoring and auditing  if required 
by [CONTACT_2371]. Any Medtronic personnel who support the study procedure must be able to review the 
subject’s signed and dated ICF and verify its completeness prio r to proceeding with the study 
procedure. In the event the Medtronic personnel identify the ICF as being incomplete, the study 
procedure will not be allowed to occur until the consent of the subject can be adequately and 
appropriately obtained.  
8.4. Enrol lment / Baseline  
When a patient and the P rincipal Investigator or authorized designee (if applicable) signs and dates the 
ICF, the patient is considered a subject enrolled in the study. The date the subject signed the IC F must 
be documented in the subject’s medical records. Enrollment can be a stand -alone visit or can occur on 
the same day as the baseline visit. Medtronic shall  be notified (via Enrollment eCRF) as soon as possible 
to aid in enrollment tracking. Once consent is obtained, report adverse events, device deficiencies, study deviations, system modifications, and subject exits or deaths as they occur.  
The following information is required to be collected at the baseline visit:  
• Confirmation of Inclusion/Exclusion Criteria  
o It is recommended to perform a  pre-implant anatomy evaluation (see section 8.4.1) 
• Demographics  
• Physical exam: A basic physical exam will be performed, including height  and weight   
• Relevant medication and relevant cardiovascular medical history  
• Relevant surgical history  
• Primary indication for ICD implant  
• Echocardiographic data  within the last 6 months  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 49 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   • SF-12 quality of life survey  
• Chest radiograph , standing  tidal inhalation breath hold (see Table 4) 
o Radiographs shall be sent to Medtronic  (see section 8.9 ) 
Table 4: Chest Radiograph collection during Baseline Visit  
Visit  Image Collection  
Baseline • Standing PA  Tidal i nhalation breath hold  
• Standing LAT  Tidal i nhalation breath hold  
 
 Subject Pre -implant Anatomy Evaluation   
Assess the subject  in a supi[INVESTIGATOR_905369]’s ability to palpate xiphoid process, costal -rib margins and left sternal 
border  to confirm  the subject does not  meet exclusion criterion 6.  
Review the baseline chest radiographs . It is also  recommended to review a CT-scan (cardiac gated 
preferred ) or MRI (taken within the last year) for the first [ADDRESS_1270828]’s anatomy . If the 
implanter feels the subject has unfavorable mediastinal anatomy, the procedure shall not be 
attempted,  and the subject shall be exited from the study  (see section 8.[ADDRESS_1270829] Withdrawal or 
Discontinuation ).  
If collected/reviewed, send CT -scan and/or MRI to Medtr onic  (see section 8.9). This information will be 
used to further characterize clinical results and anatomical considerations. 
8.5. Implant Visit  
It is recommended that the  implant visit occur s within [ADDRESS_1270830] of care (e.g., as specified by [CONTACT_905494]) is 
required. Standard hospi[INVESTIGATOR_905370] b e followed regarding antibiotic therapy for ICD  
implantation.   
 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 [ADDRESS_1270831] oral and/or systemic anticoagulants withheld peri -
procedurally in order to reduce risk of bleeding/hematoma, as follows:  
Pre-procedure:  
• Withhold anticoagulants per local protocol.  
• Follow the treatment procedures suggested by [CONTACT_905495]. 
• Recommendations by [CONTACT_905496]:  
o Suspension of novel oral anticoagulants ( NOACs) ≥24 hours pre- procedure  
o Suspension of heparin ≥6 hours pre-procedure  
o Suspension of low molecular weight heparin ≥72 hours pre-procedure  
o Suspension of warfarin ≥ [ADDRESS_1270832] -procedure:  
• It is recommended to resume oral anticoagulation as soon as possible post- procedurally unless 
clinically contraindicated ( e.g. effusion observed).  
 
• Post -procedure anticoagulation should be resumed as soon as possible unless clinically 
contraindicated  in patients who have had AF for ≥ [ADDRESS_1270833]’s BMI and abdomen when in the supi[INVESTIGATOR_2547], as it may 
challenge safe tool utiliza tion. If the investigator does not believe he/she can maintain close proximity 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 [ADDRESS_1270834] with , the posterior of the sternum with the tip of tunneling tool, the investigator should 
not proceed with the EV ICD implant procedure.  
In the event that the investigator does not proceed  with the implant procedure:  
• AP and lateral fluoroscopic images or videos must be sent to Medtronic. Th ese data will help 
further the understanding of anatomic variances for future procedure development considerations.  
In cases  where the investigator does proceed with the implant procedure:  
• Collect fluoroscopy cine recordings during the substernal tunneling with the sternal tunneling tool 
and introducer as well as during EV ICD  lead placement.  
• Two fluoroscopy cine images (AP and L ateral ) are required of the final EV ICD  lead placement and  
device placement for one full respi[INVESTIGATOR_905371].   
• Fluoroscopy cine recordings and cine images will be will be sent to Medtronic  (see section  8.9).  
 
Photography/ Videography  
If allowed per local regulations and accepted by [CONTACT_905497] , Medtronic 
personnel attending the Implant Visit may take pi[INVESTIGATOR_905372]/or videotape the implant procedure for 
training, education, and/or research purposes. These photographs and/or video recordings will not display any identifiable features of the subject. The original files will be kept at the hospi[INVESTIGATOR_905373].  
 Implant Procedure Steps  
Prior to performing the implant procedure, it is important that implanting investigators read  and 
understand the Instructions for Use (IFU)  that accompani es each device and  undergo documented 
training by [CONTACT_13735].  
It is strongly  recommended to use g eneral anesthesia with cardiac monitoring during  the implant 
procedure  to prevent subject movement and minimiz e the likelihood of adverse events during 
procedure . Additionally, general anesthesia will afford a greater level of cardiac monitoring compared 
to what is practiced when patients are under conscious sedation.  
If the procedure is aborted at any point, refer to section 8.19 for additional instructions . 
The proposed procedure steps are listed in Table 5. The steps are strongly  recommended unless 
otherwise noted as required steps.  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 52 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Table 5: Outline of the  proposed  implant procedure steps  
Implant Step  Procedure + Imaging   
1. Subject  Assessment  • Review pre -procedure  chest imaging .  
• Required:  Pre-procedural fluoroscopy in both Lateral and AP views is 
required prior to starting the implant procedure to assist in 
determining sub -xiphoid incision location for the patient anatomy, to 
determine whether the sternal tunneling tool tunnel rod curvature 
needs adjustment based on subjec t anatomy, to assist in  sternal  
tunneling to ol entry into the substernal space to inform the angle of 
insertion, and identification of appropriate device pocket location. 
• If the implanter cannot find a way to achieve or maintain consistent contact [CONTACT_905498], the procedure should be stopped . 
• Required:  If subject presents in atrial fibrillation, perform a pre-
procedure TEE to ensure the absence of LA or LV thrombus.   
2. Subject  Prep aration  
and Drape  • Place 1 set of External Defibrillation Patches  in locations that will not 
compromise the implanted system defibrillation vector or sterile operating field.  
• Position left arm to allow full l ateral fluoroscopy and pocket incision 
access on left mid-axillary chest.  
• Determine ICD pocket location using fluoroscopy (AP & Lateral 
views) and the cardiac silhouette  as guidance  with demonstration  
lead and ICD.    
• Draw surface landmarks on chest , including sternal midline, left 
sternal border, xiphoid process, costal margins, top of cardiac silhouette and incision location and device pocket location. 
• Perform s terile preparation of  the chest for implant per Standard of 
Care . 
• Drape patient chest to provide sterile operating field to access the sub-xiphoid and device pocket incisions.   
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 53 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Implant Step  Procedure + Imaging   
3. Sternal Tool and 
Introducer Preparation  • If needed, manually bend the tunneling rod of the sternal tunneling 
tool to a curvature suitable for the patient’s anatomy. The angle should  allow for the tunneling rod tip to remain in contact  [CONTACT_4490] (or 
as close as possible to) the posterior of the sternum during tunneling.  
• Prepare introducer sheath according to manufacturer’s instructions for use and load onto the tunneling rod of sternal tool. 
• Attach a pre -filled saline syringe (10 cc) to hem ostasis valve side -port 
on introducer with valve open for the implant procedure.   
4. Sub -Xiphoid Access  • Make a n incision below the xiphoid process and left of sternal 
midline.  Anatomical variation adjustments may be necessary : 
o Consider the margins of the left costal rib and xiphoid 
process.  A lower incision may be required in larger patients 
to allow for shallow blunt dissection and <30 -degree angle of 
a medical instrument or tunneling rod insertion.   
5. Blunt Dissection of 
Diaphragmatic 
Attachments  • Use a fingertip and/or curved Kelly hemostat to dissect through 
diaphragmatic attachments  and confirm the tissue plane using 
lateral fluoroscopy for visualization.  
• Once the implanter has completed blunt dissection and has entered  
the mediastinal tissue plane, if resistance is felt (e.g., fibrotic 
attachments between heart and sternum), abort procedure. 
• Pre-lay 2 sutures into the rectus fascia (to later secure lead 
anchoring sleeve).   
6. Substernal Tunneling  
Procedure (Zone 1)  • Insert prepared sternal tunneling rod using full Lateral fluoroscopy 
into anterior mediastinum. Keep tip of tunneling rod in contact [CONTACT_905499].  
• Tunnel  approximately midline or just left of sternal midline and no 
further than the top of cardiac silhouette , as determined by [CONTACT_905500].  Keep tunneling rod in contact 
[CONTACT_905501].  If any resistance is felt, 
stop  and confirm tunneling tool location in alternate fluoroscopic 
view. Redirect tunneling rod under the sternum. If patient has COPD 
or lungs crossing midline  are suspected , consider tunneling during  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 54 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Implant Step  Procedure + Imaging   
end-expi[INVESTIGATOR_905374].  
• Confirm the pre-filled saline syringe (10 cc) is connected to 
hemostasis val ve side-port on introducer  sheath with  valve open. 
• Retain the sheath in position, then slowly remove the sternal tunneling  tool from the sheath and incision. 
7. EV ICD Lead 
Insertion and 
Deployment  • Use AP fluoroscopy to insert the lead to the distal tip of the 
introducer sheath.  
• Required Lead Orientation:  Defibrillation Coils toward subject’s  right 
chest; Pace/Sense Rings toward patient ’s left chest.  
• Position the lead with respect to the cardiac silhouette and intended 
ICD location.  
• Deploy the  lead by [CONTACT_905502], pacing and defibrillation . Retain the sheath until completion 
of Step 8.  
• In the event of the lead deployment in the opposi te orientation ( Coil 
[ADDRESS_1270835] patient’s left lateral border), it is 
recommended to re -advance the introducer over the lea d body to 
the distal tip.  
• Next, withdraw the lead and reinsert in the required orientation prior to acute testing .  
• Do not reinsert the lead through the introducer valve more than 
three times during the procedure. If this occurs, use a new lead.  
  

 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 55 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Implant Step  Procedure + Imaging   
8. Assessment of EV 
ICD Lead  • Evaluate R -wave signal amplitude  for Ring1 -Ring2 configuration , 
through one full respi[INVESTIGATOR_905371],  using Medtronic CareLink 
Programmer Model [ADDRESS_1270836] the measured sensing values.  
• If R-wave amplitude is < 1mV  for the Ring1 -Ring2 configuration , or P -
wave or T -wave oversensing is suspected, attempt repositioning or 
re-tunneling the lead. If R- wave amplitude remains  < 1mV , the 
implant shall  be abandoned, and the implant of an alternative ICD 
system should be cons idered.  
• Remove introducer sheath prior to sub -xiphoid suture sleeve 
fixation.   
9. Sub -Xiphoid Suture 
Sleeve and Lead 
Fixation • Required:  Use a minimum of  three  non-absorbable sutures with high 
tension force to fixate anchoring sleeve to lead body in sub -xiphoid 
incision using each of the three grooves .  
• Required:  Tie two non- necrosing sutures to the  fascia, then tie to 
lead anchoring  sleeve grooves . Next, tie one suture on to the  lead 
anchoring  sleeve to secure to  the lead body .  
10. Create EV ICD 
device pocket • Use fluoroscopy to confirm defibrillation vector based on final  lead 
placement and cardiac silhouette for EV ICD device location.  
• Create device pocket incision near the left mid -axillary chest to form 
an optimized vector with the implanted le ad.  
11. Transverse  
Subcutaneous Tunneling  Procedure 
(Zone 2)  • Insert distal tip of transverse subcutaneous  tunneling rod in sub -
xiphoid incision, above/anterior to the costal rib margin and advance 
into the device pocket incision. 
• Remove handle to expose lead channel and insert lead connector pin 
into channel.  
• Pull tunneling rod with lead inserted in the channel into the device pocket incision.  Remove the transverse subcutaneous tunneling rod  
through the pocket incision .  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 56 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Implant Step  Procedure + Imaging   
12. Device Pocket and 
Sub-Xiphoid Incision 
Closure  • Fixate device header against fascial plane using non-absorbable 
suture in the holes provided.  
• If the TYRXTM Envelope is used, this shall  be documented. 
• Remove air from incision and close the pocket and sub -xiphoid 
incisions , at least one layer, prior to device testing.  
• Final closure of incisions shall be in  at least  three  layers, and wound 
dressings shall be applied per standard of care.   
13. Required Cine of 
final lead and device 
placement • Required:  Cine, both AP & Lateral views during a full respi[INVESTIGATOR_905375] , to document final lead and EV ICD position.   
14. EV ICD Device 
Testing  • Interrogat e the EV ICD device and perform electrical testing (sensing, 
pacing, impedance) , as described in section 8.5.6 . 
• Perform defibrillation testing protocol, as described in section 8.5.7 .  
 
 Implant T esting – EV ICD System  
Perform the following tests of the EV ICD System after the EV2401 lead is connected to the EV ICD device and the device is placed into the pocket.  
[IP_ADDRESS].  
Sensing Testing 
Perform an RV sensing test. Set ICD RV sensing vector to Ring1 -Ring2.  Adjust sensing parameters to 
avoid T -wave oversensing, P-wave oversensing, or other oversensing. Once configured, perform the 
Sensing Test. P rint the Sensing Test Report on the programmer  to PDF or paper  and store at site . 
Evaluate alternate sensing vecto rs as necessary. Program determined sensing settings.  
The R-wave amplitude for sensing shall be greater than or equal to 1mV  for the Ring1 -Ring2 
configuration. 
If the R-wave amplitude  is less  than  1mV  for the Ring1 -Ring2 configuration  after all troubleshooting 
attempts have been exhausted  (refer to step 8 in  Table 5 ), the EV ICD implant shall be abandoned and 
the implant of an alternative ICD system should be considered.  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 57 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   [IP_ADDRESS].  Impedance Testing 
Subthreshold impedance will be measured for the following electrode pairs:  
• Ring1  to Ring2  
• Ring1  to Coil2 
• High Voltage  
Print the Lead Impedance Test Report to PDF or paper and send to Medtronic . 
[IP_ADDRESS].  Pacing Testing  
Pacing capture threshold testing will be performed, potentially in multiple vectors: Ring1 -Coil2, Ring1 -
Ring2, Coil2 -Coil1.  Pacing capture is defined as at least three  consecutive captured beats.  
At the conclusion of pacing capture threshold testing, it i s recommended to leave pacing settings at the  
shipped nominal values until pre -hospi[INVESTIGATOR_2345].  
Print  final capture threshold report to PDF or paper and send to Medtronic . 
  Induction and Defibrillation Testing  
To ensure  subject safety in an ambulatory setting, sustained shockable ventricular arrhythmia (SSVA) 
induction and defibrillation testing is required at implant. Adjust device programming to ensure 
adequate safety margins for sensing and defibrillation during SSVA induction testing.  
The testing p rotocol may require up to six successful SSVA epi[INVESTIGATOR_905376] 10 EV ICD 
shocks delivered ( Figure 7 ).  
[IP_ADDRESS].  General R equirements  
Induction of SSVA will be achieved using one of the following methods:  
• Burst Induction (Coil2 -Coil1, 40V).  
• T-shock (up to 20J). 
If a subject  cannot be induced using these method s, other methods may be employed at  the discretion 
of the  investigator  (e.g., EP catheter). The investigator may choose to attempt induction on another 
day prior to discharge. If the investigator determines the subject  cannot be induced , the EV ICD System  
must be removed  (refer to s ection  8.5.8 ).  
Ensure a Wavelet template is collected and EV ICD detection is enabled prior to induction.  If the 
subject's health is at risk, defibrillation testing should be suspended or terminated.  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 [ADDRESS_1270837]  in locations that will not 
compromise the implanted system defibrillation vector or sterile operating field. 
It is recommended to wait five minutes between the end of an SSVA epi[INVESTIGATOR_905377]. Waiting period after failed induction attempts is 
at the investigator's discretion.  
Defibrillation testing may continue on a future day if epi[INVESTIGATOR_905378], but 
lead revision is not permitted on a future day if the subject  has resumed anticoagulation.   
Anticoagulation should be resumed as soon as possible post-procedurally unless clinically 
contraindicated  (e.g. effusion observed)  in subjects  who have presented in  atrial fibrillation  for ≥ 48 
hours in duration prior to the implant procedure and who convert to sinus rhythm during defibrillat ion 
testing to diminish the risk of peri -procedural stroke. 
Reminder:   After each induced SSVA epi[INVESTIGATOR_1865], save -to-media files shall be collected (see section 8.10 ). 
Print the live strip for the duration of each SSVA epi[INVESTIGATOR_1865]. Retain a copy of the live strip for each epi[INVESTIGATOR_905379]. If requested, 
send a copy of the live strip to Medtronic  (e.g., a scan). 
Print the VT/VF epi[INVESTIGATOR_905380].  
Record shock  outcome  and shock impedance  (if available) for each EV ICD and rescue shock .  A shock 
will be considered successful if it results  in termination of the ind uced SSVA epi[INVESTIGATOR_1865], with termination 
defined as a return to normal intrinsic rhythm or to a supraventricular tachycardia before the next 
shock is given. Additional processing of the VF sensing data may be performed after implant data 
collection. 
[IP_ADDRESS].  Testing and Programming Defibrillation Therapy  
Defibrillation testing success is defined as  meeting one of the following criteria : 
a. Single SSVA  conversion at 20J, or  
b. Conversion of two consecutive  epi[INVESTIGATOR_905347] 30J in final system configuration.  
Follow the defibrillation testing as outlined in Figu re 7, beginning at Epi[INVESTIGATOR_1865] 1 (20J). The following 
requirements shall  be observed while conducting defibrillation testing:  
• Defibrillation at a given energy will be deemed successful if SSVA is term inated, regardless of 
whether the shock is delivered manually or automatically by [INVESTIGATOR_16897].   
• In one of the two consecutive  SSVA epi[INVESTIGATOR_1841], up to two 30J shocks are permitted . 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 59 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   • To achieve final system configuration, changing the position of the ICD generator and/or  the 
lead, or changing shock polarity is permitted . 
• If the device or lead position are altered (e.g., position changed as part of troubleshooting), defibrillation success must be demonstrated with the new system configuration. 
• If defibrillation proto col epi[INVESTIGATOR_905381], remaining epi[INVESTIGATOR_905382] a 
subsequent day  (e.g. , next day  or during the admission)  to complete the defibrillation testing 
protocol  
• For the  first epi[INVESTIGATOR_905383] 20J therapy or the first 30J epi[INVESTIGATOR_361031] a 
“Troubleshoot System” step in Figure 7 , program Rx1 polarity to either STD or REV, and 
program Rx2 polarity the opposite of Rx1 polarity.  
• If the epi[INVESTIGATOR_905384] a defibrillation success at 30J , and the previous epi[INVESTIGATOR_905385] a 
defibrillation success with Rx1, program Rx1 and Rx2 to the polarity of Rx1 in the previous epi[INVESTIGATOR_1865]. 
• If the epi[INVESTIGATOR_905384] a defibrillation success at 30J, and the previous epi[INVESTIGATOR_905385] a 
defibrillation success with Rx2, program Rx1 to the same polarity as Rx2 in the previous epi[INVESTIGATOR_905386]2 off. 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 60 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
    
 
   
Figure 7: Diagram outlining the process of SSVA induction and defibrillation testing  

 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 61 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
    
[IP_ADDRESS].  Testing and Programming VF Detection  
VF detection success at implant is defined a s successful VF detection in a single SSVA epi[INVESTIGATOR_905387]1 -Ring2 c onfiguration at a value  greater than or equal to 0.2 mV  (e.g., 0.2, 0.45, or 0.6 mV). VF 
detection and defibrillation success do not need to be demonstrated on the same epi[INVESTIGATOR_1865](s), but each 
must be demonstrated in the final system configuration. 
Follow the VF detection testing as outlined in Figure 8 , beginning at Epi[INVESTIGATOR_1865] 1. This aligns with Epi[INVESTIGATOR_1865] 
1 for Defibrillation Testing outlined in Figu re 7. The following requirements shall be observed while 
conducting VF detection testing:  
• The VF d etection shall be demonstrated in the Ring1 -Ring2 vector with a Number of Intervals to 
Detect (NID) setting of 30/40.  
o If VF detection is demonstrated in the Ring1 -Ring2 vector, the remaining induction 
attempts may be programmed with a NID setting of 18/24. 
o Redetect NID shall be programmed to 9/12  when Rx2 is enabled . 
• Begin testing with VF Sensitivity programmed to Ring1 -Ring2, 0.45 mV.  
o Use this setting wh en restarting testing to evaluate a new lead position.  
• If the first programmed setting is unsuccessful, program VF Sensitivity to Ring1 -Ring2, 0.2 mV. 
• If the second programmed setting is unsuccessful, reposition the lead and test again with the first 
programmed VF Sensitivity setting of Ring1 -Ring2 , 0.45 mV.  
• If VF detection is demonstrated in the Ring1 -Ring2 vector, program VF Sensitivity to Ring1 -Can, 
0.45 mV. 
• Once VF detection is demonstrated in Ring1 -Ring2 and attempted in  Ring1 -Can, VF detection shall 
be programmed to the Ring1 -Ring2 vector for remaining induction attempts.  
o If desired, additional margin can be assessed by [CONTACT_905503] 0.6 mV, otherwise it is recommended to complete the remaining induction attempts with Sensitivity programmed to 0.15 mV.
xv 
• Additional inductions beyond those specified in Figure 7  are allowed if needed per medical 
judgment (e.g., to program sensitivity or to obtain  supplementary information on an alternate 
vector).  
• If the VF detection success is demonstrated in the Ring1 -Ring2 vector, and the lead position is 
preserved, it is not necessary to re -demonstrate VF d etection in the Ring1 -Ring2 configuration, 
even if the device position is altered (e.g., as part of troubleshooting).  
                                                            
xv In instances where detection has been demonstrated in the Ring1 -Ring2 vector at 0.45 mV and the lead is not repositioned, 
subsequent epi[INVESTIGATOR_905388]1 -Ring2 at 0.15 mV, Ring1 -Can at 0.45 mV, or Ring1 -Ring2 at 0.6 mV to check 
for additional margin. Programming VF Sensitivity to 0.6 mV increases the likelihood that VF Detection will not occur, and 
delivery of a manual shock will be necessary.  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 62 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   • If the lead position is altered (e.g., as part of troubleshooting), previously demonstrated VF detection success is invalidated and success must be demonstrated with the new system configuratio n with an NID setting of 30/40.  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 63 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
    
 
Figure 8 : Diagram outlining the process of VF sensing margin testing  
 
1 In instances where detection has been demonstrated in the Ring1 -Ring2 vector at 0.45 mV and the lead is not repositioned, VF Sensitivity for subsequent epi[INVESTIGATOR_905389]1 -Ring2 at 0.15 mV, Ring1 -Can at 0.45 mV, or Ring1 -Ring2 at 0.6 mV to check for additional margin. Programming VF Sensitivity to 0.6 mV increases the likelihood 
that VF d etection will not occur, and delivery of a manual shock will be necessary.  
2 Ring1 -Ring2 equal to or more sensitive than 0.20 mV programming option is only available if Ring1 -Ring2 was tested successfully at 0.6 mV; Ring1 -Ring2 equal to or more sensitive 
than 0.15 mV programming should be used if 0.6 mV was not successfully tested. 

 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 64 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
    
[IP_ADDRESS].  Implant Defibrillation Troubleshooting Recommendations  
Prior to inducing and throughout the defibrillation protocol,  it is recommended to consider the 
following to improve defibrillation outcome  or troubleshooting in the event of failure of first 
epi[INVESTIGATOR_1865](s):  
• Check for /resolve  pneumothorax  
• Check for /resolve  high impedance values  
• Check for /resolve  air in tunnel  (e.g., fluoroscopy)  
• Check for /resolve  air in pocket  (e.g., flush with saline or antibiotic wash, massage air out of 
pocket)  
• Check for/resolve gastric bubbles  (gas) 
• Press on device pocket during testing  
• Perform defibrillation during held end tidal expi[INVESTIGATOR_1516] (end expi[INVESTIGATOR_905390])  
• If all of the above measures  are exhausted, evaluate the position of the EV ICD device and the EV 
ICD Lead. If required, consider repositioning of EV ICD generator or EV ICD lead .xvi 
• Allow time (e.g., next day or during the admission) to minimize transient factors affecting 
defibrillation success  
Note: Troubleshooting attempts after Epi[INVESTIGATOR_1865] 5 (Figure 7 ) may not leave enough remaining epi[INVESTIGATOR_905391].  
[IP_ADDRESS].  Programming Requirements at End of I mplant  Procedure 
At the end of the procedure, VF Detecti on shall  be ON and VF Therapi[INVESTIGATOR_905392]-Hospi[INVESTIGATOR_905393]/undersensing prior to 
proper evaluation of threshold once the subject is ambulatory . While VF Therapi[INVESTIGATOR_905394], the  subject 
shall  have cardiac monitoring.  
 Subject Exit for Incomplete Implant Visit  
The subject shall  be exited if any of the following occur during the  implant  visit: 
                                                            
xvi Lead revision is not permitted if the subject has resumed anticoagulation. Post -procedure anticoagulation should be 
resumed as soon as possible unless clinically contraindicated (e.g. effusion observed)  in subjects who have had atrial 
fibrillation for ≥ 48 hours in duration prior to the implant procedure and who convert to sinus rhythm during defibrillation 
testing to diminish the risk of peri -procedural stroke.  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 65 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   • Incomplete  Placement of Lead and/or Device – T he EV ICD System is not fully implanted. 
• Incomplete Defibrillation Testing Protocol – T he subject cannot complete the entire defibrillation 
testing protocol because they were not inducible or failed to induce a sufficient number of 
epi[INVESTIGATOR_1841]. 
o Note: If the subject completes the initial implant procedure without completing the 
defibrillation testing protocol, the subject may be brought back prior to hospi[INVESTIGATOR_905395], as outlined in Figure 7 . 
• Failure of Defibrillation Testing Protocol – T he subject completes the defibrillation testing protocol 
but does not meet the criteria for success for defibrillation testing.  
• Inadequate Sensing – T he subject cannot achieve an R -wave ≥ 1 mV  for the Ring1 -Ring2 sensing 
vector after troubleshooting methods are exhausted.  
• Inadequate SSVA Detection – The subject cannot achieve successful  VF detection in a single SSVA 
epi[INVESTIGATOR_905396]1 -Ring2 configuration at a value greater than or equal to 0.[ADDRESS_1270838] can be exited (see section 8.19 ). If the subject receives an alternative system (e.g., S-ICD or TV ICD), any AEs related to the 
alternate system  will be recorded during the course of subject participation, but will not be co nsidered 
related to the EV ICD System . 
Incomplete placement of the lead and/or device, and incomplete or failed electrical or defibrillation 
testing (including prolongation of hospi[INVESTIGATOR_905397]) are not considered adverse events; however , any adverse events occurring during an 
unsuccessful implant attempt (e.g., subject allergy to electrodes used during implant) must be recorded 
and classified  on an AE eCRF.  Unsuccessful EV ICD s ystem impla nts and/or failed defibrillation testing  
shall be evaluated for reporting as a device deficiency. 
If the EV ICD System is explanted or repositioned after initial implant procedure  but prior to pre -
hospi[INVESTIGATOR_2345], this shall be captured on a System Modi fication  eCRF.  
8.6. Pre-Hospi[INVESTIGATOR_905398]- hospi[INVESTIGATOR_905399], but 
prior to discharge. Prior to the subject being discharged,  VF Therapi[INVESTIGATOR_905400], as appropriate, should be programmed ON.  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 66 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Programming requirements and recommendations at PHD are outlined in Table 6. 
Table 6 : PHD Programming Requirements and Recommendations  
Required Programming  Recommended Programming  
Initial NID  for VF 
Therapi[INVESTIGATOR_905401] 30/40  VF Sensing  Per implant testing 
results (most 
sensitive setting ) 
All Rx  40 J VF Sensing if PHD 
Troubleshooting is 
required Per PHD testing 
results (most 
sensitive setting)  
Pause Prevention Monitor, [ADDRESS_1270839] Shock Pacing  Per physician recommendation; 4 V 
margin minimum  
  ATP At physician discretion; [ADDRESS_1270840] -to-media file shall be collected at the beginning of the visit, and a final 
(interrogate all) save-to -media file shall be collected at the end of the visit  (see section 8.10 ). 
 Sensing Testing  
At the Pre -Hospi[INVESTIGATOR_905402], perform the Sensing Test in the following postures:  
• Sitting  
• Supi[INVESTIGATOR_050]  
• Lying on left  
• Lying on right  
Print the Sensing Test Report to PDF or paper and send a copy of the report to Medtronic.  
 Impedance Testing 
Perform the Impedance Test in a sitting posture. If necessary, impedance testing in additional postures 
may be performed. Print the Impedance Test Report to PDF or paper and send a copy of the report to 
Medtronic.  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 67 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   
 Pacing Testing  
Perform p acing testing in a supi[INVESTIGATOR_429896]. If necessary, pacing testing in additional postures may be 
performed. The following configurations may be evaluated: Ring1 -Coil2, Ring1 -Ring2, Coil2 -Coil1. 
Pacing capture is defined as at least  three consecutive captured beats.  
The clinician will evaluate for pacing sensation during testing. Note: Pacing sensation or discomfort 
observed during testing will not be considered a reportable adverse event.  
If post pace oversensing is observed, sensing parameters should be adjusted to eliminate or minimize oversensing. Print the final capture threshold report to PDF or paper and send a copy to Medtronic.  
  Imaging   
Collect the  chest radiographs at Prehospi[INVESTIGATOR_3849] ( PHD) per Table 7 and send to Medtronic (see 
section  8.9). Additional radiographs may be collected at the discretion of the physician at any post -
implant time point if electrical testing at follow -up reveals deterioration in sensing or pacing 
performance.  
Table 7: Chest Radiograph collection during Pre- Hospi[INVESTIGATOR_905403]-hospi[INVESTIGATOR_514636] • Standing PA  Tidal i nhalation breath hold  
• Standing LAT  Tidal i nhalation breath hold  
Collection of echocardiogram at pre-hospi[INVESTIGATOR_905404], for 
example, if suspi[INVESTIGATOR_905405]. 
If additional images (CT scans, radiographs, TEE, MRI or other imaging modalities) are collected at 
physician discretion throughout the duration of the study, it is requested that a copy of the images be 
sent to Medtronic  (see section 8.9 ).  
8.7. Scheduled Follow -up V isits 
Subjects will undergo assessments at  scheduled  follow-up visits to characterize the safety and efficacy 
of the EV ICD System.  
Medtronic will provide the target dates and window s for each follow-up visit to the implanting site . 
Follow-up visit windows open on the Window Start date and remain open as defined in  Table 8. It is 
recommended that subjects are scheduled as close as possible to the target date for a given follow-up 
visit. 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 68 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Table 8 : Scheduled visit windows  
Study Follow -up Visit  Window  
(Calculated days post -implant procedure) 
Window Start (days 
post-procedure)  Target (days post -
procedure)  Window End (days 
post-procedure)  
2 Week  7 14 50 
3 Month  90 90 120 
6 Month  182 182 210 
12 Month (1  Year)  335 365 395 
18 Month  518 548 578 
24 Month (2  Year)  701 730 760 
30 Month  883 913 943 
36 Month (3  Year)  1066  1096  1126  
42 Month  1248  1278  1308  
48 Month (4  Year)  [ADDRESS_1270841].  The original files will be kept at the hospi[INVESTIGATOR_905406].  Report any adverse events , incl uding infections,  per section 10.5.  
  2-Week Follow -up Visit  
The following data will be collected at the 2-week follow -up visit: 
• Electrical Testing (Sensing, Impedance, and Pacing tests (see section 8.7.6 ) 
• Initial  (interrogation) and final (interrogate all)  save-to-media files (see section  8.10) 
• Adverse Event assessment  
• Device Deficiencies assessment  
• Healthcare Utilizations  
• Study Deviations  
• Other Cardiac Imaging  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 69 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   • Medication Log updates  
 3-Month Follow -up Visit  
The following data will be collected at the 3 -month follow -up visit: 
• Electrical Testing (Sensing, Impedance, and Pacing tests (see section 8.7.6 )) 
• Initial  (inte rrogation) and final (interrogate all)  save -to-media files (see section 8.10) 
• Adverse Event assessment  
• Device Deficiencies assessment  
• Healthcare Utilizations  
• Study D eviations 
• Other Cardiac Imaging  
• Medication Log updates  
 6-Month Follow -up Visit  
The following data will be collected at the 6 -month follow -up visit: 
• Electrical Testing (Sensing, Impedance, and Pacing tests (see section 8.7.6 )) 
• Initial (interrogation) and final (interrogate all) save -to-media files  (see section 8.10) 
• Adverse E vent assessment  
• Device Deficiencies assessment  
• Healthcare Utilizations  
• Study Deviations  
• Other Cardiac Imaging  
• Medication Log updates  
• SF-12 quality of life survey  
• [LOCATION_012] Patient Acceptance Survey (FPAS)  (only for subjects who complete their ICF in English) 
• Chest Radiographs per  Table 9 (required for subjects participating in chronic defibrillation 
testing , for other subjects this is recommended)  (see section 8.9 ) 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 70 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   • Chronic Defibrillation Test ing, for those subjects who consent to this testing  (see CIP 
Addendum for 6 -Month Defibrillation Testing and Appendix I: Chronic  Defibrillation Testing 
Protocol ) 
Table 9: Chest Radiograph collection during 6-Month Follow -up Visit.  
Visit  Image Collection  
6-Month  Visit • Standing PA  Tidal i nhalation breath hold  
• Standing LAT  Tidal i nhalation breath hold  
Chest radiograph s should  be reviewed by [CONTACT_905504] -month visit. Chest 
radiographs  for subjects participating in chronic defibrillation testing shall  be sent to Medtronic (see 
section 8.9), and for all other subjects shall be retained at the site and may be sent to Medtronic upon 
request.  
Prior to chronic defibrillation testing, both chest radiographs  and the EV ICD System ’s electrical 
performance should be considered to decide whether or not to proceed with chronic defibrillation 
testing . If there is evidence for deterioration of electrical performance or  significant movement of the 
lead, the clinician may consider either changing the device programming or moving the lead ( Note: lead 
repositioning involves a system modification and overall subject health and safety should be 
considered be fore proceeding) to ensure adequate functioning of the EV ICD System.  
 Long -term follow -up Visits 
Subjects will be followed up at [ADDRESS_1270842] -implant and every 6 months  thereafter  until the study is 
closed. The following data will be collected at these visits: 
• Electrical Testing (Sensing, Impedance, and Pacing tests ; see section 8.7.6 ) 
• Initial (interrogation) and final (interrogate all) save -to-media files  (see secti on 8.10) 
• Adverse Event assessment  
• Device Deficiencies assessment  
• Healthcare Utilizations  
• Study Deviations  
• Other Cardiac Imaging  
• Medication Log updates  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 [ADDRESS_1270843] of care for ICD systems and may require 
additional testing. Additional imaging or data collection may be necessary, and a DR220 Digital Holter 
Recorder  (North East Monitoring, Inc.; investigational in Australia, Canada, New Zealand, and Japan ) 
may be used  for up to [ADDRESS_1270844], it is recommended to  follow the steps outlined 
in Appendix I: Chronic Defibrillation Testing Protocol. After conducting a chronic defibrillation test, it is  
required to  complete a Chronic Defibrillation Testing eCRF .  
 Electrical Testing  
Subjects ’ medical records shall be made available prior to performing electrical testing. An initial 
interrogation save -to-media file shall be collected at the beginning of the visit, and a final (interrogate 
all) save -to-media file shall be collected at the end of the visit  (see section 8.10 ).    
[IP_ADDRESS].  Sensing Test ing 
At the [ADDRESS_1270845] 
Report to PDF or paper and send a copy of the report to Medtronic.  
[IP_ADDRESS].  Impedance  Test ing 
At the [ADDRESS_1270846] Report to PDF or paper and send a copy of the report to Medtronic.  
[IP_ADDRESS].  Pacing Testing  
At the 2 -Week, 3 -Month,  6-Month, and Long-Term  follow up visits, perform pacing testing in a sitting 
posture. If necessary, pacing testing in additional postures may be performed. The following 
configurat ions may be evaluated: Ring [ADDRESS_1270847] to the 
investigative study site due to the EV ICD System between CIP -required visits.  
If an Unscheduled Visit occurs:  
• Document any adverse events and /or device deficiencies on the associated eCRFs , as applicable.   
• Where possible, initial (beginning of the visit) and final (end of the visit) device interrogation data 
should  be collected  via a save -to-media file  (see section  8.10) .  
• If electrical testing is conducted, print the Testing Reports to PDF or paper and send a copy of the 
reports to Medtronic.  
8.9. Imag es and recordings  
All images and recordings shall  be retained in  the subject’s file. C opi[INVESTIGATOR_905407].  
8.10.  Save -to-Media Files   
When a save -to-media file/save-to -media files should be collected, a device interrogation (full 
summary interrogation/interrogate all is best practice) must be performed  and saved in a digital format 
(.pdd) on a USB or other removable electronic media . Save -to-media files  shall  be sent to Medtronic, 
with a copy being maintained at the site in the subject’s file. It is recommended that data are not 
cleared during any interrogation.  
8.11.  Care Link Transmissions  
At the time of C IP approval, CareLink will not be available for subjects implanted with the EV ICD 
System . In the event it becomes available, it is acceptable to collect and utilize data via CareLink 
transmissions.  A CareLink file collected within a visit window will be considered equivalent to an in-
office s ave-to-media file,  but a s ave-to-media file for in-office visits is preferred. If review of a CareLink 
transmission  results in a subject visit to the study center between scheduled visit windows , an 
Unscheduled Visit eCRF  shall  be completed . 
8.12.  Healthcare Utilizations  
Health C are Utilization  (HCU)  information will be collected when the utilizations are related to the 
following characteristics of the EV ICD S ystem : 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 73 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   • All procedure, system, and accessory related adverse events  
• Shocks  delivered by [CONTACT_905505]  (inclusive of in appropriate shocks and appropriate shocks 
delivered to treat ventricular arrhythmias)  
• Cardiovascular syncope  
All inpatient hospi[INVESTIGATOR_602], outpatient hospi[INVESTIGATOR_85423], emergency department visits, clinic visits, 
urgent care, or rehab center utilizations  associated with the  characteristics listed above are considered 
reportable HCUs for this study.  CIP-required utilizations (except unscheduled visits) should not be 
reported on HCU eCRF s. 
8.13.  System Modification  
A System Modification eCRF form shall be completed in the event the EV ICD System requires an 
invasive modification after the subject has been transported out of the procedure room f rom their 
initial implant  (e.g., explant, replacement, repositioning).  
Prior to a system revision a save -to-media file (initial, see section  8.10) shall be collected and the 
physician should consider the following actions:  
• Evaluate electrical performance  
• Reprogramming  
• Imaging  (e.g., chest radiographs ), images  reviewed by [CONTACT_905506] 
(see section 8.9 ). 
• Chronic defibrillation test, it is recommended to  follow the steps outlined in Appendix I: Chronic 
Defibrillation Testing Protocol. After conducting a chronic defibrillation test, it is required to complete a Chronic Defibrillation Testing eCRF.  
• Risk-benefit to subject    
Unless urgent, the physician should consult with a member of the steering committee for questions 
about moving forward with a system modification.  
In the event of a system modification where an EV ICD System remains in the body, the follow up 
schedule for the subject will remain unchanged. In cases where an EV ICD System is explanted and not 
replaced with an EV ICD System, the subject will be exited according to section 8.[ADDRESS_1270848] a 10J safety margin . Repeat all data collection 
from the PHD visit  (see section 8.6), including a final save -to-media file (see section 8.10 ).     
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 74 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   8.14.  Role of the S ponsor  Representatives  
Sponsor representatives will provide support as required for the study under supervision of the 
Principal Investigator, including:  
• Provide study training, including but not limited to training on the: CIP, Informed Consent 
process, data collection tools, and  regulations  
• Technical support in installing/uninstalling the programmer software into/from the 
Programmer manually or via the SDN   
• Technical support at all study visits under the supervision of the P rincipal Investigator, 
including device programming, but  no data entry on eCRF s shall be performed by [CONTACT_600520]  
• A trained Medtronic representative may support a study investigator at the Implant Visit by 
[CONTACT_905507].  
• Sponsor representatives may conduct monitoring and auditing activities for this study.  
8.15.   Assessment of Efficacy   
Efficacy of the EV ICD System with regards to defibrillation testing success will be assessed per the primary efficacy objective at t he implant visit (see section 12.5 ). In addition, efficacy of ATP and shock 
for termination of spontaneous ventricular arrhythmias  will be character ized as part of the ancillary 
objectives (see sections 12.6 and 12.10 ). 
8.16.   Assessment of Safety  
Safety of the EV ICD System with regard to major complications related to the system or procedure will 
be assessed by [CONTACT_905508] (see section 12.4 ). All Adverse Events will be 
collected throughout the study duration, starting at the time of signing the Informed Consent Form. 
The prevalence of these adverse events will further be summarized by [CONTACT_905509]  (see s ection 
12.11).  Additionally, any device deficiencies related to the EV ICD system  or accessory  will be collected.  
Further information on the collection of Adverse Events is discussed in section 10. 
8.17.   Recording Data  
This study will be conducted using an electronic data capture system (e.g., Oracle Clinical Remote Data 
Capture system , or OC RDC). The electronic data capture system , which allows the study s ites to enter 
study data into the sponsor’s database over a secure internet connection, will be used to capture study 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 75 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   required eCRF information . The Principal Investigator [INVESTIGATOR_905408]. The Principal Investigator [INVESTIGATOR_59778]-Investigator designee (if allowed by [CONTACT_1295]) is required to approve all data on eCRFs via electronic signature.  The data r eported on the eCRFs shall be derived from source documents, and any 
discrepancies shall be explained in writing.  
Save -to-media files will be collected and stored at the site. Copi[INVESTIGATOR_905409] c file transfer services (e.g.,  Box) and/ or secure mail . 
Programmer printouts will be collected in hard or electronic copy and stored at the site. Copi[INVESTIGATOR_905410] (e.g.,  
Box) and/or secure mail . 
Fluoro scopy  /radiograph/ CT images , if collected,  shall be stored on a CD/DVD or USB flash drive at the 
site. Copi[INVESTIGATOR_905411] (e.g., Box ) and/ or secure mail.  
8.18.  Deviation Handling  
A study deviation is defined as an event within a study that did not occur according to the Clinical Investigation Plan or the Clinical Trial Agreement.  
Prior approval by [CONTACT_905510], contemplates, 
or makes a conscious decision to deviate. Prior approval is not required when a deviation is necessary to protect the safety, rights or well -being of a subject in an emergency or in unforeseen situations 
beyond the investigator’s control (e.g. , subject failure to attend scheduled follow-up visit, inadvertent 
loss of data due to computer malfunction, inability to perform required procedures due to subject illness). 
For medically justifiable conditions which preempt a subject’s ability to complete a study -required 
procedure, it may be permitted to report only one deviation which will apply to all visits going forward. 
This may also apply for other unforeseen situations (e.g., the subject permanently refuses to complete 
a study required procedure and the data will not contribute to the primary endpoint analysis). 
However, prior approval from Medtronic is required for such situations. 
All study deviations must be reported on an e CRF regardless of whether medically justifia ble, pre-
approved by [CONTACT_13735], an inadvertent occurrence, or taken to protect the subject in an emergency. In 
the occurrence of a corrupted device interrogation file, Medtronic may request a deviation to 
document that a readable interrogation file is unav ailable. 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 76 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Refer to  section 14.7.2 for deviation reporting requirements and timeframes for reporting to 
Medtronic, Ethics Committee and/or regulatory bodies, as required per local law.  
Medtronic is responsible for analyzing deviations, assessing their significance, and identifying any 
additional corrective and/or preventive actions (e.g. , amend the Clinical Investigation Plan, conduct 
additional traini ng, terminate the investigation). Repetitive or serious investigator compliance issues 
may result in initiation of a corrective action plan with the investigator and site, and in some cases, necessitate suspending enrollment until the problem is resolved or ultimately terminating the 
investigator's participation in the study. Medtronic will provide site -specific reports to investigators 
summarizing information on deviations that occurred at their investigational site on a periodic basis.  
Examples of study deviations include but are not limited to:  
• Failure to obtain proper Informed Consent  
• Failure to collect required study data (e.g. , required imaging ) 
• Inclusion  criteria not met /exclusion criteria met  at enrollment  
• Missing required save -to-media  files 
8.19.  Subject  Withdrawal or Discontinuation  
Subjects may be exited from the study for reasons such as: 
• Subject has completed the study  
• Subject lost to follow -up 
• Subject death  
• Subject did not meet inclusion  or met  exclusion criteria  or meets exclusion due to change sin ce 
initial evaluation 
• Subject chooses to withdraw (e.g., consent withdrawal, relocation to another geographic location)  
• Subject does not have or no longer has EV ICD System implanted  
• Subject completes but does not pass defibrillation testing prior to pre-hospi[INVESTIGATOR_2345]  
• Investigator deems withdrawal necessary (e.g., medically justified)  
A withdrawn subject will be treated according to standard of medical care and will not be replaced. 
Subjects will be included in the analyses up to the time that consent was withdrawn , or up to the time 
that the subject is exited .  
Subjects who had undergone an implant attempt and  did not have an EV ICD System implanted or had 
their EV ICD System removed without replacement with an EV ICD System may be exited by [CONTACT_905511][INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 77 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   the end of 30 days following implant attempt or system removal, or once all system and procedure-
related AEs are resolved.   
The following information is required to be collected at study exit:  
• Reason for exit (this shall  be documented o n the Study Exit eCRF and in the subject’s medical 
record)  
• Save -to-media  
In the case that the subject is determined to be lost to follow -up, details of a minimum of two attempts 
and the method of attempt (e.g., one letter and one phone record or two letters) to contact [CONTACT_905512]. In addition, follow the regulations set forth by [CONTACT_181020]. 
Upon withdrawal from the study, no further study data will be collected , and no additional  study visits 
will occur for the subject.  
9. Risks and Benefits  
9.1. Potential Risks  
Medtronic follows rigorous Quality Assurance and Control procedures throughout the development and clinical study of a research system. The formal Hazard/ Risk Analysis for the EV ICD  System is 
performed according to ISO [ZIP_CODE]:2012 (Medical Device Risk Management)  and is used to ensure that  
the level of risk is acceptable and reduced as low as possible prior to starting the  EV ICD Pi[INVESTIGATOR_112688] . 
  
The EV ICD System is assessed via a System Hazard Analysis to ensure all potential ris ks, at individual 
component and at system- levels, are evaluated and minimized  via risk controls. The  subject risk 
assessment evaluates potential risks associated with: system implant/explant, biological compatibility, therapy delivery, diagnostic data integrity and security, and potential failure modes associated with the 
finished devices.  Risk control strategies for the EV ICD Pi[INVESTIGATOR_905412] a cross -
functional team and in accordance with the Risk Management process. Risk controls are  implemented 
via safety  design inputs, and acceptable safety performance is demonstrated via system design 
verification and validation activities . During the course of the study, risks will be continuously 
monitored, assessed and documented by [CONTACT_473]. It is the Principal Investigator’s decision to 
assess whether to continue the study at the respective site, should safety -related concerns arise.   
The risks are reduced as much as possible, with residual risk being documented within the Risk 
Manage ment Report (DSN0 [ZIP_CODE], Version 2.0 or currently approved version) and disclosed in the  
Informed Consent Forms  provided to subjects. A summary of the risk analysis and risk assessment will 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 78 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   also be listed in the EV ICD Pi[INVESTIGATOR_905413]’s Brochure.  
 
A summary  of potential risks and risk mitigation  strategies associated with the EV ICD System and EV 
ICD Pi[INVESTIGATOR_905414] 10. Potential risks associated with the study are further  
minimized by [CONTACT_905513] -on 
training program. 
Table 10: Potential Risks and Mitigation Strategies  
Risks  Mitigation Strategies  
Procedural risks such as acute trauma, 
infection, or chronic trauma  i. Procedural technique instructions intended to optimize 
safety are provided in the CIP 
ii. The CIP requires that the EV ICD implant procedure is to 
be performed by [CONTACT_905514] s received timely 
hands -on training on all aspects of the implant procedure  
iii. Medtronic intends to use a proctorship strategy during 
the EV ICD implant in order to ensure the knowledge and skills are transferred to a non-surgical physician specialty (EP/Cardiologist). Cardiothoracic surgeons will also provide 
emergency support during the clinical study.  
Failure to provide effective high 
voltage shock  therapy when needed 
by [CONTACT_423] i. An external defibrillation system(s) is required to be 
present and  ready at all times during the implant 
defibrillation testing procedure. The external defibrillator(s) 
is to be prepared to be used in case of emergency.  
ii. Exclusion of subjects with current implantation of a 
pacemaker, ICD, neurostimulator or any other chronically 
implanted device which delivers current in the body, that 
may interfere with therapy delivery  
iii. Testing during the implant  procedure to ensure proper 
system set -up connections and lead integrity  
iv. Defibrillation therapy configuration instructions 
provided in the protocol which help promote optimal 
tachyarrhythmia detection and therapy   
v. EV ICD System design verification and end- to-end system 
design validation ensuring defib rillation therapy as 
specified  
Inappr opriate delivery of high voltage i. Exclusion of subjects with current implantation of a 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 [ADDRESS_1270849]  i. Exclusion of subjects with current imp lantation of a 
pacemaker, ICD, neurostimulator or any other chronically implanted device which delivers current in the body, that 
may interfere with therapy delivery  
ii. Testing during the implant procedure to ensure proper 
system set -up connections and lead integrity  
iii. Pacing  therapy configuration instructions provided in the 
CIP and training which help avoid oversensing and resulting 
failure to deliver pacing therapy when needed (e.g. , post -
shock)  
iv. EV ICD System design verification and end -to-end sy stem 
design validation ensuring pacing therapy as specified  
Delivery of bradycardia pacing therapy 
at an excessive rate causing symptoms  i. EV ICD System reliability analysis  ensuring freedom from 
failures as specified  
Arrhythmia induction (pacing during  
vulnerable period, proarrhythmic 
pauses, electrical/mechanical 
stimulus)  i. An external defibrillation system(s) is required to be 
present and ready at all times during the implant 
defibrillation testing procedure. The external defibrillator(s) 
is to be prepared to be used in case of emergency.  
ii. EV ICD System reliability analysis ensuring freedom from 
failures as specified  
Acceleration of an existing 
tachyarrhythmia i. Defibrillation  therapy configuration instructions provided 
in the protocol and trai ning which help avoid ineffective 
shock therapy and resulting arrhythmia acceleration  
ii. EV ICD System design verification and end- to-end system 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 80 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Risks  Mitigation Strategies  
design validation ensuring defibrillation  therapy as 
specified 
Extracardiac stimulation  i. Clinician training and CIP procedures for preventive 
measures regarding pain/ stimulation thresholds, including the use of general anesthesia , for the potential discomfort 
or pain associated with the pacing stimulation outputs and 
shocks  
ii. Pacing therapy  configuration instructions provided in the 
CIP and training which help avoid unnecessary therapy 
energy delivery such that extracardiac stimulation can be 
minimized/avoided  
iii. EV ICD System design verification and end-to -end system 
design validation ensuring pacing therapy as specified  
Thermal/electrical injury to subject 
tissues i. EV ICD System reliability analysis ensuring freedom from 
failures as specified  
Subject exposure to toxic materials  i. EV ICD System design utilizes materials that have 
sufficient biological compatibility and performance as 
demonstrated by a biocompatibility assessment  
Subject exposure to allergic materials  i. EV ICD System design utilizes materials that have 
sufficient biological compatibility and performance as 
demonstrated by a biocompatibility assessment  
Product degradation due to bio 
instability i. EV ICD System design utilizes materials that have 
sufficient biological compatibility and performance as 
demonstrated by [CONTACT_905515] i. EV ICD System design verification and end -to-end system 
design validation ensuring data corruption monitoring as specified 
Catastrophic failure of implanted 
product necessitating procedural 
revision of implanted components  i. EV ICD System reliability analysis ensuring freedom from 
failures as specified  
ii. EV ICD System design verification and end- to-end system 
design validation ensuring system integrity monitoring 
mechanisms as specified  
Exposure to radiation energy via 
diagnostic imaging modalities  i. Expected medical practice includes shielding the subject 
against unnecessary radiation exposure during diagnostic 
imaging.  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 81 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Risks  Mitigation Strategies  
ii. Practicing as low as reasonably achievable ( ALARA ) 
principles during the device implantation.  
During travel, subject s may not have 
immediate access to programmers 
with applicable software i. Subjects will be provided with subject ID cards. Softw are 
may be downloaded upon request by [CONTACT_905516]’s doctor or Medtronic.  
 
If a subject becomes pregnant during the study, there may be risks that are not yet known. Radiation 
exposure may cause miscarriage, birth defects or other unforeseen medical  conditions.  
There may be other discomforts and risks related to the EV ICD System and/or this study that are not 
foreseen at this time . 
The potential adverse events related to the EV ICD S ystem  and procedure and the EV ICD Pi[INVESTIGATOR_905415] 11. The additional procedural  steps 
beyond  traditional ICD implant such as increased radiation due to additional required radiographs and 
the substernal placement of the lead were considered in the creation of this list. In addition, the risks 
associated with the optional 6 -month defibrillation te sting (see CIP Addendum for 6 -Month 
Defibrillation Testing) are the same as for the implant defibrillation testing  and therefore also included 
in the list.   
Table 11: EV ICD System/Procedure - and EV ICD Pi[INVESTIGATOR_112688] -related Potential Adverse Events  
EV ICD System/Procedure -related Potential Adverse Events  EV ICD Pi[INVESTIGATOR_112688] -related Potential Adverse Events  
Acute tissue trauma  Acute tissue trauma  
Allergic reaction of local tissues  Allergic reaction of local tissues  
Bradyarrhythmia Cardiac arrest  
Cardiac arrest  Chronic tissue trauma  
Cardiac perforation Discomfort associated with implant  
Cardiac tamponade  Dizziness  
Chronic tissue trauma  Dyspnea  
Death  Hiccups  
Device migration  Infection  
Discomfort associated with fibrotic growth  Mental anguish*  
Discomfort associated with implant  Organ damage (liver, mammary arteries, diaphragmatic arteries) 
Discomfort associated with product migration  Pain  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 82 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   EV ICD System/Procedure -related Potential Adverse Events  EV ICD Pi[INVESTIGATOR_112688] -related Potential Adverse Events  
Dizziness  Palpi[INVESTIGATOR_905416]/thermal ti ssue damage  Skeletal muscle twitching  
Erosion  Syncope  
Extracardiac stimulation  Tachyarrhythmia 
Failure to provide necessary therapy   
Hematoma  
Haemorrhage   
Hemothorax   
Hiccups   
Hospi[INVESTIGATOR_905417]*   
Organ damage (liver, mammary arteries, diaphragmatic arteries)  
Pain   
Palpi[INVESTIGATOR_905418]1 6028 Version  1.0, 02- JUL -2019 Page 83 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   EV ICD System/Procedure -related Potential Adverse Events  EV ICD Pi[INVESTIGATOR_112688] -related Potential Adverse Events  
Toxic reaction to implant   
Twiddler's syndrome   
Wound dehiscence  
*Subjects susceptible to frequent shocks despi[INVESTIGATOR_905419]:  
• Dependency  
• Depression 
• Fear of premature battery depletion  
• Fear of shocking while conscious  
• Fear that shocking capability may be lost 
• Imagined shocking (phantom shock)  
9.2. Potential Benefits  
The EV ICD  Pi[INVESTIGATOR_905420] a 
transvenous system because they have occluded vessels or anatomical anomalies, and for patients that 
can benefit from preservation of cardiac vasculature. For other patients, there is no proven benefit . 
Furthermore, the EV ICD S ystem introduces additional potential  benefits as compared to subcutaneous 
ICD systems currently on the ma rket, specifically:  
• Better  signal to noise ratio from the substernal space as compared to a subcutaneous 
configuration, resulting in better detection/discrimination algorithms for sensing arrhythmias (and 
potentially fewer inappropriate shocks)  
• Reduced defibrillation energy required to defibrillate as compared to a subcutaneous configuration, resulting in improved battery longevity  
• Longer battery longevity and corresponding reduction in adverse events associated with device replacement  
• Asystole  pacing  
• Anti-tachycardia pacing  
• Smaller device which increases patient comfort and acceptance  
The information gained from this study could result in the improved management of  patients with the 
EV ICD  System. Additionally, information collected from this study  may assist in the design of new  
product(s)/therapy(ies) and/or instructions for use.  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 84 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   9.3. Risk-Benefit Rationale  
The majority of the risks associated with the EV ICD S ystem are similar to the risks associated with 
existing transvenous and subcutaneous ICD systems o n the market. The unique risks introduced by [CONTACT_905517]: unique harms associated with procedural complications (e.g., liver laceration, 
cardiac trauma/ tamponade), unique harms associated with defibrillating from a substernal  lead 
position ( e.g., tissue heating/necrosis), unique harms from chronic lead implant in the substernal space 
(e.g., dislodgment due to absence of fibrosis), and the general risk that an EV ICD System has not yet 
been chronically implanted in humans  for greater than [ADDRESS_1270850] 
Analysis confirm that the patient risks are reduced as far as possible and the residual risks are deemed 
acceptable.  
The foreseeable benefits of the EV ICD S ystem for patients with occluded vessels or anatomical 
anomalies and for patients that can benefit from preservation of cardiac vasculature  include: a 
reduction in procedural risk as compared to transvenous systems, enhanced tachyarrhythmia therapi[INVESTIGATOR_905421] (i.e., improved signal/noise, reduced shock energy, and offering 
of ATP), and improved patient comfort and acceptance due to the smaller size of device as compared to subcutaneous systems. Although there is no proven benefit for patients  who are able to receive a 
transvenous system , there may be benefits specific to the novel design of the EV ICD System. As 
compared to a transvenous system, the EV ICD System is expected to result in fewer extraction complications. Since the EV ICD System avoids implanting a lead in the heart, risks such as: systemic 
infection, embolism, vascular/SVC tears, and lead extraction injuries are expected to be significantly 
reduced or eliminated . 
10. Adverse Events and Device Deficiencies  
Timely, accurate, and complete reporting and analysis of safety informati on for clinical studies are 
crucial for the protection of subjects. Reporting and analysis of safety data are mandated by [CONTACT_181021]. Medtronic has established procedures in conformity with worldwide regulatory 
requirements to ensure appropriate reporting of safety information. The study is conducted in 
accordance with these procedures and regulations.  
Since the safety reporting requirements and classification systems vary for each regulatory agency, 
requirements from all geographies are taken into account for the collection and reporting of safety information.  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 85 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   10.1.   Assessment  
 Adverse Events Assessment  
Adverse Event (AE)  definitions are provided in Table 12 .  All AEs will be collected throughout the study 
duration, starting at the time the Informed Consent Form is signed . For purposes of reporting, events 
shall be captured on an AE eCRF.  
All instances of shocks delivered by [CONTACT_905518] a reportable AE. 
Shocks delivered appropriately to treat a ventricular arrhythmia should be noted as treatment 
delivered within the AE for the  ventricular arrythmia (s) experienced.  If shocks  are delivered 
inappropriately due to an EV ICD issue, the issue  should be reported as the underlying system related 
AE. 
Reporting of these events to Medtronic will occur on an Adverse Event eCRF, including a description of 
AE, date of onset of AE, date of awareness of site, treatment, resolution, assessment of both the 
seriousness and the relatedness to the system and/or procedure. Each AE must be recorded on a 
separate AE Form. Subject deaths are also required to be reported. Refer to section 10.[ADDRESS_1270851] 
Death collectio n and reporting requirements.  
Documented pre-existing conditions are not considered AEs unless the nature or severity of the 
condition has worsened.  Worsening may  be identified if there is a change in frequency, associated 
symptoms, or the need for new/add itional treatment  (e.g. , ventricular arrhythmias would be 
considered worsened if there are new associated  symptoms or treatment/shock is warranted) . In all 
geographies, Unavoidable Adverse Events, listed in Table [ADDRESS_1270852] (ADE) to the subject should be 
captured as an AE only.  Device deficiencies that did not lead to an AE but could have led to a Serious 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 [ADDRESS_1270853] (SADE) (i.e., if suitable action had not been taken, if intervention had not been 
made, or if the circumstances had been less fortunate) require immediate reporting.  
Examples of instances that may be considered device deficiencies in the absence of an untoward 
clinical occurrence to the subject may include, but are not limited to: 
• Damaged comp onents observed out of packaging  
• Unsuccessful EV ICD System implant and/or failed defibrillation testing  
• Pervasive/persistent sensing issues occurring outside of device testing  
• System placement outside of labeling (e.g., lead in pleural space)  
10.2.   Processing Updates and Resolution  
For any changes in status of a previously reported AE  (i.e., change in actions taken, change in outcome, 
change in relatedness), information needs to be updated on or added to the original AE form. All AEs 
must be followed until the AE  has been resolved, the subject exits the study, or until study closure, 
whichever occurs first.  
All efforts should be made to continue following subject s until all system or procedure related AEs  that 
are not resolved, as classified by [CONTACT_093], are resolved.   
At the time of study exit, all collected AEs with an outcome of “not recovered/not resolved”, 
“recovering/resolving” or “unknown” must be reviewed and updates provided as applicable.  
10.3.   Adverse Events and Device Deficiency Definitions  
For the purposes of the clinical report, Medtronic will classify each AE  according to ISO [ZIP_CODE]:2011. 
Where the definition indicates “device”, it refers to any device used in the study. This might be the 
device under investigation, or any market released c omponent of the EV ICD  System  or accessory .  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 87 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Table 12: Adverse Event and Device Deficiency definitions  
General  
Adverse Event (AE ) Any untoward medical occurrence, unintended disease or injury, or untoward clinical 
signs (including  abnormal laboratory findings) in subjects, users or other persons, 
whether or not related to the investigational medical device.  
Note: This definition includes events related to the investigational medical device or the 
comparator.  
Note: This definition i ncludes events related to the procedures involved.  
Note: For users or other persons, this definition is restricted to events related to 
investigational medical devices.  
(ISO [ZIP_CODE]:2011  section  3.2) 
Adverse Device Effect (ADE ) AE related to the use of an investigational medical device.  
Note: This definition includes AEs resulting from insufficient or inadequate instructions for use, deployment, implantation, installation, or operation, or any malfunction of the 
investigational medical device.  
Note: This de finition includes any event resulting from use error or from intentional 
misuse of the investigational medical device.  
(ISO [ZIP_CODE]:2011  section  3.1) 
Device Deficiency (DD)  Inadequacy of a medical device with respect to its identity, quality, durability, reliability, 
safety or performance.  
 Note: Device deficiencies include malfunctions, use errors , and inadequate labeling .  
(ISO [ZIP_CODE]:2011, 3.15) 
Relatedness  
Procedure Related  An adverse event that is directly related to the implantation or modification of the EV 
ICD System.  
NOTE: In general, this excludes events that are inherent to any surgical procedure (e.g., 
anesthesia complications , anticoagulation interruption ) as well as indirect subsequent 
consequences of the procedure (e.g., reaction to pain medication). 
System Related  An adverse event that results from the presence or performance of any component of 
the EV ICD System.  
 
Device Related: An adverse event that results from the presence or performance 
(intended or otherwise) of the device.  
 
Lead Related: An adverse event that results from the presence or performance 
(inte nded or otherwise) of the lead.  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 88 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Accessory Related  An adverse event that results from the  presence or performance of the EV ICD  System 
accessory. 
 
Sternal Tunneling Tool Related: An adverse event that results from the presence or 
performance (intended or otherwise) of the sternal tunneling tool. 
 
Transverse Tunneling Tool Related : An adverse event that results from the presence or 
performance (intended or otherwise) of the transverse tunneling tool.  
 
Safesheath II Related : An adverse event that results from the presence or performance 
(intended or otherwise) of the SafeSheath II.  
 
Programmer Related:  An adverse event that results from the presence or performance 
(intended or otherwise) of the programmer.  
 
Programmer Software Related : An adverse event that results from the presence or 
performance (intended or otherwise) of the programmer  software . 
 
MyCareLink Patient Monitor Related : An adverse event that results from the presence 
or performance (intended or otherwise) of the patient monitor.  
Not Related  Relationship to the device or procedures can be excluded when:  
• The event  is not a known side effect of the product category the device belongs 
to or of similar devices and procedures;  
• The event has no temporal relationship with the use of the device or the 
procedures;  
• The serious event does not follow a known response pattern to the medical device (if the response pattern is previously known) and is biologically implausible;  
• The discontinuation of medical device application or the reduction of the level of 
activation/exposure – when clinically feasible – and reintroduction of i ts use (or 
increase of the level of activation/exposure) do not impact the serious event;  
• The event involves a body -site or an organ not expected to be affected by [CONTACT_5746];  
• The serious event can be attributed to another cause (e.g., an unde rlying or 
concurrent illness/clinical condition, an effect of another device, drug, treatment, or other risk factors);  
• The event does not depend on a false result given by [CONTACT_132621] (when applicable);  
• Harm to the subject are not clearly  due to use error;  
• In order to establish the non -relatedness, not all the criteria listed above might 
be met at the same time, depending on the type of device/procedures and the event.
 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 89 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Unlikely  The relationship with the use of the device seems not relevant and/or the event can be 
reasonably explained by [CONTACT_5748], but additional information may be obtained.  
Possible  The relationship with the use of the investigational device is weak but cannot be ruled 
out completely. Alternative causes are also possible (e.g. , an underlying or concurrent 
illness/ clinical condition or/and an effect of another device, drug or treatment). Cases 
where relatedness cannot be assessed or no information has been obtained should also 
be classified as possible.  
Prob able  The relationship with the use of the investigational device seems relevant and/or the 
event cannot reasonably be explained by [CONTACT_5748], but additional information may 
be obtained.  
Causal Relationship  The event is associated with the device or study procedures beyond reasonable doubt 
when:  
• The event is a known side effect of the product category the device belongs to 
or of similar devices and procedures;  
• The event has a temporal relationship with device use/application or 
procedures;  
• The event i nvolves a body -site or organ that the device or procedures are 
applied to or the device or procedures have an effect on;  
• The serious event follows a known response pattern to the medical device (if the response pattern is previously known);  
• The discontinuation of medical device application (or reduction of the level of activation/exposure) and reintroduction of its use (or increase of the level of activation/exposure) impact on the serious event (when clinically feasible);  
• Other possible causes (e.g., an underlying or concurrent illness/clinical condition or/and an effect of another device, drug, or treatment) have been adequately ruled out;  
• Harm to the subject is due to error in use;  
• The event depends on a false result given by [CONTACT_132621]  
(when applicable);  
• In order to establish the relatedness, not all the criteria listed above might be met at the same time, depending on the type of device/procedures and the serious event.
 
 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 90 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Seriousness  
Serious Adverse Event (SAE ) 
 Adverse event that  
a) led to death,  
b) led to serious deterioration in the health of the subject, that either resulted in  
1) a life -threatening illness or injury, or  
2) a permanent impairment of a body structure or a body function, or  
3) in -patient or prolonged hospi[INVESTIGATOR_059],  or 
4) medical or surgical intervention to prevent life -threatening illness or injury 
or permanent impairment to a body structure or a body function,  
c) led to fetal distress, fetal death or a congenital abnormality or birth defect  
 
NOTE: Planned hospi[INVESTIGATOR_235099] a pre -existing condition, or a procedure required by 
[CONTACT_10396], without serious deterioration in health, is not considered a serious adverse event.  
(ISO [ZIP_CODE]:2011 , 3.37)  
Serious Adverse Event (SAE) – [LOCATION_013] 
Definition  A serious adverse event i s an event that occurs in a clinical investigation subject to 
approval or occurring in a performance evaluation which led, might have led or could lead directly or indirectly to death or serious deterioration of health of the subject, the user or a third p arty, without consideration if the event has been caused by [CONTACT_905519]; this applies accordingly to serious adverse events occurring in a clinical investigation or performance evaluation for which an exemption of the approval 
authorization as per MPG § 20 paragraph 1 sentence 2 has been granted. (MPSV § 2 
Definitions Abs 5)  
 
Serious Adverse Device Effect (SADE ) ADE that has resulted in any of the consequences characteristic of a SAE.  
(ISO [ZIP_CODE]:2011  section  3.36)  
Unanticipated Adverse Device Effect 
(UADE)  
 Any serious adverse effect on health or safety or any life -threatening problem or death 
caused by, or associated with, a device, if that effect, problem, or death, was not 
previously identified in a nature, severity, or degree of inci dence in the investigational 
plan or application (including a supplementary plan or application), or any other 
unanticipated serious problem associated with a device that relates to the rights, safety, 
or welfare of subjects. (21 CFR 812.3(s)) 
Unanticipated Serious Adverse Device 
Effect ([LOCATION_003]DE ) 
 SADE which by [CONTACT_5942], incidence, severity or outcome has not been identified in the 
current version of the risk analysis report.  
Note: Anticipated Serious Adverse Device Effect (ASADE) is an effect w hich by [CONTACT_5942], 
incidence, severity or outcome has been identified in the risk analysis report. 
(ISO [ZIP_CODE]:2011  section  3.42) 
Significant Safety Issue (SSI)  A safety issue that could adversely affect the safety of participants or materially impact 
on the continued ethical acceptability or conduct of the trial.  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 91 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Urgent Safety Measure (USM)  A measure required to be taken in order to eliminate an immediate hazard to a 
participant’s health or  safety.  
 
Note: This type of significant safety issue can be instigated by [CONTACT_905520]. 
Complication  An adverse event that includes the following is considered a complication:  
• Results in death,  
• Involves any termination  of significant device function  (i.e., defibrillation 
therapy) , or  
• Requires an invasive intervention 
Non -invasive (21 CFR 812.3(k)):  when applied to a diagnostic device or procedure, 
means one that does not by [CONTACT_180996]:  
 Penetrate or pi[INVESTIGATOR_180989], the ocular cavity, or 
the urethra, or e nter the ear beyond the external auditory canal, the nose beyond the 
nares, the mouth beyond the pharynx, the anal canal beyond the rectum, or the vagina beyond the cervical os  
  
For purposes of this part, blood sampling that involves simple venipuncture is considered non-invasive, and the use of surplus samples of body fluids or tissues that 
are left over from samples taken for non- investigational purposes is also considered 
non-invasive.  
 
Note: Only system or procedure related AEs will be classified as complication  (major, 
minor) or observation . 
Major complication  A system or procedure -related  complication which results in:  
• Death  
• Permanent loss of defibrillation function due to mechanical or electrical 
dysfunction of the device  
• Hospi[INVESTIGATOR_059]  
• Prolongation of an existing hospi[INVESTIGATOR_905355] 48 hours   
• System revision (reposition, replacement, explant)  
 
Note: Only system or procedure related AEs will be classified as complication  (major, 
minor) or observation . 
Minor complication  Any complication that is not a major complication (e.g., event classified as a 
complication solely based on intravenous drug administration) . 
 
Note : Only system or procedure related AEs will be classified as complication  (major, 
minor) or observation . 
Observation  Any adverse event that is not a complication.  
 
Note : Only system or procedure related AEs will be classified as complication  (major, 
minor) or observation . 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 [ADDRESS_1270854] -Implant P rocedure  Occurs after the completion of skin closure for  the EV ICD  implant procedure . 
Other  
Unavoidable Adverse Event  An Adverse Event inherent to a surgical procedure that is expected to occur in all 
subjects for a projected duration according to the Investigator’s opi[INVESTIGATOR_1649], including, but 
not limited to:  
Event Description  Timeframe (hours) 
from the Surgical 
Procedure 
Anesthesia related nausea / vomiting  24 
Low-grade fever ( oral temperature >98.6 °F 
(>37°C) but <100.4°F (<38.0°C)) 48 
Pocket site / Incisional pain  72 
Mild to moderate bruising / ecchymosis  168 
Sleep problems (insomnia)  72 
Back pain related to laying on table  72 
Shoulder pain/discomfort/stiffness related to 
shoulder immobilization during procedure 72 
 
Hospi[INVESTIGATOR_059]  A therapeutic inpatient hospi[INVESTIGATOR_059] (excludes observation unit, emergency room and 
outpatient visits) lasting greater than or equal to 24 hours . 
10.4.   Adverse Event and Deficiency Classification  
All adverse events and device deficiencies will be reviewed by a Medtronic representative. AEs will be 
classified according to the definitions provided in section 10.3.  
Upon receipt of AEs  at Medtronic, a Medtronic representa tive will review the adverse event/device 
deficiency for completeness and accuracy and when necessary will request clarification and/or additional information from the Investigator. Medtronic will utilize MedDRA, the Medical Dictionary for 
Regulatory Activ ities, to assign a MedDRA term for each AE  based on the information provided by [CONTACT_1275].  
Regulatory reporting of AEs and device deficiencies that could have led to a SADE will be completed 
according to local regulatory requirements. Refer to  section 14.[ADDRESS_1270855], refer to  Appendix E: Foreseeable Adverse Event List . The 
Foreseeable Adverse Event List  consists of observed adverse device effect s in similar Medtronic 
studies, adverse events reported in published literature and other s pecial considerations. An evaluation 
of potentially anticipated events, adverse device effects observed in previous clinical studies, and 
reported events in literature may be used in combination with device labeling, current event reporting 
information, and other published data to assess if an adverse event is unexpected.  
Adverse Events and Deaths will be classified according to the standard definitions as outlined in Table 
12. 
Table 13: Adverse Event classification responsibilities  
What is classified  Who classifies  Classification Parameters  
Timing of the Event  Investigator  Pre-implant  procedure , During implant  procedure, Post -
implant procedure  
Relatedness  
 Investigator  Procedure , Device, Lead, Sternal Tunneling Tool, 
Transverse Tunneling Tool, SafeSheath II, Programmer, 
Programmer Software, Patient Monitor  
Sponsor  Procedure , Device, Lead, Sternal Tunneling Tool, 
Transverse Tunneling Tool, SafeSheath II, Programmer,  
Programmer Software, Patient Monitor  
Severity  Investigator  SAE, Device Deficiency with SADE potential  
Sponsor  SAE, UADE/ [LOCATION_003]DE, Device Deficiency with SADE 
potential  
Diagnosis  Investigator  Based on presenting signs and symptoms and other 
supporting data  
Sponsor  MedDRA term assigned based on the data provided by 
[CONTACT_54437], Non -sudden Cardiac, Non -Cardiac, 
Unknown  
 
An independent Clinical Events Committee (CEC) will review and adjudicate, at a minimum, all events 
classified by [CONTACT_905521] (major, minor)  or observation classifications.  In addition, the CEC will also review and 
adjudicate all Adverse Events resulting in death.  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 94 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   When determining whether a [LOCATION_003]DE has occurred, where the sponsor’s causality assessment conflicts 
with the assessment made by [CONTACT_6962], the site investigator’s assessment cannot be 
dow ngraded by [CONTACT_456] (i.e., altered from ‘related’ to ‘not related’). In this case, if an investigator’s 
judgment triggers the reporting of a [LOCATION_003]DE, the opi[INVESTIGATOR_905422] y reporting as required.  
10.5.   Reporting of Adverse Events  
Adverse events and Device Deficiencies will be reported according to local regulatory requirements. It 
is the responsibility of the investigator to abide by [CONTACT_84204]/DD reporting requirements stipulated b y 
local law and the Ethics Committee.  Reporting requirements in Table [ADDRESS_1270856] been summarized at the 
time of CIP creation ; however, changes may occur during the course of the study. Updates may be 
provided under separate cover and it is the investigator’s responsibility to comply with current local regulatory and institutional reporting requirements.  
Refer to  section 14.[ADDRESS_1270857] of additional required investigator and Medtronic reporting 
requirements and timeframes.  
For AEs/DDs that require immediate reporting, initial reporting may be done by [CONTACT_905522]. For emergency contact [CONTACT_169280] a UADE /[LOCATION_003]DE , SAE and/or SADE, contact a clinical study r epresentative immediately (refer 
to the study contact [CONTACT_181023]’s study documents binder/investigator site file or refer to 
the contact [CONTACT_131484]).   
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 95 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Table 14: Adverse Event Reporting Requirements  
Serious Adverse Events (SAEs ) 
Investigator submit to:  
Medtronic  Australia:  Without unjustified delay.  (The National Health and Medical Research Council (NHMRC ) 
Safety monitoring and reporting in clinical trials involving therapeutic goods  November 2016 section 
C.2.b)  
Europe : To the sponsor in acceptable timely conditions, but not later than within 3 calendar days 
after investigational site study personnel’s awareness of the event , including new information in 
relation to  an already reported event (ISO [ZIP_CODE] :2011 and l ocal law)  
Japan:  Immediately (no later than 72 hours ) (Japan GCP Article 68 ) 
All geographies:  Submit per local reporting requirements  
Ethics Committee  All geographies:  Submit per local reporting requirements  
Regulatory authorities  All geographies: Submit per local reporting requirements  
Head of Medical Institution 
(HOMI)  Japan:  Immediately (Japan GCP Article 68 ) 
Sponsor submit to:  
Investigators  Japan:  Annually  (Japan GCP Article 28)  
All geographies:  Submit per local reporting requirements  
Regulatory authorities  Europe:   No later than 7 calendar days after awareness;  Report immediately, but no later than 2 
calendar days after awareness by [CONTACT_502996]/or DD that may have led to a SADE which 
indicates an imminent risk of death, serious injury, or serious illness and that requires prompt remedial action for other patients/subjects, users or other persons or a new finding to it (occurred in the study under same CIP*)  
Japan: Annually  (Enforcement Regulation  of the PMDL Article 274 - 2) 
All geographies : Submit per local reporting requirements  
Ethics Committee  All geographies:  Submit per local reporting requirements  
HOMI  Japan:  Annually  (Japan GCP Article 28)  
Serious Adverse Device Effects (SADEs)  
Investigator submit to:  
Medtronic  Australia:  Without unjustified delay.  (NHMRC Safety monitoring and reporting in clinical trials 
involving therapeutic goods  November 2016 section C.2.b)  
Canada: SADEs on the patient, the user or any other person must be reported to the regulator and to 
the Sponsor within 72 hours after it comes to the attention of the qualified investigator.  
Japan:  Immediately (no later than 72 hours)  (Japan GCP Article 68 ) 
All geographies: Submit per local reporting requirements  
Ethics Committee  All geographies: Submit  per local reporting requirements  
Regulatory authorities  Canada: SADEs on the patient, the user or any other person must be reported to the regulator and to 
the Sponsor within 72 hours after it comes to the attention of the qualified investigator.  
All geo graphies: Submit per local reporting requirements  
HOMI  Japan:  Immediately  (Japan GCP Article 68 ) 
Sponsor submit to:  
Investigators  Japan:  Annually  (Japan GCP Article 28)  
All geographies: Submit per local reporting requirements  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 96 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Regulatory authorities  Canada:  Report  within 10 days after the sponsor becomes aware.  
Japan:  [Life threatening or death ] Individual reporting  within 15 calendar days after awareness, and 
[All SADEs ] Annually (Enforcement Regulation  of the PMDL Article 274 - 2) 
Saudi Arabia:  Within 15 working days  
All geographies: Submit per local reporting requirements  
Ethics Committee  All geographies: Submit per local reporting requirements  
HOMI  Japan:  Annually  (Japan GCP Article 28)  
Unanticipated Adverse Device Effects (UADEs) and Unanticipated Serious Adverse Device Effects ([LOCATION_003]DEs)  
Investigator submit to:  
Medtronic  Canada: [LOCATION_003]DEs on the patient, the user or any other person must be reported to the regulator and 
to the Sponsor within 72 hours after it comes to the attention of the qualified investigator. 
US: An investigator shall submit to the sponsor and to the reviewing IRB a report of any UADE 
occurring during an investigation as soon as possible, but in no event later than [ADDRESS_1270858]. (21 CFR 812.150(a))  
Europe:  Immediately after the investigator learns of the event or of new information in relation to an  
already reported event. (ISO [ZIP_CODE] :2011 and local law)  
Japan:  Immediately (no later than 72 hours)  (Japan GCP Article 68 ) 
All geographies: Submit per local reporting requirements  
Regulatory Authority  Canada: [LOCATION_003]DEs on the patient, the user or any other person must be reported to the regulator and 
to the Sponsor within 72 hours after it comes to the attention of the qualified investigator. 
All geographies: Submit per local reporting requirements  
Ethics Committee  Australia:  Report [LOCATION_003]DE to their institution without undue delay and no later than 72 hours of the 
Principal Investigator [INVESTIGATOR_223305]. (NHMRC Safety monitoring and reporting in clinical trials involving therapeutic goods November 2016 section C.2.g)  
US: An investigator shall submit to the sponsor and to the reviewing IRB a report of any UADE 
occurring during an investigation as soon as possible, but in no event later than [ADDRESS_1270859]. (21 CFR 812.150(a))  
All geographies: Submit per local reporting requirements  
Institution  Australia:  Report [LOCATION_003]DE to their institution without undue delay and no later than 72 hours of the 
Principal Investigator [INVESTIGATOR_223305]. (NHMRC Safety monitoring and reporting in 
clinical trials involving therapeutic goods November 2016 section C.2.g)  
HOMI  Japan:  Immediately  (Japan GCP Article 68 ) 
Sponsor submit to:  
Investigator  US: Notification as soon as possible, but not later than [ADDRESS_1270860] . (21 CFR 812.150(b))  
Japan: Immediately (Japan GCP Article 28)  
All geographies: Submit per local reporting requirements   
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 97 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Regulatory authorities  Australia:  Fatal or life -threatening Australian [LOCATION_003]DE  – No later than 7 calendar days after being made 
aware of the case with any follow up information within a further 8 calendar days. Other Australian 
[LOCATION_003]DEs - No later than 15 calendar days after being made aware of the case.  (NHMRC Safety 
monitoring and reporting in clinical trials involving therapeutic goods November 2016 section C.1.f)  
Canada:  Report within 10 days after the sponsor becomes aware.  
Japan:  [Life -threatening or death ) Individual reporting within 7 calendar days  after awareness, [Non -
life threatening or death) Individual reporting  within 15 calendar days after awareness , and [All 
[LOCATION_003]DE] Annually .  (Enforcement Regulation of PMDL Article 274 -2) 
US: Notification as soon as possible to FDA, but not later than [ADDRESS_1270861]. (21 CFR 812.150(b) ) 
All geographies: Submit per local reporting requirements  
Ethics Committee  US: Notification as soon as possible, but not later than [ADDRESS_1270862] . (21 CFR 812.150(b))   
All geographies: Submit per local reporting requirements   
HOMI  Japan: Immediately (Japan GCP Article 28)  
Significant Safety Issue (SSI) : Sponsor reporting in Australia  
Events to Report  Reporting Requirement and Timeframe  
Significant  Safety  Issue  • Urgent Safety Measure (USMs): within 24 hours (where possible) to TGA and without undue 
delay to investigators & HREC and in any case, no later than 72 hours of the measure being taken.  
- Reasons for the urgent safety measure, Measures taken, Further actions planned 
- Reasons for the termination, Measures taken, Further actions planned  
(NHMRC Safety monitoring and reporting in clinical trials involving therapeutic goods November 
2016 section C.1.k)  
Significant  Safety  Issue 
(continued)  Submit to TGA  
• Other significant safety measures: Without undue delay and no later than 15 calendar days 
of the sponsor being aware of the issue.  
Details of significant safety issue, Further actions planned  
• Notification of an amendment: Without undue delay and no later than 15 calendar days  
Note: TGA should receive notification that a SSI has occurred but the amendment revising 
trial documentation should be submitted to the HREC only  
• Action taken with respect to safety that has been taken by [CONTACT_502997]’s regulatory 
agency (relevant to an ongoing clinical trial in Australia): Without undue delay and no later 
than 72 hours of the trial sponsor becoming aware of the action (Australian clinical trial 
handbook version 2.2)  
Significant  Safety  Issue 
(continued)  Submit to TGA, any Australian investigator  and HREC  
• Temporary halt of a trial for safety reasons: Without undue delay and no later than 15 
calendar days of the sponsor’s decision to halt the trial.  
                     Reasons for the halt, the scope of the halt, Measures taken, Further actions planned  
• Early termination of a trial for safety reasons: Without undue delay and no later than 15 calendar days of the sponsor’s decision to termination the trial.  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 98 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Significant  Safety Issue  (SSI) : Investigator Reporting in Australia  
Events to Report  Reporting Requirements and Timeframe  to submit to Sponsor, HREC and institution  
Significant Safety Issues  
 
 • Urgent Safety Measure (USMs): Within 24 hours  
(NHMRC Safety monitoring and reporting in clinical trials involving therapeutic goods November 2016 section C.2.c)  
• All other significant safety issues: without undue delay and no later than 72 hours of the principal 
investigator [INVESTIGATOR_223305]  
(NHMRC Safety  monitoring and reporting in clinical trials involving therapeutic goods November 2016 
section C.2.g)  
Device Deficiencies with SADE potential  
Investigator submit to:  
Medtronic  Australia:  Without unjustified delay.  (NHMRC Safety monitoring and reporting in clinical trials 
involving therapeutic goods  November 2016 section C.2.b)  
Canada: DDs that have resulted in any of the consequences characteristic of an SAE on the patient, 
the user or any other person or could do so were it to reoccur must be reported to the regulator and 
the Sponsor within 72 hours after it comes to the attention of the qualified investigator.  
Europe : To the sponsor in acceptable timely conditions, but not later than within 3 calendar days 
after investigational site study personnel’s awareness of the event  , including new information in 
relation to an already reported event (ISO [ZIP_CODE] :2011 and local law)  
Japan:  Immediately (no later than 72 hours)  (Japan GCP Article 68 ) 
All geographies: Submit per local reporting requirements  
Regulatory authorities  Canada: DDs that have resulted in any of the consequences characteristic of an SAE on the patient, 
the user or any other person or could do so were it to reoccur must be reported to the regulator and 
the Sponsor within 72 hours after it comes to the attention of the qualified investigator.  
All geographies: Submit per local reporting requirements  
Ethics Committee  All geographies: Submit per local reporting requirements  
HOMI  Japan:  Immediately  (Japan GCP Article 68 ) 
Sponsor submit to:  
Investigator  Japan: Immediately  per the direction of PMDA and/ or annually  (Japan GCP Article 28)  
All geographies: Submit per local reporting requirements   
Regulatory authorities  Canada:  Submit to regulatory authorities within 30 calendar days of awareness by [CONTACT_2728].  
Japan: Within 30 calendar days after awareness and annually  (Enforcement Regulation of PMDL 
Article 274 -2) 
Europe:   No later than 7 calendar days after awareness;  Report immediately, but no later than 2 
calendar days after awareness by [CONTACT_502996]/or DD that may have led to a SADE  which 
indicates an imminent risk of death, serious injury, or serious illness and that requires prompt remedial action for other patients/subjects, users or other persons or a new finding to it (occurred in the study under same CIP*)  
Saudi Arabia:  Within 15 working days  
All geographies: Submit per local reporting requirements  
Ethics Committee  All geographies: Submit per local reporting requirements   
HOMI  Japan: Immediately per the direction of PMDA and/ or annually (Japan GCP Article 28)  
All other  Adverse Events, Device Deficiencies , and n ew information that may  
adversely affect safety of the subjects or the conduct of the study  
Investigator submit to:  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 99 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Medtronic  Europe: Submit in a timely manner after the investigator first learns of the event  
All geographies: Submit per local reporting requirements   
Regulatory Authorities  All geographies: Submit per local reporting requirements   
Ethics Committee  All geographies: Submit per local reporting requirements   
Sponsor submit to:  
Investigator  All geographies:  Submit per local reporting requirements  
Regulatory authorities  All geographies: Submit per local reporting requirements   
Ethics Committee  All geographies: Submit per local reporting requirements   
 
10.6.  Subject Death  
All subject deaths must be reported by [CONTACT_905523] (AE with fatal 
outcome ) as soon as possible  after the investigator first learns of the death.  In case of death, there 
should be o ne SAE with a n outcome of fatal . 
A de-identified copy  of the death  certificate, if available  and allowed by [CONTACT_54443]/local law, should be sent  
to the Medtronic  clinical  study  team.  When  a death  occurs  in a hospi[INVESTIGATOR_307], a copy  of the death summary  
report and all relevant  hospi[INVESTIGATOR_905423],  if available.  If an autopsy  is 
conducted, the autopsy  report should  also be sent to  Medtronic  if available  and allowed by [CONTACT_54443]/local  
law. When  the death  occurs  at a remote  site, it is the investigative site’s responsibility to attempt 
retrieval of information about  the death.  In summary,  the following data  will be collected: 
• Date  of death  
• Detailed  description of death  
• Cause  of death 
• Relatedness  to system and/or procedure 
• Device interrogation  (if available)  
• Death  summary/hospi[INVESTIGATOR_20112]  (if available  and allowed  by [CONTACT_54443]/local  law)  
• Autopsy  report (if available  and allowed  by [CONTACT_54443]/local  law) 
• Death  certificate  (if available and/or  allowed by [CONTACT_54443]/local law) 
10.7.   Death  Classification and Reporting  
Sufficient  information will be required  in order  to properly  classify the subject’s  death.  The Investigator  
shall  classify  each subject death  per the following  definitions:  
Cardiac  Death: A death directly  related  to the electrical or mechanical  dysfunction  of the heart.  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 100 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   • Sudden Cardiac  Death  (SCD) : Natural  death  due to cardiac  causes, indicated by [CONTACT_905524]; preexisting heart  disease  may  
have  been  known to be present,  but the time  and mode of death  are unexpected. If  time  of 
onset cannot be determined, SCD will alternatively be defined as any unexpected  cardiac  death  
occurring out of the hospi[INVESTIGATOR_905424].  
• Non-sudden  Cardiac Death : All cardiac  deaths  that are not classified as sudden  deaths,  
including all cardiac  deaths  of hospi[INVESTIGATOR_905425].  
Non-cardiac  Death : A death not classified  as a cardiac  death.  
Unknown Cardiac  Classification : Unknown death  classification  is intended for use only  when  there  is 
insufficient or inadequate  information  to classify the death.  
The Clinical Events Committee will also review all deaths and provide an adjudication of the death 
classification. See section 11.[ADDRESS_1270863] complaints is not part of the EV ICD Pi[INVESTIGATOR_905426]/DD reporting requirements.  It is the responsibility of the investigator to report all 
product complaints  associated with a medical device distributed by [CONTACT_13735], regardless of whether 
they are related to intended use, misuse or abuse of the product. Reporting must be done immediately 
and via the regular channels for market- released products.   
Product Complaint:  any written, electronic or oral communication that alleges deficiencies related to 
the identity, quality, durability, reliability, safety, effectiveness or performance of a medical device that has been placed on the market.  
11. Data Review Committees  
11.1.   Clinical Events Committee  
The stud y will utilize a n independent Clinical Events Committee (CEC). At regular intervals, an 
independent CEC will  review events and adjudicate at a minimum all system and procedure -related 
events. Additionally, the  CEC will provide an adjudication of the death classification for all reported 
deaths.  
The CEC will consist of a minimum of three (3) non -Medtronic -employed physicians whose site is not  
participating in the study, including a CEC chairperson.  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 101 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Medtronic personnel may facilitate and participate in CEC meetings but will be non -voting members.  
For AEs and deaths reviewed by [CONTACT_15741], Medtronic will provide the CEC with the Investigator’s  
description and supportive documentation (when available). The CEC is responsible for reviewing the 
Investigator’s description and supportive documentation (when available), reviewing applicable 
definitions, and determining final classifications for all adjudication parameters. For AEs,  classification 
includes system/procedure relatedness and complication (major, minor ) or observation. Additionally, 
the CEC will provide an adjudication for all reported deaths, including system/procedure relatedness 
and cardiac relatedness. 
If the CEC disagrees with the investigator’s classification of the event, the difference will be provided to  
the investigator. If the investigator agrees with the CEC’s adjudication, the e CRF documenting the AE 
will be updated accordingly. 
If the investigator does not agree with the CEC’s adjudication classification, both determinations will be  
provided within the final report; however , the CEC’s adjudication will be used for data analysis. The  
disagreement will also be included in reporting to ethics committees and regulatory authorities, if  
required. 
11.2.   Data Monitoring Committee  
An independent Data Moni toring Committee will be established by [CONTACT_905525] , and make 
recommendations to Medtronic and/or the Steering Committee regarding study conduct and subject 
safety . The DMC for this study will consist of a minimum of three and up to seven non -Medtronic 
members with study related backgrounds  and not from sites participating in the study . Medtronic will 
appoint members of the Committee and the Chairperson. Up to two additional investigators 
participating in this study may participate in the meetings to offer clarification of events, but none will be given voting privileges. Medtronic personnel may facilitate the DMC meeting (e.g., study manager, 
statistician), but they will not be voting members.  
 
A quorum of the committee may review interim analys es in which the results are analyzed against the 
primary objective. A summary of adverse events will be reviewed at this time also. Review and consensus by [CONTACT_905526].   
The DMC Member list will be under a separate cover and available  upon request . 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 102 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   11.3.  Epi[INVESTIGATOR_905427] (ERC) will be established to evaluate device -treated ventricular epi[INVESTIGATOR_905428]. Committee membership, meeting frequency, roles and responsibilities 
and procedures will also be described in the ERC C harter. Device- treated ventricular epi[INVESTIGATOR_905429] (shocks and ATP) delivered to subjects  and success of the therapy. Inappropriate therapy will 
be identified based on adjudication rhythm truth and  device epi[INVESTIGATOR_905430].  
This committee may include independent physicians and /or Medtronic personnel. The ERC Member list 
will be under a separate cover and available  upon request.  
12. Statistical Design and Methods  
12.1.   General C onsiderations   
Data analysis will be performed by a Medtroni c statistician or designee. 
The cohort will include all enrolled subjects who undergo the study procedures  unless the subject does 
not complete the required testing , and there are no pre-specified subgroups for assessment . For 
endpoints involving only measurements collected at follow -up visits, only subjects who complete those 
visits will be included in the analysis of those endpoints. 
Any tests of treatment effects will be conducted at a two -sided alpha level of  0.[ADDRESS_1270864] completed their 3 Month follow -up visit. This 
analysis will include characterizing both defibrillation efficacy a t implant and incidence of major EV ICD 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 103 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   System/procedure-related complications  through at least 3 months . All subjects will continue to be 
followed and the timeline for other marketing applications will not be impacted by [CONTACT_273528].  
12.3.   Sample Size   
There  are two primary objectives (safety and efficacy), and each objective requires 292 subjects to, in 
the case of the safety objective, undergo an implant attempt of the EV ICD System, and in the case of 
the efficacy objective, complete  the pre -specified defibrillation testing protocol (see section  8.5.7 for 
details).  Since the defibrillation protocol may not be initiated until an implant attempt occurs, the 
overall sample size requirement will be derived from the efficacy objective; at least 292 subjects will 
undergo the  defibrillation testing protocol, which may result in more than 292 subjects undergoing an 
implant attempt to satisfy this requirement .  To further account for subjects who enroll in the study but 
exit prior to an implant attempt (19% of 26 enrolled subjects in the EV ICD Pi[INVESTIGATOR_905431]), up to 400 subjects may be enrolled.   
 Primary Objective #1: Safety  
An Objective Performance Criterion (OPC) of 79% was chosen based on prior precedent to evaluat e the 
primary safety objective metric of the EV ICD System/procedure-related major complication- free rate 
at 6 months.  The estimated EV ICD System/procedure-related major complication -free rate s through 6 
months are provided in Figure 9 . They  are modeled using a Weibull distribution assuming a rate of 90% 
at one month and 86% at 6 months.  A solid line denoting the Objective Performance criterion o f 79% is 
also provided.  It is also assumed that attrition (exit or death) will follow a Weibull distribution, with an attrition rate of 9% at one month (allowing for unsuccessful implants) and 16% through one-year post -
implant.   
The trial was simulated 1 0,000 times. Each time a sample size of 292 subjects had a time to safety 
endpoint simulated and a time to attrition simulated using the assumptions  above. Using  these data, a 
lower confidence bound for the 6 -month Kaplan -Meier freedom from safety endpoint rate was 
generated using the log scale for each simulation of the trial . It was determined that based on  these  
assumptions and the requirements of a false positive ra te (alpha)  controlled at  2.5%, a sample size of 
292 subjects undergoing an implant attempt is required to allow for 90% power of assessing this objective. 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 104 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Figure 9 : Estimated Freedom from System/Procedure -related Major Complication s 
 
 
 Primary Objective #2 : Efficacy  
An OPC of 88 % was chosen to evaluate the primary efficacy  objective metric of implant testing success 
defined as successfully terminating one or more induced ventricular fibrillation epi[INVESTIGATOR_1841] (see sections 
8.5.7  and 12.5.2 for more details).  E ach subject who completes  the defibrillation protocol will be 
counted as a success or failure; it is assumed the true success rate is 93.5%. The required sample size to evaluate this objective using a two -sided exact binomial 95% confidence bound and OPC o f 88% with 
90% power is 292 subjects completing  the defibrillation protocol.  
12.4.   Primary Objective #1 : Safety  
Demonstrate  the freedom from major complications related to the EV  ICD System and/or procedure at 
[ADDRESS_1270865] -implant  exceeds an OPC of 79%.  

 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 105 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   
 Hypothesis 
The hypotheses for this objective  are as follows, with π6 denoting the 6-month  freedom from major EV 
ICD System/procedure-related complications  rate: 
 
HO: π6 ≤ 0.79  
HA: π6 > 0.[ADDRESS_1270866]’s first occurrence of a major complication related to the EV ICD System and/or procedure as determined by [CONTACT_905527] (CEC) that occurs on or prior to 
6 months ( 182 days) post -implant.  
For an adverse event to meet the endpoint , the event must have occurred within 182 days (inclusive) 
of the EV ICD System implant  attempt  and be adjudicated by [CONTACT_905481] a major complication 
related to the EV ICD System and/or procedure. Major complications are those complications  resulting 
in: 
• Death  
• Permanent loss of defibrillation function due to mechanical or electrical dysfunction of the 
device  
• Hospi[INVESTIGATOR_059] (see Table 12 for Hospi[INVESTIGATOR_857248])  
• Prolong ation of an existing  hospi[INVESTIGATOR_905355] 48 hours  
• System revision (reposition, replacement, explant ) 
The pre-specified OPC  for the major complication free rate at 6 months is 0.79, meaning the 95% lower 
confidence bound for the freedom from EV ICD major complication incidence rate must exceed 0.79.  
 Rationale for Performance Criteria  
The determination of the pre-specified OPC  (79%) for the major complication objective was based on 
review of internal Medtronic transvenous ICD trial data as well as literature involving alternative 
devices.  An assessment of comparable major complication-free rates at 6 months for Medtronic 
transvenous devices showed observed rates as low as 85%  (Figure 10).  In each such  study , only ICD 
subjects with no history of CABG or valve surgery were analyzed, as that subset of subjects was 
considered representative of the possible EV ICD population.   
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 106 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Figure 10: Historical ICD Generator/RV  Lead/Procedure -related Major Complication -free Rates 
 
*SCD -HeFT rates may include major and minor complications 
 
The following table provides further detail regarding these trials.  

 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 107 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Table 15: Historical Medtronic Transvenous ICD Trial  Major System/Procedure Complication- free Rates  
Study  Study Description  30-day Freedom 
Rate (95% CI)  6-Month 
Freedom Rate 
(95% CI)  
Marquis VRxvii Medtronic Market Release Study Evaluating 
Marquis VR ICD 90.2%  
(79.8%, 96.3%)  N/A, subjects 
not followed to 
6 months  
SCD-HeFTxviii Randomized  study comparing ICD therapy to 
placebo  89.8% * 
(87.1%, 92.0%)  88.5% * 
(85.6%, 90.8%)  
MVPxix Post -market study comparing MVP to VVI pacing 
in ICD population without pacing indication  95.4%  
(93.5%, 96.8%)  93.2%  
(91.0%, 94.9%)  
BLOCK HFxx IDE (G030156) study comparing efficacy of CRT to 
RV pacing in AV block patients  89.3%  
(83.8%, 95.2%)  85.3%  
(79.0%, 92.3%)  
REVERSExxi IDE (G040004) study comparing efficacy of CRT  to 
ICD/OMT therapy in NYHA II patients  92.6%  
(88.2%, 95.4%)  89.4%  
(84.5%, 92.8%)  
Evera MRIxxii IDE (G140039) study evaluating safety and 
efficacy of the Medtronic Evera MRI ICD System  94.6%  
(90.5%, 97.0%)  93.1%  
(88.6%, 95.8%)  
PainFREE SSTxxiii Randomized study  to evaluate the Medtronic 
Protecta ICD System  96.7%  
(93.5%, 98.3%)  93.8%  
(89.9%, 96.2%)  
*Included both major and minor complications  
 
                                                            
xvii Data on file. 
xviii Bardy G, et al.  Amiodarone or an Implantable Cardioverter -Defibrillator for Congestive Heart Failure.  NEJM. 2005; 352:3: 
225-237.  
xix Sweeney M, et al.  Atrial pacing or ventricular backup -only pacing in implantable cardioverter -defibrillator patients.  Heart 
Rhythm .  2010; 7(11); 1552-1560. 
xx Curtis A, et al.  Biventricular Pacing for Atrioventricular Block and Systolic Dysfunction.  N EJM.  2013; 368:17: 1585-1593. 
xxi Linde C, et al.  Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in 
asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms.  JACC .  2008; 52(23): 1834-1843. 
xxii Gold MR, et al.  Full -Body MRI in Patients With an Implantable Cardioverter -Defibrillator: Primary Results of the 
Randomized Study .  JACC .  2015; 65(24):2581-2588. 
xxiii Auricchio A, et al.  Low inappropriate shock rates in patients with si ngle - and dual/triple- chamber implantable 
cardioverter- defibrillators using a novel suite of detection algorithms; PainFree SST trial primary results.  Heart Rhythm.   2015; 
12(5):926-936. 
 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 108 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Additionally, the OPC threshold of 79% has been used to evaluate only system-related complications in 
a pi[INVESTIGATOR_905432], and so there is precedent for 79% 
being considered an acceptable criterion for evaluating safety at 6 months for defibrillation products. 
In that S-ICD  study the observed 6-month freedom from system -related or procedure-related 
complications was 92.1% with a lower confidence limit of 88.9%.  A pooled analysis of the S -ICD IDE and 
EFFORTLESS Post Market S -ICD Registryxxv reported that 92.3% of subjects were free of a system or 
procedure -related complication through [ADDRESS_1270867].  The 182 -day freedom from 
major complication rate will be generated using the Kaplan -Meier method, along with a two -sided 95% 
confidence bound.  If the lower bound is at least 0.79  (79%) , the objective will be considered met.   
 Determinatio n of Subjects /Data for Analysis  
All subjects with  an implant attempt of the investigational product will be included in the analysis . 
12.5.   Primary Objective #2 : Efficacy   
Demonstrate  the EV ICD defibrillation testing success rate at implant  is greater than an OPC of 88%.  
 Hypothesis 
The hypotheses for this objective  are as follows, with P I denoting the probability of EV ICD defibrillation 
success at implant:  
 H
O: PI ≤ 0.88  
HA: PI > 0.88  
                                                            
xxiv Weiss R, et al.  Safety and Efficacy of a Totally Subcutaneous Imp lantable -Cardioverter Defibrillator.  Circulation .  2013; 
128: 944-953.  
xxv Burke M, et a.  Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2 -Year Results From a Pooled Analysis of the IDE 
Study and EFFORTLESS Registry.  JACC (Apri l 2015); 65 (16).    
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 109 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   
  Performance Requirements  
Performance requirements for this objective  define both the endpoint and the OPC. The endpoint, 
defibrillation testing success , is defined as: 
• Single SSVA  conversion at 20J, or  
• Conversion of two consecutive  epi[INVESTIGATOR_905347] 30J in final system configuration.  
Notes:  
• In one of the two consecutive  SSVA epi[INVESTIGATOR_1841], up to two 30J shocks are permitted . 
• To achieve final system configuration, changing the position of the ICD generator and/or the lead or changing shock polarity is permitted . 
• Subjects can return for testing on another day if testing is not fully completed on  the day of 
implant.  
The pre-specified OPC  for this objective is 0.88 (88%) , meaning the 95% lower confidence bound for the 
proportion of EV ICD pts who achieve defibrillation testing success at implant must exceed 0.88.    
 Rationale for Performance Criteria 
Defibrillation implant success for transvenous devices , though no longer routine ly performed, has 
historically been shown to be as low as 88%  (Table 16). A literature search combined with prior 
Medtronic trial data showed transvenous defibrillation testing rates commonly in the 90 -93% range, 
which is in line with the hypothesized defibr illation efficacy of EV ICD .   
Table 16: Historical Transvenous ICD Defibrillation Testing Success Rates  
Reference  Sample Size  Defibrillation 
Implant 
Success  
Medtronic 6932 Lead Study  
(MDL #[ZIP_CODE] , Data on file ) N=165 Model 6932 leads  
N=166 Model 6936 leads  87.7%  
83.5% 
Medtronic 6944 Lead Study  
(MDL #[ZIP_CODE] , Data on file ) N=112 Model 6944 leads  
N=122 Model 6942 leads  91.1%  
91.8% 
Leong -Sit AMJ: 2006; 152:1104 -8 N=168  90.5%  
Pi[INVESTIGATOR_905433] 2006; 17:1 -6 DFT at implant (N=129)  
Safety Margin Testing at Implant (N=503)  
No Testing at Implant (N=203)  77%  
93% 
N/A 
Michowitz Europace 2011; 13:683 -88 N=204  91.7%  
SIMPLE Study Lancet 2015; 385:785 -91 Safety Margin Testing at Implant (N=1218)  91.8%  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 110 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Reference  Sample Size  Defibrillation 
Implant 
Success  
No Testing at Implant (N=1227)  N/A 
 
The OPC threshold of 88% has also been used in a pi[INVESTIGATOR_905434]  (S-
ICD) , so there is precedent for an OPC of 88% being consider ed an acceptable criterion for evaluating 
termination of induced ventricular rhythms at implant . The S -ICD litera ture shows acute defibrillation 
testing results less than 93% when testing at 65J (applying a 15J safety margin).    
 Defibrillation results in the post market  setting support the belief of S-ICD efficacy being 91-94%.  The 
first results from the EFFORTLESS Study
xxvi provided a report on the full patient cohort and study 
endpoint with follow -up ≥[ADDRESS_1270868], with 777 of these tests (91.6%) using a defibrillation energy of ≤65 J, which allows for a safety margin .
 
In a retrospective analysis, Friedman et alxxvii reported on trends and in -hospi[INVESTIGATOR_905435] S-ICD compared to single- and dual -chamber transvenous ICD implants. 
Table 17 provides in- hospi[INVESTIGATOR_905436] S-ICD implants.  Among 2791 patients with 
S-ICD who underwent DFT testing, 2588 (92.7%), 2629 (94.2%), 2635 (94.4%), and 2784 (99.7%) were successfully defibrillated ( ≤65, ≤70, ≤75, and  ≤80 J, respectively). The 92.7% defibrillation efficacy at 65J 
is the best comparator , as it offers a 15J safety margin.  
 Additionally, there have been other studies and sub -analyses that have reported on the defibrillation 
threshold testing performance of the S -ICD device.  Frankel DS et al
xxviii evaluated 65J first shock success 
in acute DFT testing in the S-ICD IDE trial among subgroups define by [CONTACT_44207], while Peddareddy L et alxxix 
reported acute DFT testing results at their site only .  These studies show evidence of defibrillation 
                                                            
xxvi    Boersma L, et al.  Implant and Midterm Outcomes of the Subcutaneous Implantable Cardioverter -Defibrillator Registry – The 
EFFORTLESS Study.  JACC (August 2017); 70(7): 830 -841.  
xxvii     Friedman D, et al.  Trends and In- Hospi[INVESTIGATOR_905437].  JAMA Cardiol (November 2016); 1(8): 900- 911. 
xxviii      Frankel DS et al.  Impact of Body Mass Index on Safety a nd Efficacy of the Subcutaneous Implantable Cardioverter -Defibrillator.  JACC:  
Clinical Electrophysiology (May 2018): 4(5): [ADDRESS_1270869] of Defibrillation Threshold Testing on Effectiveness of the Subcutaneous Implantable Car dioverter 
Defibrillator.  Pacing Clin Electrophysiol (PACE) June 12 2018. doi: 10.1111/pace.[ZIP_CODE] [epub]  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 111 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   testing performance of less than the OPC  of 88% in subgroups of patients, further justifying the clinical 
relevance of such a threshold. 
Table 17: S -ICD EFFORTLESS Defibrillation Testing Results  
Final Conversion Result  Without 
Repositioning  With 
Repositioning  Total  
EFFORTLESS  Trial Results  (N=861)     
   Success ≤ 65J (15J Safety Margin)  777 (90.2%)  12 (1.4%)  789 (91.6%)  
   Success at 70 -80J (0 -10J Safety Margin)  36 (4.2%)  2 (0.2%)  38 (4.4%)  
   Success at Unknown Energy  29 (3.4%)  1 (0.1%)  30 (3.5%)  
   Summary of Success Conversion  842 (97.8%)  15 (1.7%)  857 (99.5%)  
Friedman et al Retrospective Analysis (N=2791)     
   Success ≤ 65J (15J Safety Margin)  N/A N/A 2588 (92.7%)  
   Success ≤ 70J (10J Safety Margin)  N/A N/A 2629 (94.2%)  
   Success ≤ 75J (5J Safety Margin)  N/A N/A 2635 (94.4%)  
   Success ≤ 80J  N/A N/A 2784 (99.7%)  
Frankel DS et al  Assessment of S -ICD IDE by [CONTACT_44207] 
(Evaluating 65J First Shock Success)     
   BMI < 25.0 kg/m2 (N=79)  N/A N/A 75 (94.9%)  
   BMI 25.0 -29.9 kg/m2 (N=105)  N/A N/A 91 (86.7%)  
   BMI ≥ 30.0 kg/m2 (N=137)  N/A N/A 114 (83.2%)  
Peddareddy L et al Single Site DFT Success (N=135)  N/A N/A 113 (83.7%)  
 Analysis Methods 
Results will be summarized in aggregate using descriptive statistics. Subjects will be partitioned by [CONTACT_905528] (e.g. , no rescue shocks required, one rescue shock required), with 
counts and percentage falling into each subgroup reported . Each subject who  completes the 
defibrillation protocol will be determined to either have successfully met the defibrillation endpoint or  
not met the endpoint. A 95% two -sided binomial confidence interval for the proportion of subjects who 
met the endpoint will be generated. If the lower bound exceeds  0.88, the objective will be met.   
Subjects who do not complete the defibrillation protocol will be reported separately and will not be 
included in the calculation of the 95% confidence interval. 
 Determination of Subjects /Data for Analysis  
All subjects who complete the defibrillation protocol  will be included in the analysis . 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 112 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   12.6.   Ancillary Objective #[ADDRESS_1270870] to sensing 
ventricular arrhythmias and delivering shocks when the epi[INVESTIGATOR_905438]-terminate or is not 
terminated by [CONTACT_533950] . There are no pre-specified performance criteria.  
 Analysis Methods 
Results will be summarized in aggregate using descriptive statistics. All shocks delivered by [CONTACT_905529] a VT/VF epi[INVESTIGATOR_1865], 
and by [CONTACT_905530][INVESTIGATOR_1865]. Both the number of epi[INVESTIGATOR_905439] , as well as the  energy delivered.  Kaplan -Meier curves for 
time to first appropriate shock and time to first inappropriate shock may be provided to demonstrate shock incidence.  
 Determination of Subjects /Data for Analysis  
All subjects successfully implanted with an EV ICD having at least one device interrogation post -implant 
will be included in the analysis . At minimum, all epi[INVESTIGATOR_905440]  [ADDRESS_1270871] -implant will be included.  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 113 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   12.7.   Ancillary Objective # 2 
Characterize electrical performance (pacing capture thresholds, pacing impedance, sensing amplitudes) 
over time. 
 Hypothesis 
There are no hypotheses for this objective. Pacing capture performance, as well as pacing impedance 
and sensing amplitudes, will be summarized.  
  Performance Requirements  
Performance requirements are not pre-specified for this objective.  The endpoint s are  defined as  pacing 
capture threshold, pacing impedance, and sensing amplitude. The pacing testing will be performed at 
pre-hospi[INVESTIGATOR_2345], as well as visits at [ADDRESS_1270872] amplitudes will also be reported at each follow -up 
for which the testing occurs (pre -hospi[INVESTIGATOR_2345], [ADDRESS_1270873] -implant , and every 
6 months thereafter ). 
 Determination of Subjects /Data for Analysis  
All subjects successfully implanted with an EV ICD having relevant data ( pacing tests , impedance, 
sensing amplitudes)  will be included in the analysis  of that endpoint at that timepoint. 
12.8.   Ancillary Objective #3   
Charac terize extracardiac pacing sensation . 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 114 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   
 Hypothesis 
There are no hypotheses for this objective.  
  Performance Requirements  
Performance requirements are not pre-specified for this objective. The endpoint will be defined as  
whether pacing therapi[INVESTIGATOR_905441].  
 Rationale for Performance Criteria  
There are no pre-specified performance criteria ; pacing sensation at follow -up will be summarized and 
reported. 
 Analysis Methods 
Results will be summarized in aggregate using descriptive statistics. Descriptive statistics will be used to 
summarize distribution among the subjects who completed each follow-up visit, and whether pacing 
therapi[INVESTIGATOR_014], specifically ATP, were programmed OFF due to the subject reporting pacing sensation.  This 
objective will be analyzed using data from the pre-hospi[INVESTIGATOR_2345], 2 weeks, 3- and 6 -month , and 
long-term  visits. 
 Determination of Subjects /Data for Analysis  
For each visit (e.g., PHD, 2 weeks), all subjects successfully implanted with an EV ICD  who complete 
that visit will be included in the analysis .     
12.9.   Ancillary Objective #[ADDRESS_1270874] received.  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 115 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   
 Rationale for Performance Criteria  
This objective is for the purpose of characterizing  prevalence of need for asystole pacing in this 
population . There are no pre -specified performance criteria.  
 Analysis Methods 
Descriptive statistics will be used to summarize the number of subjects and amount of asystole pacing 
experienced during follow -up.   
 Determination of Subjects /Data for Analysis  
All subjects successfully implanted with an EV ICD with at least one device interrogation post -implant 
will be eligible for  the analysis. At minimum, all instances occurring on or before the date at which all 
implanted subjects have had the opportunity to be followed  for [ADDRESS_1270875] -implant will be 
included.  
12.10.  Ancillary  Objective # 5 
Summarize ATP performance with  spontaneous arrhythmias . 
 Hypothesis 
There are no hypotheses for this objective, as the purpose is to characterize defibrillation performance 
through use of ATP .  
  Performance Requirements  
Performance requirements are not pre-specified for this objective.  The endpoint is defined as whether 
a spontaneous ventricular tachycardia epi[INVESTIGATOR_905442]. Spontaneous arrhythmias will be adjudicated to determine the underlying rhythm  
and whether they were terminated by [CONTACT_533950] .  
 Rationale for Performance Criteria  
It is projected that only a small subset of implanted subjects may experience one or more ventricular arrhythmias during follow -up. Therefore, device performance regarding such epi[INVESTIGATOR_905443].  There are no pre-specified performance cr iteria.  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 116 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   
 Analysis Methods 
Results will be summarized in aggregate using descriptive statistics. All monomorphic and polymorphic 
ventricular arrhythmias with EGM will be partitioned by [CONTACT_905531]/or shock , whether it successf ully terminated as a result, and by [CONTACT_905530][INVESTIGATOR_1865] 
(monomorphic vs. polymorphic VT/VF ). Both the number of epi[INVESTIGATOR_905444]. A 95% confidence interval will be provided for t he 
percentage of monomorphic VT epi[INVESTIGATOR_905445].  
 Determination of Subjects /Data for Analysis  
All subjects successfully implanted with an EV ICD having at least one device interrogation post -implant 
will be included in the analysis . At minimum, all VT/VF  epi[INVESTIGATOR_905446] [ADDRESS_1270876]-implant will be 
included in the analysis.  
12.11.  Ancillary  Objective # 6 
Summarize adverse events . 
 Hypothesis 
There are no hypotheses for this objective, as safety of the EV ICD System is being evaluated by [CONTACT_905532] #1 (see section 12.4).   This objective is to provide a comprehensive summary of adverse 
events experienced during follow -up.  
 Performance Requirements  
Performance requirements are not pre-specified for this objective. The endpoint is an adverse event 
(see Table 12 for definition of adverse event) experienced by a subject post -enrollment and prior to 
exit. Adverse events will be adjudicated by a Clinical Events  Committee for relatedness to the EV ICD 
System and procedure.  
 Rationale for Performance Criteria  
This objective is for the purpose of gathering comprehensive data pertaining to subject health over at 
least the first six months post -implant . There are no pre-specified performance criteria.  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 117 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   
 Analysis Methods 
Results will be summarized in aggregate using descriptive statistics. Counts and percentages of subjects 
experiencing system and/or procedure-related adverse events will be reported, as well as, in the case 
of system -related events, the specific component of the system to which the event was related.  
Adverse Events will be broken out by [CONTACT_905533], with both counts of events and counts of 
subjects experiencing each type of event reported.  
 Determination of Subjects /Data for Analysis  
All subjects for whom an implant of the investigational product is attempted will be included in the analysis. At minimum, all adverse events recorded by [CONTACT_905534] [ADDRESS_1270877] -implant will be included.
 
12.12.  Ancillary  Objective # [ADDRESS_1270878] 0.88 .  The endpoint, d efibrillation testing success , is defined as  
successful completion of the chronic defibrillation testing protocol  at the 6-month visit. 
 Sample Size 
Consecutive subjects at centers that agree with and obtain approval from their EC and associated 
regulatory authority if applicable will be approached for consent to undergo chronic defibrillation 
testing (see CIP Addendum for 6 -Month Defibrillation Testing) until a  minimum of [ADDRESS_1270879] .  
Therefore, this trial will gather minimal chronic defibrillation testing data to assess efficacy of the EV 
ICD System in a chronic defib testing, as defined by [CONTACT_905535] 0.88.    
 Analysis Methods 
Results will be summarized in aggregate using descriptive statistics.  Subjects will be partitioned by [CONTACT_905528] (e.g., no rescue shocks required, one rescue shock required), wi th 
counts and percentage falling into each subgroup reported.  As supplemental data of chronic 
performance, if spontaneous VF epi[INVESTIGATOR_49634] a shock by [CONTACT_905536] [ADDRESS_1270880] -implant are available, they will be summarized separately.  Additionally, subjects 
who do not consent to chronic defibrillation testing but who undergo chronic defibrillation testing at 6 -
month or later follow -up per physician discretion will be analyzed separately.  
 Determination of Subjects /Data for Analysis  
All subjects for whom defibrillation testing is attempted at [ADDRESS_1270881] -implant will be included in 
the analysis . 
12.13.  Supplemental Analysis  
Quality of Life/patient acceptance  will also be measured through the SF -[ADDRESS_1270882] response in this 
study may  be compared to response to such tools in other ICD studies.  
13. Ethics  
13.1.   Statement(s) of Compliance  
The study will be conducted according to the Declaration of Helsinki, CIP , Good Clinical Practice (GCP) 
and in accordance to the national and local laws, regulations, standards, and requirements of the countries/geographies in which the study is conducted. The principles of the Declaration of Helsinki are 
implemented in this study by [CONTACT_905537], Ethics Committee approval, study 
trainin g, clinical trial registration, and risk benefit assessment.  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 [ADDRESS_1270883] been received. Any additional requirements 
imposed by [CONTACT_905538], if appropriate.  
This EV ICD Pi[INVESTIGATOR_905447], known as good clinical practice (GCP). GCP includes review and approval by [CONTACT_905539] a study, continuing review of an ongoing study by [CONTACT_871568], and obtaining and documenting the freely given I nformed Consent of a subject before 
initiatin g the study.  
The EV ICD Pi[INVESTIGATOR_905448] [ZIP_CODE]:[ADDRESS_1270884] and credibility of the clinical 
investigation and the definition of responsibilities of the sponsor and investigators. In accordance with ISO [ZIP_CODE]:2011, the sponsor shall avoid improper influence on, or inducement of, the subject, monitor, any investigator(s) or other parties participating in, or contributing to, the clinical investigation. All 
investigators shall avoid improper influence on or inducement of the subject, sponsor, monitor, other 
investigator(s) or other parties participating in or contributing to the clinical investigation.  Adverse 
Event and Device Deficiency handling in the EV ICD Pi[INVESTIGATOR_905449] [ZIP_CODE]:2011 compliant for all 
participating geographies.  
Ultimately, all sites in all geographies will follow and comply with:  
• The Clinical Trial Agreement  
• The procedures described within this CIP  
• Local Ethics C ommittee Requirements  
In addition to the  requirements outlined above, the study will be conducted according to federal, 
national and local laws, regulations, standards, and requirements of the countries/geographies where the study is being conducted. These include but are not limited to  the following :  
• In Australia and New Zealand: local laws will be complied with and below will be followed:  
• Princi ples of Declaration of Helsinki and all of its subsequent amendments, including 
the latest version 2013  
• ISO [ZIP_CODE]:2011 
• 21 CFR Part 11: Electronic Records, Electronic Signatures  
• 21 CFR Part 54: Financial Disclosure by [CONTACT_6230]  
• In Canada  below will be followed: 
• SOR/98 -282, Section 59-88  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 120 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   • Principles of Declaration of Helsinki and all of its subsequent amendments, including 
the latest version 2013  
• 21 CFR Part 11: Electronic Records, Electronic Signatures  
• 21 CFR Part 54: Financial Disclosure by [CONTACT_6230]  
• In Europe, Middle East, Africa, the study will be conducted in compliance with : 
• ISO [ZIP_CODE]:2011  
• Active Implantable  Medical Device Directive ( AIMDD)  
• Principles of Declaration of Helsinki and all of its subsequent amendments, including 
the latest version 2013  
• 21 CFR Part 11: Electronic Records, Electronic Signatures  
• 21 CFR Part 54: Financial Disclosure by [CONTACT_6230]  
• In Hong Kong , the study will be conducted in compliance with:  
• ISO [ZIP_CODE]:2011 
• Principles of Declaration of Helsinki and all of its subsequent amendments, including 
the latest version 2013  
• 21 CFR Part 11: Electronic Records, Electronic Signatures  
• 21 CFR Part 54: Financial Disclosure by [CONTACT_6230]  
• In Japan, the study will be conducted in compliance wi th: 
• Ministerial Ordinance Concerning Good Clinical Practice for Medical Devices (The 
Ministry of Health, Labour and Welfare (MHLW) Ministerial Ordinance No.[ADDRESS_1270885] 2017)  
• 21 CFR Part 11: Electronic Records, Electronic Signatures  
• 21 CFR Part 54: Financial Disclosure by [CONTACT_6230]  
• Principles of Declaration of Helsinki and all of its subsequent amendments, including 
the latest version 2013  
• In the [LOCATION_002], the study will be conducted under an FDA Investigational Device Exemption 
(IDE) in compliance with : 
• 21 CFR Part 11: Electronic Records, Electronic Signatures  
• 21 CFR Part 50: Protection of Human Subjects  
• 21 CFR Part 54: Financial Disclosure by [CONTACT_6230]  
• 21 CFR Part 56: Institutional Review Boards  
• 21 CFR Part 812: Investigational Device Exemptions  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 121 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   • Principles of Declaration of Helsinki and all of its subsequent amendments, including 
the latest version [ADDRESS_1270886] (FDAAA ) and Declaration of Helsinki on http://clinicaltrials.gov (PL 110 -
85, section 810(a)). In addition, the study may be registered in local regulatory databases where 
required by [CONTACT_1769].  
Approval of the CIP and CIP am endments , if applicable, is required from the following groups prior to 
any study procedures at a study site:  
• Medtronic  
• Principal Investigators  
• Geography -specific regulatory authorities (if regulatory approval is required)  
• Ethics Committee s 
Similarly, approval of subsequent revisions to the CIP is required from the above -mentioned groups 
prior to implementation of the revised CIP at each study  site. 
14. Study Administration  
14.1.   Monitoring  
It is the responsibility  of Medtronic  to ensure  proper  monitoring  of this clinical  study.  Trained  
Medtronic  personnel  or delegates  appointed by [CONTACT_905540] e the study  is conducted  in accordance  with  the CIP, the Clinical Trial  Agreement,  and 
applicable  regulatory  and local  requirements. Medtronic,  or delegates, must therefore  have access  to 
the subjects’  case  histories  (clinic and hospi[INVESTIGATOR_20112], and other source data/documentation)  upon  
request  as per the Informed Consent  Form, Authorization to Use and Disclose Personal Health 
Information/Research Authorization/HIPAA/other privacy language (where  applicable)  and Clinical Trial  
Agreement.  The Principal  Investigator  [INVESTIGATOR_905450].  
Frequency  of monitoring  visits  may  be based upon  subject enrollment, duration  of the study,  study  
compliance, number  of adverse  events, number  of deviations, findings  from  previous  monitoring  visits  
and any suspected inconsistency  in data  that requires  investigation. Monitoring  for the study, including  
site initiation visits,  interim monitoring  visits, and closeout  visits,  will be done in accordance  to the 
study -specific monitoring  plan.  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 122 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Monitoring  visits  may  be conducted  periodically  in accordance with the study monitoring plan to assess  
site study  progress, the investigator’s  adherence to the CIP, regulatory  compliance  including but not 
limited  to Ethics  Committee approval  and review  of the study,  maintenance of records  and reports,  
and review  of source  documents  against eCRFs.  Monitors review  site regulatory  and study  compliance 
by [CONTACT_600551]-compliance and communicating  those  findings  along with  
recommendations  for preventative/corrective  actions  to site personnel. Monitors may  work  with  study  
personnel  to determine appropriate  corrective  action  recommendations  and to identify trends  within  
the study  or at a particular site. 
14.2.   Data Management  
Data will be collected using an electronic data management system for clinical studies.  Electronic Case 
Report Form ( eCRF) data will be stored in a secure, password- protected database which will be backed 
up nightly. Data will be reviewed using programmed and manual data checks. Data queries will be made 
available to sites for resolution. Study management reports may be generated to monitor data quality 
and study progress. At the end of the study, the data will be frozen and will be retained by [CONTACT_13735].  
 
The data reported on the eCRFs shall be derived from source documents and be consistent with these 
source documents .  Source documents, which may include  patient medical records , device interrogation 
files, programmer printouts, and worksheets, must be created and maintained by [CONTACT_8786]. The 
eCRF may be considered as source for the following data points: 
• Adverse Event: date site became aware of event   
• Non-Subject Adverse Event: date site became aware of event   
• Device Deficiency:  date s ite became aware of deficiency   
• Protocol Deviation : reason for deviation  
• EV ICD Device Accountability eCRFs: 
o DVEX 3E4 EV ICD  (except for  date used/date explanted)  
o EV2401 EV ICD Lead (except for  date used/date explanted)  
o EAZ101 and EAZ201 Tunneling Tool s (except for  date used)  
o Oscor SafeSheath® II Model SSCL9  introducer (except for date used)  
o SW041 Programmer Software  
o DR220 NorthEast Monitoring Digital Holter Recorder  
Device data from transmissions provided to Medtronic will be uploaded to secure servers and made accessible to the study team. Save -to-media  files and other non-e CRF data such as Radiographs and 
Fluoroscopi[INVESTIGATOR_905451]. Upon receipt via 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 [ADDRESS_1270887] Access to Source Data/Documents  
The sponsor or a regulatory authority may audit or inspect the study site  to evaluate the conduct of the 
study. The clinical investigator(s)/institution(s) shall allow study related monitoring, audits, Ethics 
Committee review, and regulatory inspection(s) by [CONTACT_20618]/documents. If study site’s documents are electronic, these must be made av ailable in their original form (or printouts 
signed and dated with the statement that this is complete and true reproduction of the original source document) if requested by [CONTACT_23638]/or regulatory authority. Study sites should inform Medtronic 
upon notification of an audit by a regulatory body immediately.  
14.4.  Confidentiality  
All records  and other information about subjects  participating in this study  will be treated as 
confidential. Data  will be transferred  and processed by [CONTACT_905541] a third  party  designated by 
[CONTACT_600552] a key coded  form, unless  it is impossible  to make  it anonymous, for instance,  where  the 
subject ’s name [CONTACT_905555], such  as fluoroscopy  images. Participating 
subjects  will not be identified  by [CONTACT_905542].  
14.5.  Liability  
Medtronic  Australasia Pty Ltd is a wholly  owned  subsidiary of Medtronic,  Inc., which  as the parent 
company  of such entity  maintains  appropriate clinical  study  liability insurance coverage  as required  
under  applicable  laws  and regulations  and will comply  with applicable  local  law and custom  concerning 
specific  insurance coverage. If required,  a Clinical  Study  insurance  statement/certificate  will be provided 
to the Ethics  Committee.  
Medtronic  New Zealand  Ltd. is a wholly  owned  subsidiary of Medtronic,  Inc., which  as the parent 
company  of such entity  maintains  appropriate clinical  study  liability insurance coverage  as required  
under  applicable  laws  and regulations  and will comply  with applicable  local  law and custom  concerning 
specific  insurance coverage. If required,  a Clinical  Study  insurance  statement/certificate  will be provided 
to the Ethics  Committee.  
Medtronic Bakken Research Center B.V. (Eur ope, Middle East)  is a wholly owned subsidiary of 
Medtronic, Inc., which as the parent company of such entity maintains appropriate clinical study liability 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 124 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   insurance coverage as required under applicable laws and regulations and will comply with applicable 
local law and cu stom concerning specific insurance coverage. If required, a Clinical Trial insurance 
statement/certificate will be provided to the Ethics Committee.  
Medtronic International (Hong Kong), Ltd. is a wholly owned subsidiary of Medtronic, Inc., which as the parent company of such entity maintains appropriate clinical trial liability insurance coverage as 
required under applicable laws and regulations and will comply with applicable local law and custom 
concerning specific insurance coverage. If required, a Clinical Trial insurance statement/certificate will 
be provided to the Ethics Committee.  
Medtronic  Japan Co., Ltd is a wholly owned subsidiary of Medtronic, which as the parent company of 
such entity maintains appropriate clinical study liability insurance coverage as required under applicable 
laws and regulations and will comply with applicable local law and custom concerning specific insurance 
coverage. If required, a clinical study insurance statement/certificate will be provided to the Institutional 
Review B oard . 
14.6.  CIP Amendments  
Approval  of CIP amendments  is required from  the following  groups  prior to any study  procedures  at 
a study  site: 
• Medtronic  
• Principal  Investigators  (where  required  by [CONTACT_169291])  
• Geography -specific  regulatory  authorities  (if regulatory  approval  is required)  
• An independent  Ethics  Committee. 
14.7.  Required Records and Reports  
 Investigator R ecords  
The investigator is responsible for the preparation and retention of the records cited below. All of the below records, with the exception of case hist ory records and case report forms, should be kept in the 
Investigator Site File ( e.g., the study binder provided to the investigator) or Subject Study Binder. 
Electronic CRFs must be maintained and signed electronically within the electronic data capture system 
during the study. The following records are subject to inspection and must be retained : 
• All correspondence between the Ethics Committee, sponsor, monitor, regulatory authority and 
the investigator that pertains to the investigation, including required reports.  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 125 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   • Subject’s case history records, including:  
o Signed and dated I nformed Consent Form .  
o Observations of adverse events/adverse device effects/device deficiencies . 
o Medical history . 
o Implant and follow -up data (if applicable) . 
o Documentation of the dates and rationale for any deviation from the CIP . 
• Subject identification log. 
• List of investigation sites . 
• Financial disclosure . 
• All approved versions of the CIP, IC, other information given to the subject  and Investigator’s 
Brochure.  
• Signed and dated Clinical Trial Agreement.  
• Current signed and dated curriculum vitae of Principal I nvestigator and key members of the 
investigation site team (as required by [CONTACT_1769]).  
• Documen tation of delegated tasks .  
• Ethics Committee approval documentation. Written information that the investigator or other 
study staff, when member of the Ethics Committee, did not participate in the approval process. 
Approval documentation must include the E thics Committee composition, where required per 
local law.   
• Regulatory authority notification, correspondence and approval, where required per local law. 
• Study training records for site staff.  
• Insurance certificates.  
• Shippi[INVESTIGATOR_502931]. 
• Equipment maintenance records, if applicable.  
• Any other records that local regulatory agencies require to be maintained.  
• Final Study Report including the statistical analysis. 
 The above -mentioned documentation shall be kept for a period of at least [ADDRESS_1270888] device has been placed on the market  or longer as 
local law or hospi[INVESTIGATOR_54387] .  
 Investigator R eports   
The investigator is responsible for the preparation (review and signature) and submission to the 
sponsor of all case report forms, including adverse events and adverse device effects (reported per the 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 126 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   country -specific collection requirements), device deficiencies, deaths, and any deviations from the CIP . 
If any action is taken by [CONTACT_503015], copi[INVESTIGATOR_248938] a timely manner. Reports are subject to inspection and to the retention requirements as described above for investigator records.  
Safety data investigator reporting requirements are listed in Table 14 of the Adverse Event section  
10.5. The investigator shall prepare and submit in a complete, accurate and timely manner the reports listed in this section.  
Table 18: Investigator reports applicable for all geographies per Medtron ic requirements  
Report  Submit to  Description/Constraints  
Withdrawal of Ethics 
Committee approval  Sponsor and 
Relevant 
Authorities , where 
applicable per local 
requirements  The investigator must report a withdrawal of approval by [CONTACT_905543]’s part of the investigation within [ADDRESS_1270889] ’s consent, 
or is made to protect the life or physical well -being of a subject in an emergency 
shall be given within [ADDRESS_1270890] 
be complied with.  
Australia: Report any suspected breaches to the sponsor  and confirmed serious 
breaches to their institution (research governance office)  within 72 hours of 
becoming aware or notified of the same; provide  any follow -up information  as 
required and work with the institution or sponsor, as appropriate, to implement 
any corrective and preventative action s. 
Progress report  Sponsor and  
Ethics Committee  As required by [CONTACT_5277] . 
Final Report  Ethics Committees 
and Relevant 
Authorities  This report must be submitted per local requirements. 
 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 127 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Table 19: Investigator reports applicable to the [LOCATION_002] per FDA regulations  
Report  Submit to  Description/Constraints  
Withdrawal of Ethics 
Committee approval (either 
suspension or termination)  Sponsor  The investigator must report a withdrawal of approval by [CONTACT_905544]’s part of the investigation within 5 
working days.  (21 CFR 812.150(a)(2))  
For any action taken by [CONTACT_905545].  
Progress report  Sponsor and  
Ethics Committee  The investigator must submit this report to the sponsor and Ethics 
Committee at regular intervals, but in no event less than yearly. (21 CFR 
812.150 (a)(3)) .   
Study deviations  Sponsor and  
Ethics Committee  Notice of deviations from the CIP to protect the life or physical wellbeing 
of a subject in an emergency shall be given as soon as possible, but no 
later than [ADDRESS_1270891] be 
approved by [CONTACT_13735], the EC, and the FDA/applicable regulatory 
authorities.  If the deviation does not affect these issues then only 
Medtronic must approve it.  (21 CFR 812.150(a)(4))  
Failure to obtain Informed 
Consent prior to 
investigational device use  Sponsor and  
Ethics Committe e If an investigator uses a device without obtaining Informed Consent, the 
investigator shall report such use within 5 working days after device use.  (21 CFR 812.150(a)(5))  
Final report  Sponsor  
Ethics Committee  
Relevant Authorities  This report must be submitted within 3 months of study completion or termination of the investigation or the investigator’s part of the 
investigation.  (21 CFR 812.150(a)(6)) 
Other Ethics Committee 
and FDA  An investigator shall, upon request by a reviewin g Ethics Committee  or 
regulatory agency, provide accurate, complete, and current information 
about any aspect of the investigation. (21 CFR 812.150(a)(7))  
 
 
 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 128 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Table 20: Investigator reports applicable to Europe, Middle East and Africa per ISO [ZIP_CODE] :2011  
Report  Submit to  Description/Constraints  
Progress Report  Sponsor and  
Ethics Committee  Provide if required by [CONTACT_905546].   
Study Deviations  Sponsor and  
Ethics Committee  Any deviation from the CIP shall be recorded together with an explanation for the 
deviation.  Deviations shall be reported to the sponsor who is responsible for 
analyzing them and assessing their significance.   
Note: When relevant, Ethics Committees, comp etent authorities or the appropriate 
regulatory bodies should be informed.  
Failure to obtain 
Informed Consent  Sponsor and  
Ethics Committee  Informed Consent shall be obtained in writing and documented before a subject is 
enrolled into the clinical investi gation.   
 
Table 21: Investigator reports applicable to Japan  
Report  Submit to  Description/Constraints  
Co-Investigator/ 
Clinical Trial 
Collaborator List  Head of Medical 
Institution (HOMI)  When the principal Investigator [INVESTIGATOR_905452]-Investigators and/or clinical trial collaborators, he or she shall prepare a list of 
the assigned duties and the individual performing the assigned duties, submit the list to the HOMI on the list, and rece ive the appointments of such individuals. 
(MHLW Ordinance 36, 2005 Article 63)  
Study Deviations  Sponsor and HOMI The Investigator may implement a deviation from, or a change in, the CIP to 
eliminate an immediate hazard(s) to study subjects without prior Ethics Board approval. In this case, the Investigator shall immediately submit to the sponsor, the HOMI, and to the Ethics Board via the HOMI, the description and reason for the 
deviation  and the proposed revision to the CIP , if one is necessary, to receive 
agreement. All deviations, regardless of the reason, shall be submitted to the 
sponsor. (MHLW Ordinance 36, 2005 Article 66)  
Summary of the 
Clinical Study Status HOMI  The principal Inv estigator shall submit a summary of the clinical study status to the 
HOMI in writing once a year, or more frequently if requested by [CONTACT_54457], to 
receive the continuation review by [CONTACT_21980]. (MHLW 
Ordinance 36, 2005 Article 68 ) 
Premature 
Termination or Suspension of the Clinical 
Investigation  HOMI  When the principal Investigator [INVESTIGATOR_905453], he or 
she shall promptly notify the HOMI thereof in writing, and explain in detail in writing 
the discontinuation or suspension. (MHLW Ordinance 36, 2005 Article 69) 
Completion of the 
Clinical 
Investigation  HOMI  When the clinical study is completed, the principal Investigator [INVESTIGATOR_905454] a summary of the clinical study results in 
writing. (MHLW Ordinance 36, 2005 Article 69)  
 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 129 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Additional reporting requirements and if stricter timelines of reporting are required per EC and/or local 
regulation, the same should be complied with, including any reporting needs to regulators, when 
required by [CONTACT_1769].  
 Sponsor R ecords  
Medtronic shall maintain the following accurate, complete, and current records: 
• All correspondence which pertains to the investigation. 
• Investigational device traceability records.  
• Software traceability records.  
• Signed Clinical Trial Agreements, financial disclosure and current signed and dated (Europe, 
ANZ, and Hong Kong only) curriculum vitae of Principal I nvestigator and key members of the 
investigation site team (as required by [CONTACT_1769]), delegated task list . 
• All approved Informed Consent templates, and other information provided to the subjects, 
including translations . 
• Copi[INVESTIGATOR_905455]/roster/letter of assurance . 
• Names of the institutions in which the clinical study will be conducted . 
• Regulatory authorities’ correspondence, notification and approval as required by [CONTACT_169294]. 
• Insurance certificates  (if applicable per local law).  
• Names/contact [CONTACT_54459] . 
• Site visit reports and follow -up letters . 
• Statistical analyses and underlying supporting data . 
• Final report of the clinical study . 
• The Clinical Investigation Plan, Investigator’s Brochure  and study related reports, and 
revisions. 
• eCRF s, including AE and D evice D eficiency (DD)  forms and eCRF corrections . 
• Study training records for site personnel and Medtronic personnel involved in the study . 
• Any other records that local regulatory agencies require to be maintained.  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 130 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   
 Sponsor R eports  
Medtronic shall prepare and submit the following complete, accurate, and timely reports listed in the 
tables below (by [CONTACT_13736]). In addition to the reports listed below, Medtronic shall, upon request of 
reviewing Ethics Committee  or regulatory agency, provide accurate, complete and current information 
about any aspect of the investigation. Safety data Medtronic reporting requirements are listed in Table 
14 of the Adverse Event section  10.5 . 
Table 22: Sponsor reports for Australia and New Zealand  
Report  Submit to  Description/Constraints  
Premature termination or 
suspension of the clinical 
study  Investigators, Ethics 
Committee, and 
relevant authorities  Provide prompt notification of termination or suspension and reason(s).  
Recall and device disposition  Investigators,  Ethics 
Committee,  relevant 
authorities,  Notification as required per local regulations in country  
Study deviation  Investigators  Ensure that all deviations from the Clinical Investigation Plan are reviewed 
with the appropriate clinical inv estigator(s), are reported on the case report 
forms and the final report of the clinical investigation. Site specific study 
deviations will be submitted to investigators periodically.   Reporting of 
serious breaches to required parties in Australia as per l ocal requirements 
will be done . 
Annual safety reports and 
single case Adverse events   TGA Submit upon request from TGA  
[LOCATION_003]DEs for Australia and 
international / Safety Report 
/ updated IB / approved 
Product Information  Investigator and HREC  Per EC requirements, but at least annually:  
• Annual safety report including ; - a summary of the evolving safety 
profile of the trial, a brief description  and analysis of new/relevant 
findings, implications of safety data to the risk -benefit ratio for the 
trial, a description  of any measures taken or proposed to minimize  
risks  
(NHMRC Safety monitoring and reporting in clinical trials involving 
therapeutic goods  November 2016 section C.1.i ) 
• An updated/addenda of IB or IFU, if appropriate (e.g., whe n an IB is 
no long er maintained). 
(NHMRC Safety monitoring and reporting in clinical trials involving therapeutic goods  November 2016 section C.1.h)  
 
 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 131 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Table 23: Sponsor reports for Canada  
Report  Submit to  Description/Constraints  
Premature termination or 
suspension of the clinical 
study  Investigators, 
Ethics Committee,  
Relevant authorities, and  
Head of the 
Institution  Provide prompt notification of termination or suspension and reason(s).  
Recall and device disposition  Investigators,  
Head of Institution,  
Ethics Committee,  
relevant 
authorities, and  
FDA Notification within [ADDRESS_1270892] that an investigator return, repair, or otherwise dispose of any 
devices.   
Study deviation  Investigators  Ensure that all deviations from the Clinical Investigation Plan are reviewed 
with the appropriate clinical investigator(s), are reported on the case report forms and the final report of the clinical study .  
Site specific study deviations will be submitted to  investigators periodically.   
Table 24: Sponsor reports for Europe, Middle East, Africa  
Report  Submit to  Description/Constraints  
Premature termination or suspension of the clinical study  Investigators,  
Ethics Committee,  
Relevant  
authorities and Head of the 
Institution  Provide prompt notification of termination or suspension and reason(s). (ISO [ZIP_CODE]:2011)  
Withdrawal of Ethics Committee approval  Investigators,  
Head of Institution,  
Ethics Committee and  
relevant authorities  Investigators, Ethics Committee will be notified only if required by [CONTACT_131501]. 
Withdrawal of CA approval  Investigators,  
Head of Institution,  
Ethics Committee, 
and 
relevant authorities  Investigators, Ethics Committee will be notified only if required by [CONTACT_131501]. 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 132 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Report  Submit to  Description/Constraints  
Progress Reports  Ethics Committee 
and 
regulatory 
authorities  This will be submitted to the Ethics Committee only if required by [CONTACT_20592].  
Final report  Investigators,  
Ethics Committee, 
and 
Regulatory 
authorities upon 
request  For studies with sites complying to ISO [ZIP_CODE]:2011:  
 
• The investigator shall have the opportunity to review and 
comment on the final report. 
• If a clinical investigator does not agree with the final report, his/her comments shall be communicated to the other 
investigator(s).    
• The coordinating investigator [INVESTIGATOR_131447]. If no coordinating investigator [INVESTIGATOR_54396], then the signature [CONTACT_905556] [INVESTIGATOR_905456].    (ISO 
[ZIP_CODE]:2011) 
Study deviation  Investigators  Ensure that all deviations from the Clinical Investigation Plan are reviewed 
with the appropriate clinical investigator(s), are reported on the case report forms and the final report of the clinical investigation.  (ISO [ZIP_CODE]:2011)  
Site specific study deviations will be submitted to investigators periodically.   
Table 25: Sponsor reports for Hong Kong  
Report  Submit to  Description/Constraints  
Premature termination or 
suspension of the clinical 
study  Investigators,  
Ethics Committee  Provide prompt notification of termination or suspension and reason(s).  
Recall and device disposition  Investigators,  
Ethics Committee,  
relevant authorities  Notification within [ADDRESS_1270893] that an investigator return, repair, or otherwise dispose of any 
devices.   
Study deviation  Investigators  Ensure that all deviations from the CIP are reviewed with the appro priate 
clinical investigator(s), are reported on the case report forms and the final 
report of the clinical study.     
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 133 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Table 26: Sponsor reports for the [LOCATION_002]  
Report  Submit to  Description/Constraints  
Withdrawal of Ethics 
Committee approval  Investigators, 
Ethics Committee, FDA, and relevant 
authorities  Notification within five working days.  (21 CFR 812.150(b)(2))   
Withdrawal of FDA approval  Investigators, 
Ethics Committee, 
and relevant 
authorities  Notification within five working days.  (21 CFR 812.150(b)(3))  
Investigator List  FDA Submit at [ADDRESS_1270894] of the names and addresses of all 
investigators participating in the investigation.  (21 CFR 812.150(b)(4))  
Progress Reports  Ethics Committee 
and FDA  Progress reports will be submitted at least annually.  (21 CFR 812.150(b)(5), 
812.36(f)   
Recall and device disposition  Investigators, Head 
of Institution, Ethics Committee, 
relevant 
authorities, and  
FDA Notification within [ADDRESS_1270895] that an investigator return, repair, or otherwise dispose of any 
devices.  (21 CFR 812.150(b)(6)) 
Failure to obtain Informed 
Consent  FDA Investigator’s report will be submit ted to FDA within five working days of 
notification.  (21 CFR 812.150(b)(8)) 
Final report  Investigators, 
Ethics Committee, Regulatory authorities upon 
request, and FDA Medtronic will notify FDA within 30 working days of the completion or 
termination of the investigation.  A final report will be submitted to the 
FDA, investigators, and Ethics Committee within six months after completion or termination of this study.  (21 CFR 812.150(b)(7))  
Study deviation  Investigators  Ensure that all deviations from the Clinical Investigation Plan are reviewed 
with the appropriate clinical investigator(s), are reported on the case report forms and the final report of the clinical study.  
Site specific study deviations will be submitted to investigators periodically.   
Other IRB, FDA  Accurate, complete, and current information about any aspect of the 
investigation. (21 CFR 812.150(b)(10)) 
 
Table 27: Sponsor reports for Japan  
Report  Submit to  Description/Constraints  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 134 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Premature termination or 
suspension of the clinical investigation  HOMI  
PMDA  When the sponsor suspends or discontinues the clinical trial, he or she 
shall promptly notify the heads of all the medical institutions and regulatory authorities thereof and the detailed reason therefor in writing. 
(MHLW Ordinance 36, 2005 Article 32)  
Suspension of development of investigational device  HOMI  
PMDA  When the sponsor decides not to attach the documents concerning 
clinical trial records collected in the clinical trial to the authorization 
application, he or she shall promptly notify the heads of all the medical 
institutions other facilities engaged in the clinical trial thereof and the 
detailed reason therefor in writing. (MHLW Ordinance 36, 2005 Article 32)  
Investigator List  HOMI  
PMDA  The sponsor shall beforehand submit the list of Investigators to PMDA and 
HOMI. (Pharmaceutical and Medical Device Act Enforcement Regulations)  
The sponsor shall submit the list of Investigators to PMDA and  HOMI 
when making any changes in the list. (Pharmaceutical and Medical Device 
Act Enforcement Regulations)  
Important information concerning the quality, 
effectiveness, and safety of the 
investigational device  Investigators  
HOMI  
PMDA  When new, important information is obtained, the sponsor shall revise 
the Investigator’s brochure. In addition, prior to revising the Investigator’s 
brochure, the sponsor shall report the information to the principal Investigator, HOMI, and regulatory authorities. (MHLW Ordinance 36, 
2005 Article 28)  
Clinical Trial Report  PMDA upon request  The sponsor shall prepare, according to the procedure, a clinical study 
report that summarizes the results, etc., of a clinical study when it is 
completed or discontinued. (MHLW Ordinance 3 6, Article 33)  
Study deviation  Investigators  
HOMI as  
necessary  Ensure that all deviations from the Clinical Investigation Plan are reviewed 
with the appropriate clinical Investigator(s), are reported on the case report forms and the final report of the clinical investigation. (ISO [ZIP_CODE]:2011) Site specific study deviations will be submitted to Investigators periodically . When the monitor confirms deviation as a 
result of monitoring, the monitor shall notify the principal Investigator [INVESTIGATOR_1238], as necessary, the HOMI thereof. The monitor shall also request for 
appropriate measures to be taken to prevent such deviation in the future. 
(MHLW Ordinance 36, 2005 Article 30)  
 
Medtronic records and reports will be maintained in a password-protected document management 
system, and paper documents (where applicable) will be stored in secured file cabinets at Medtronic 
during the course of this study.  
After closure of the study , Medtronic will archive records and reports and these will be retained per 
Medtronic standard an d applicable regulations . 
14.8.  Suspension or Early Termination 
Early Termination is the closure of a clinical study that occurs prior to meeting defined endpoints. This is possible for the whole study or a single site . Suspension is a temporary postponement of study 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 [ADDRESS_1270896]. This is possible for the whole study or a 
single site. 
 Study- wide Suspension or Early T ermination  
Possible reasons for considering study suspension or termination of the study include but are not 
limited to:  
• Adverse  events  associated  with the system  or product  under  investigation  which  might  
endanger the safety  or welfare  of the subject  
• Observed/suspected  performance  different  from  the product’s  design  intent  
• Decision  by [CONTACT_600558]  (where the study  is operating  under  regulatory  
body  authority)  
• Technical  issues  during  the manufacturing process  
 Investigator/ Site Suspension or Early T ermination  
Possible  reasons  for clinical  investigator  or site termination  or suspension  include  but are not limited  to: 
• Failure to obtain initial  Ethics  Committee approval  or annual  renewal of the study  approval  
• Persistent  non-compliance  to the CIP (e.g., failure  to adhere  to inclusion/exclusion  criteria, 
failure to follow  subjects  per scheduled  follow- ups)  
• Lack  of enrollment  
• Noncompliance to regulations  and the terms  of the Clinical  Trial  Agreement (e.g ., failure  to submit  
data  in a timely manner,  failure  to follow -up on data  queries  and monitoring  findings  in a timely 
manner)  
• Ethics  Committee  suspension of the site  
• Fraud  or fraudulent misconduct  is discovered  (as defined  by [CONTACT_600559])  
• Investigator request (e.g., no longer able to support  the study)  
 Procedures for Suspension or Early T ermination  
Below  procedures  will apply in addition  to any other  specific  requirement  per local  regulations. 
Medtronic -initiated and regulatory authority -initiated  
• Medtronic  will promptly  inform the clinical investigators  of the termination  or suspension  
and the reasons  and inform the regulatory  authority(ies)  where  required  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 136 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   • In the case  of study  termination  or suspension  for reasons other than a temporary  EC approval  
lapse, the investigator will promptly  inform the EC. A detailed  written  explanation  of the 
termination  or suspension  will be provided,  where  required  per regulatory  requirements.  
• In the case  of study  termination,  the investigator  must inform the subjects  and may  inform the 
personal  physician  of the subjects  to ensure appropriate  care  and follow -up is provided 
• In the case  of a study  suspension,  subject  enrollment must stop  until  the suspension  is 
lifted  by [CONTACT_13735] 
• In the case  of a study  suspension,  enrolled subjects  should continue to be followed  out of 
consideration  of their  safety, rights  and welfare  
 
Investigator -initiated  
• The investigator  will immediately  or promptly inform  Medtronic  and provide  a detailed  
written  explanation  of the termination  or suspension  
• The investigator  will promptly  inform the institution  (where required per regulatory  
requirements)  
• The investigator  will promptly  inform the EC, along  with a detailed  written  explanation  of the 
termination  or suspension (where required per regulatory  requirements)  
• The investigator  will promptly  inform the subjects  and/or the personal  physician of the subjects  
to ensure  appropriate  care  and follow- up is provided 
• In the case  of a study  suspension,  subjects  enrolled should continue  to be followed  out of 
consideration  of their  safety, rights  and welfare  
Ethics Committee -initiated 
• The investigator  will inform  Medtronic  and provide  a detailed  written  explanation  of the 
termination  or suspension  within  5 business  days,  or sooner if  required  per local requirements  
• Subject enrollment must stop until  the suspension  is lifted  
• Subjects  already enrolled should  continue to be followed  in accordance  with  EC policy  or its 
determination that an  overriding  safety  concern  or ethical  issue  is involved  
• The investigator  will inform  his/her institution (where  required  per local  requirements)  
• The investigator  will promptly  inform the subjects and/or the personal  physician of the subjects, 
with the rationale  for the study  termination or suspension to  ensure appropriate  care  and 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 137 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   follow- up is provided 
  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 138 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   15. References   
 
1. Weiss R, et al.,  Safety and efficacy of a totally subcutaneous implantable-cardioverter 
defibrillator, Circulation, 2013;128:944- 53 
2. U.S. Food and Drug Administration. (2012). A Patient Guide - Living with your S -ICD 
System. U.S. Food and Drug Administration/Devices@FDA. Retrieved 16 -Jan-2018 from: 
http://www.accessdata.fda.gov/cdrh_docs/pdf11/P110042c.pdf.  
3. U.S. Food and Drug Administration. (2012). FDA Circulatory Systems Device Panel 
Transcript for April 26, 2012. U.S. Food and Drug Administration Medical Device 
Advisory Committees. Retrieved 26 -Jan-2018 from: 
https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/CirculatorySystemDevicesPanel/ucm124182.htm. 
4. Ellenbogen KA, Wood MA, Shepard RK, Clemo HF, Vaughn T, et  al. 2003. Detection and 
management of an implantable cardioverter defibrillator lead failure: incidence and clinical implications. J Am Coll Cardiol 41:[ADDRESS_1270897] in Implantable 
Cardioverter-Defibrillators over a Period of >10 Years. Circulation. 2007;115:2474-2480. 
6. Bardy GH, et al., An entirely subcutaneous implantable cardioverter -defibrillator, N Engl 
J Med., 2 010;363:36-44.  
7. Cappato R, Smith WM, Hood MA, Crozier IG, Jordaens L, Spi[INVESTIGATOR_318961], Ardashev AV, 
Boersma L, Lupo P, Grace AA, Bardy GH. Subcutaneous chronic implantable 
defibrillation systems in humans, J Interv Card Electrophysiol., 2012;34:325 –332. 
https:/ /doi.org/10.1007/s10840-012-9665-6. 
8. Tomaske M, Prêtre R, Rahn M, Bauersfeld U. Epi[INVESTIGATOR_905457] [ADDRESS_1270898];10(10):1152-6. 
9. Molina JE, Benditt DG. An epi[INVESTIGATOR_371542] s ubxiphoid implantable defibrillator lead: superior 
effectiveness after failure of standard implants. Pacing Clin Electrophysiol. 2004 
Nov;27(11):1500-6.  
10. Tung SK, Bennett M, Yeung-Lai-wah JA, Ling H.  Minimal invasive extra cardiac 
placement of high voltage  defibrillator leads. Heart Rhythm 2007; 4(5, Suppl.):S200 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 139 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   11. Bauersfeld U, Tomaske M, Dodge-Khatami A, Rahn M, Kellenberger CJ, Prêtre R. Initial 
experience with implantable cardioverter defibrillator systems using epi[INVESTIGATOR_905458]. Ann Thorac Surg 2007;84:303-5.  
12. Gold, M., Aasbo, J., El -Chami, M. et al ., Subcutaneous implantable cardioverter -
defibrillator Post-Approval Study: Clinical characteristics and perioperative results. Heart Rhythm. 2017;14:1456– 1463.  
13. Boersma L, Barr C, Knops R et al. Implant and Midterm Outcomes of the Subcutaneous Implantable Cardioverter -Defibrillator Registry: The EFFORTLESS Study. J Am Coll 
Cardiol 2017;70:830-841. 
14. Jacob S, Lieberman RA. Percutaneous epi[INVESTIGATOR_905459]: a viable technique to manage refractory defibrillation threshold. Circ Arrhythm Electrophysiol. 2010 Apr;3(2):214-7.  
15. Haydin S, Saygi M, Ergul Y, Ozyilmaz I, Ozturk E, Akdeniz C, Tuzcu V. Subxiphoid 
approach to epi[INVESTIGATOR_905460]. Pacing Clin Electrophysiol. 2013 Aug;36(8):926 -30. 
16. Hajj-Chahine J, Houmaida H, Tomasi J, Corbi P. Epi[INVESTIGATOR_905461]? Interact Cardiovasc Thorac Surg. 2011 Apr;12(4):630.  
17. Guenther M, Kolschmann  S, Knaut M. Letter to the Editors: Substernal lead 
implantation: A Novel Option to Manage DFT failure in S -ICD Patients. Clin Res Cardiol, 
DOI 10.1007/s00392-014-0764-5.  
18. Boyle TA, Cohen J, Carrillo R. Substernal implantation of a subcutaneous implantable cardioverter- defibrillator in a patient with preexisting Hemodialysis Reliable Outflow 
graft. HeartRhythm Case Rep 2016;2:412-414. 
19. Bhagwandien RE, Kik C, Yap SC, Szili -Torok T. Substernal ICD lead implantation in a 
patient not suitable for subcutaneous ICD  implantation without venous access due to 
superior vena cava syndrome. HeartRhythm Case Rep 2017;3:97-99. 
20. Hata H, Sumitomo N, Nakai T, Amano A. Retrosternal Implantation of the Cardioverter -
Defibrillator Lead in an Infant. Ann Thorac Surg 2017;103:e449-e4 51. 
21. Chan JYS, Lelakowski J, Murgatroyd FD, Boersma  LV, Cao J, Nikolski  V, Wouters  G, Hall 
MCS.  Novel Extravascular Defibrillation Configuration With a Coil in the Substernal 
Space: The ASD Clinical Study, JACC: Clinical Electrophysiology, Volume 3, Issue 8 , 2017, 
Pages 905-910, ISSN 2405-500X, https://doi.org/10.1016/j.jacep.2016.12.026.  
22. Sholevar DP, Tung S, Kuriachan V, et al. Feasibility of extravascular pacing with a novel 
substernal electrode configuration: The Substernal Pacing Acute Clinical Evaluatio n 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 140 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Study. Heart Rhythm. Published online 29Nov2017. DOI: 
http://dx.doi.org/10.1016/j.hrthm.2017.11.[ADDRESS_1270899], Knight BP. Therapy from a No vel Substernal 
Lead: The ASD2 study. JACC: Clinical Electrophysiology, Volume 5, Issue 2, 2019, Pages 186-196. 
24. Blatt JA, Poole JE, Johnson GW, et al. No benefit from defibrillation threshold testing in the SCD -HeFT (Sudden Cardiac Death in Heart Failure Trial). J Am Coll Cardiol. 2008 Aug 
12;52(7):551- 6. 
25. Neuzner J, Hohnloser SH, Kutyifa V, et al. Effectiveness of single - vs. dual -coil 
implantable defibrillator leads: An observational analysis from the SIMPLE study. J Cardiovasc Electrophysiol. 2019 Apr 4.  doi: 10.1111/jce.[ZIP_CODE].  
26. Crozier IG, Haqqani H, Kotschet E, Shaw D, Prabhu A, Roubos N, Alison J, Melton I, 
Denman R, Lin T, Almeida A, Portway B, Sawchuk B, Sherfesee L, Liang S, BENG, Thompson AE, Lentz L, DeGroot PJ, O’Donnell D. First -in-human Chronic Implant 
Experience of the Substernal Extravascular Implantable Cardioverter Defibrillator. Heart Rhythm 2018 S-LBCT04 -01.  
16. Appendices  
  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 141 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Appendix A: Draft Data Collection Elements (Case Report Forms) 
Draft Case Report Forms for the EV ICD Pi[INVESTIGATOR_905462]. Final eCRFs 
will be provided to sites via the electronic data management system after the site has fulfilled all 
requirements for database access.   
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 142 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Appendix B: Preliminary Publication P lan 
Publications from the EV ICD  Pi[INVESTIGATOR_905463]’s Standard 
Operating Procedures and as indicated in the Clinical Trial Agreement.  
Publication Committee  
The Steering  Committee will serve as the Publication Committee  as they  will play a role in 
disseminating the study outcomes to the broader medical community. Additional members of the 
Publication Committee may include representation from Medtronic study management, st atistics, 
marketing, research, etc. This committee will manage study publications with the goal of publishing findings from the data.  Together with Medtronic  representatives, the Publication Committee will 
develop a final Publication Plan as a separate document .  
The Publication Committee’s role is to:  
1) manage elements addressed in the publication plan as outlined in this appendix,  
2) develop the final Publication Plan under separate cover,  3) finalize the Publication Plan,  
4) oversee the publication of primary and ancillary study results,  
5) review and prioritize publication proposals,  
6) provide input on publication content, and  
7) determine authorship.   
In addition, the committee will apply and reinforce the authorship  guidelines set forth in the 
Publication Plan. Membership in the Publication Committee does not guarantee authorship. The 
committee will meet as needed.  
Management of Primary and Ancillary Publications  
The Publication Committee reviews, prioritizes, and ma nages all publications including primary and 
ancillary publications.  Primary and ancillary publications are those that address analyses of any or all primary objectives or ancillary objectives, respectively, as specified in the Clinical Investigation Plan.  
An ancillary publication is any publication that does not address the study objectives identified in the 
Clinical Investigation Plan.  They include publications proposed and developed by [CONTACT_181031], clinicians participating in this clinical study, and clinicians not participating in 
this clinical study. The committee will work with Medtronic to ensure that requests do not present 
conflicts with other proposals, are not duplicative, and to determine which ancillary publication 
proposals, if any, will be supported.   
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 143 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   The committee may decide that no publications, including abstracts, will be published prior to the end 
of the study or with individual site  data. Requests for publications on study objectives utilizing subset 
data (e .g., regional) will be evaluated for s cientific validity and the ability of Medtronic to provide 
resources. 
Criteria for Determining Authorship  
Publications will adhere to authorship criteria defined by [CONTACT_65646] (ICMJE, Uniform requirements for manuscripts submitted to biomedical journals, 
www.icmje.org). Individual authorship criteria defined by [CONTACT_503021].  
Authors, including Medtronic personnel, must at a minimum meet all conditions below:  
• Substantial contribution to conception and design, or acquisition of data, or analysis and 
interpretation of data; and  
• Drafting the article or revising it critically for important intellectual co ntent; and  
• Final approval of the version to be published; and  
• Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.  
Decis ions regarding authorship and contributor -ship will be made by [CONTACT_942]. The selected 
authors will be responsible for drafting the publication. All selected authors must fulfill the authorship 
conditions stated above to be listed as authors, and all c ontributors who fulfill the conditions must be 
listed as authors.  
Contributors who make substantial contributions, but do not meet authorship criteria may be considered for inclusion in an Acknowledgement section of the publication.  Depending on the degree, these contributions might merit contributor -ship in the publication.  
Transparency 
Transparency of study results will be maintained by [CONTACT_54465]:  
• a final report, describing the results of objectives and analysis, will be distributed to all 
investigators, Ethic Committees and Regulatory  Authorities of participating countries when 
required by [CONTACT_1769]  
• registering and posting the study results on ClinicalTrials.gov based on the posting rules stipulated  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 144 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   • Medtronic intends to publish the primary study results in a manner that is sensitive to the 
commercial application of the results. Publication may  be delayed until closer to the potential 
release of a device feature  
• disclosing conflicts of interest (e.g., financial) of the co -authors of publications according to the 
policies set forth by [CONTACT_54466]  
• making an individual site’s study data accessible to the corresponding inv estigator after the 
completion of the study, if requested . 
  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 145 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Appendix C: Instructions for Use 
Instructions for Use (IFU) for the components of the EV ICD System and accessories, and equipment are 
provided with each component under separate cover. The cover of each IFU  will have a clinical 
statement on the cover indicating the device is an investigational device.   
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 146 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Appendix D: Informed Consent T emplates 
Medtronic legal-approved Informed Consent Templates for each geography where the study will be 
conducted will be distributed under separate cover.  
  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 147 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Appendix E: Foreseeable Adverse Event List  
Potential risks associated with the implantation of the EV ICD System , associ ated harms and adverse 
events, as well as risk minimization are discussed in more detail within section 9, Risks and Benefits . 
The information provided in this section includes additional reference information and may collectively 
assist in identifying those events for a given device or therapy  that are unexpected in nature. The 
foreseeable adverse event  information consists of three  parts:  (1) rates of adverse events reported 
from previous Medtronic studies evaluating transvenous ICD systems, (2) adverse event rates reported 
in published litera ture  for procedures similar to EV ICD, and (3) additional adverse events for 
consideration.  An evaluation of potentially anticipated events, adverse device effects observed in 
previous clinical studies, and reported events in literature may be used in combination with device labeling, current event reporting information, and other published data to assess for an unexpected 
occurrence.  
The implantation of the EV ICD System  involves surgery ; therefore, standard adverse events associated 
with a surgical procedure may be experienced (e.g., anesthesia complications, injury, infections, 
bleeding, exacerbation of pre-existing conditions, healing complications). However, the focus of this section is to address in more detail, those events that are foreseeable due to the implantation, use, 
performance, and/or presence of the system under invest igation or comparable systems. 
Treatment required for procedure and/or system related adverse events may include medication, device reprogramming, device modification (e.g., repositioning, electrical  abandonment, surgical 
removal), or other surgical and medical remedies.  
Adverse Events Reported in Previous Clinical Studies of Transvenous ICD 
Systems 
Table 28 provides examples of adverse events associated with the use of transvenous ICD systems 
reported in three previous Medtronic studies. These three predicate studies were selected as a 
reference for EV ICD performance as they were contemporary and used adverse event definitions 
consistent with those utilized in the EV ICD Pi[INVESTIGATOR_427698]. The three predicate Medtronic studies 
include BLOCK HF, REVERSE, and Evera MRI. These studies collected adverse  event data from 1035 
subjects that underwent an ICD implant. The average follow -up time exceeded 9 months in all three 
trials. Table 28 displays the adverse event rates classified as related to the implanted system and/or 
procedure. To characterize the safety profile of a single lead ICD system, all adverse events related to 
an atrial or left ventricular pacing lead wer e excluded from consideration. Ka plan -Meier estimates and 
associated 95% confidence intervals of the adverse event rates are provided in the Table below at 30-days and 12 -months (365 days) post-implant to characterize both peri -procedural and long -term 
adverse events related to the procedure or implanted system.  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 148 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Table 28: System and/or Procedure Related AEs Associated with Transvenous ICD Systems (n=1035)  
 Within 30- days of Implant  Within 12- months of Implant  
MedDRA Preferred Term No. Events  
(No. Subjects, %)  95% CI No. Events  
(No. Subjects, %)  95% CI  
ACUTE PULMONARY OEDEMA 2 (2, 0.19%)  0.05% - 0.77%  2 (2, 0.19%)  0.05% - 0.77%  
ADVERSE DRUG REACTION 5 (5, 0.39%)  0.15% - 1.03%  5 (5, 0.39%)  0.15% - 1.03%  
ANGINA UNSTABLE 1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01%  - 0.68%  
ANXIETY 0 (0, 0%)  -- 1 (1, 0.13%)  0.02% - 0.93%  
ARRHYTHMIA SUPRAVENTRICULAR  1 (1, 0.10%)  0.01% - 0.68%  2 (1, 0.10%)  0.01% - 0.68%  
ATELECTASIS 3 (3, 0.29%)  0.09% - 0.90%  3 (3, 0.29%)  0.09% - 0.90%  
ATRIAL FIBRILLATION 8 (7, 0.68%)  0.32% - 1.41%  8 (7, 0.68%)  0.32% - 1.41%  
ATRIAL FLUTTER  1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
ATRIAL THROMBOSIS  0 (0, 0%)  -- 1 (1, 0.10%)  0.01% - 0.74%  
ATRIOVENTRICULAR BLOCK COMPLETE 3 (2, 0.19%)  0.05% - 0.77%  3 (2, 0.19%)  0.05% - 0.77%  
ATRIOVENTRICULAR BLOCK THIRD DEGREE  6 (6, 0.58%)  0.26% - 1.29%  6 (6, 0.58%)  0.26% - 1.29%  
BACTERAEMIA 0 (0, 0%)  -- 1 (1, 0.10%)  0.01% - 0.71%  
BODY TEMPERATURE INCREASED 1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
BRADYCARDIA  2 (2, 0.19%)  0.05%  - 0.77%  2 (2, 0.19%)  0.05% - 0.77%  
BRONCHITIS  1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
CARDIAC FAILURE  16 (16, 1.55%)  0.95% - 2.52%  16 (16, 1.55%)  0.95% - 2.52%  
CARDIAC FAILURE CHRONIC  1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
CARDIAC PERFORATION 2 (2, 0.19%)  0.05% - 0.77%  2 (2, 0.19%)  0.05% - 0.77%  
CARDIAC PROCEDURE COMPLICATION 2 (2, 0.19%)  0.05% - 0.77%  2 (2, 0.19%)  0.05% - 0.77%  
CARDIAC TAMPONADE 2 (2, 0.19%)  0.05% - 0.77%  3 (3, 0.29%)  0.09% - 0.91%  
CEREBROVASCULAR ACCIDENT  2 (2, 0.19%)  0.05% - 0.77%  2 (2, 0.19%)  0.05% - 0.77%  
CHEST PAIN 1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
CHRONIC OBSTRUCTIVE PULMONARY DISEASE  3 (1, 0.10%)  0.01% - 0.68%  3 (1, 0.10%)  0.01% - 0.68%  
COMPLICATION OF DEVICE INSERTION 2 (2, 0.19%)  0.05% - 0.77%  2 (2, 0.19%)  0.05% - 0.77%  
CONTRAST MEDIA REACTION 1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
CORONARY SINUS DISSECTION 9 (9, 0.87%)  0.45% - 1.66%  9 (9, 0.87%)  0.45% - 1.66%  
DECREASED SENSING  0 (0, 0%)  -- 2 (2, 0.28%)  0.07% - 1.10%  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 149 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Table 28: System and/or Procedure Related AEs Associated with Transvenous ICD Systems (n=1035)  
 Within 30- days of Implant  Within 12- months of Implant  
MedDRA Preferred Term No. Events  
(No. Subjects, %)  95% CI No. Events  
(No. Subjects, %)  95% CI  
DEEP VEIN THROMBOSIS 2 (2, 0.19%)  0.05% - 0.77%  4 (4, 0.40%)  0.15% - 1.05%  
DEFIBRILLATION THRESHOLD INCREASED  1 (1, 0.10%)  0.01% - 0.68%  2 (2, 0.20%)  0.05% - 0.79%  
DEHYDRATION  2 (2, 0.19%)  0.05% - 0.77%  2 (2, 0.19%)  0.05% - 0.77%  
DEVICE ELECTRICAL FINDING 1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
DEVICE LEAD DAMAGE 0 (0, 0%)  -- 2 (2, 0.23%)  0.06% - 0.91%  
DEVICE MALFUNCTION 0 (0, 0%)  -- 1 (1, 0.10%)  0.01% - 0.74%  
DEVICE MIGRATION 1 (1, 0.10%)  0.01% - 0.69%  2 (2, 0.20%)  0.05% - 0.78%  
DEVICE RELATED INFECTION 1 (1, 0.10%)  0.01% - 0.69%  1 (1, 0.10%)  0.01% - 0.69%  
DIZZINESS  1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
DRUG HYPERSENSITIVITY 2 (2, 0.19%)  0.05% - 0.77%  2 (2, 0.19%)  0.05% - 0.77%  
DYSPNOEA  3 (3, 0.29%)  0.09% - 0.90%  3 (3, 0.29%)  0.09% - 0.90%  
DYSPNOEA EXERTIONAL 1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
ELECTRICAL RESET OF DEVICE  0 (0, 0%)  -- 2 (2, 0.21%)  0.05% - 0.82%  
ELECTROMECHANICAL DISSOCIATION  1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
ELEVATED PACING THRESHOLD  0 (0, 0%)  -- 2 (2, 0.20%)  0.05% - 0.81%  
ENTERITIS  1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
EXTRASYSTOLES 1 (1, 0.10%)  0.01% - 0.69%  1 (1, 0.10%)  0.01% - 0.69%  
FAILURE TO CAPTURE  0 (0, 0%)  -- 1 (1, 0.10%)  0.01% - 0.73%  
FLUID RETENTION  1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
HAEMATOMA 1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
HAEMOPNEUMOTHORAX 1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
HAEMORRHAGE 1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
HYPOTENSION  8 (8, 0.77%)  0.39% - 1.54%  8 (8, 0.77%)  0.39% - 1.54%  
HYPOXIA 1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
IMPAIRED HEALING 1 (1, 0.10%)  0.01% - 0.68%  2 (2, 0.20%)  0.05% - 0.78%  
IMPLANT SITE CELLULITIS  0 (0, 0%)  -- 1 (1, 0.10%)  0.01% - 0.71%  
IMPLANT SITE EROSION 0 (0, 0%)  -- 2 (2, 0.20%)  0.05% - 0.80%  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 150 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Table 28: System and/or Procedure Related AEs Associated with Transvenous ICD Systems (n=1035)  
 Within 30- days of Implant  Within 12- months of Implant  
MedDRA Preferred Term No. Events  
(No. Subjects, %)  95% CI No. Events  
(No. Subjects, %)  95% CI  
IMPLANT SITE HAEMATOMA 21 (21, 2.03%)  1.33% - 3.10%  23 (23, 2.23%)  1.49% - 3.34%  
IMPLANT SITE HAEMORRHAGE  1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
IMPLANT SITE INFECTION 8 (8, 0.78%)  0.39% - 1.54%  14 (14, 1.38%)  0.82% - 2.31%  
IMPLANT SITE INFLAMMATION 0 (0, 0%)  -- 1 (1, 0.10%)  0.01% - 0.72%  
IMPLANT SITE PAIN 10 (10, 0.97%)  0.52% - 1.79%  19 (18, 1.78%)  1.13% - 2.81%  
IMPLANT SITE RASH 1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
INAPPROPRIATE DEVICE STIMULATION OF TISSUE  3 (3, 0.29%)  0.09% - 0.90%  4 (4, 0.39%)  0.15% - 1.03%  
INAPPROPRIATE DEVICE THERAPY 1 (1, 0.10%)  0.01% - 0.69%  6 (6, 0.61%)  0.27% - 1.35%  
INCISION SITE HAEMORRHAGE  1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
IODINE ALLERGY  1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
JUGULAR VEIN THROMBOSIS  1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
KELOID SCAR 0 (0, 0%)  -- 1 (1, 0.10%)  0.01% - 0.72%  
LEAD DISLODGEMENT 14 (14, 1.35%)  0.80% - 2.27%  20 (20, 1.96%)  1.27% - 3.02%  
MEDICAL DEVICE CHANGE 0 (0, 0%)  -- 1 (1, 0.10%)  0.01% - 0.74%  
MEDICAL DEVICE COMPLICATION 0 (0, 0%)  -- 1 (1, 0.10%)  0.01% - 0.72%  
MEDICAL DEVICE DISCOMFORT  0 (0, 0%)  -- 1 (1, 0.10%)  0.01% - 0.72%  
MUSCLE SPASMS  1 (1, 0.10%)  0.01% - 0.68%  2 (2, 0.22%)  0.05% - 0.89%  
MUSCLE STRAIN  1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
MYOCARDIAL INFARCTION  1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
OEDEMA PERIPHERAL 3 (3, 0.29%)  0.09% - 0.90%  4 (4, 0.39%)  0.15% - 1.04%  
ORTHOSTATIC HYPOTENSION  2 (2, 0.19%)  0.05% - 0.77%  2 (2, 0.19%)  0.05% - 0.77%  
OVERSENSING 1 (1, 0.10%)  0.01% - 0.68%  4 (4, 0.41%)  0.15% - 1.08%  
OXYGEN SATURATION DECREASED 1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
PAIN IN EXTREMITY 2 (2, 0.19%)  0.05% - 0.77%  2 (2, 0.19%)  0.05% - 0.77%  
PERICARDIAL EFFUSION 8 (8, 0.77%)  0.39% - 1.54%  9 (9, 0.87%)  0.45% - 1.67%  
PERICARDITIS  0 (0, 0%)  -- 1 (1, 0.10%)  0.01% - 0.71%  
PHANTOM SHOCK  1 (1, 0.10%)  0.01% - 0.69%  1 (1, 0.10%)  0.01% - 0.69%  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 151 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Table 28: System and/or Procedure Related AEs Associated with Transvenous ICD Systems (n=1035)  
 Within 30- days of Implant  Within 12- months of Implant  
MedDRA Preferred Term No. Events  
(No. Subjects, %)  95% CI No. Events  
(No. Subjects, %)  95% CI  
PLEURAL EFFUSION  7 (7, 0.68%)  0.32% - 1.41%  8 (8, 0.78%)  0.39% - 1.55%  
PLEURITIC PAIN 1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
PNEUMONIA 3 (3, 0.29%)  0.09% - 0.90%  3 (3, 0.29%)  0.09% - 0.90%  
PNEUMONIA ASPI[INVESTIGATOR_374820] 1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
PNEUMOTHORAX 4 (4, 0.39%)  0.15% - 1.03%  4 (4, 0.39%)  0.15% - 1.03%  
PNEUMOTHORAX TRAUMATIC  1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
PROCEDURAL HYPOTENSION  2 (2, 0.19%)  0.05% - 0.77%  2 (2, 0.19%)  0.05% - 0.77%  
PROCEDURAL NAUSEA 1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
PULMONARY EMBOLISM  0 (0, 0%)  -- 1 (1, 0.10%)  0.01% - 0.72%  
PULMONARY OEDEMA 1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
PUNCTURE OF PERIOSTEUM 1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
PYREXIA 1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
RENAL FAILURE 3 (3, 0.29%)  0.09% - 0.90%  3 (3, 0.29%)  0.09% - 0.90%  
RENAL FAILURE ACUTE  3 (3, 0.29%)  0.09% - 0.90%  3 (3, 0.29%)  0.09% - 0.90%  
SHOULDER PAIN  4 (4, 0.39%)  0.15% - 1.03%  4 (4, 0.39%)  0.15% - 1.03%  
SLEEP APNOEA SYNDROME 1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
SUBCLAVIAN VEIN THROMBOSIS  2 (2, 0.19%)  0.05% - 0.77%  2 (2, 0.19%)  0.05% - 0.77%  
SUPRAVENTRICULAR TACHYCARDIA  0 (0, 0%)  -- 2 (2, 0.21%)  0.05% - 0.85%  
SUTURE RELATED COMPLICATION 0 (0, 0%)  -- 2 (2, 0.20%)  0.05% - 0.79%  
SYNCOPE VASOVAGAL 2 (2, 0.19%)  0.05% - 0.77%  2 (2, 0.19%)  0.05% - 0.77%  
THERMAL BURN  1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
UNDERSENSING  1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
UPPER RESPI[INVESTIGATOR_905464] 1 (1, 0.10%)  0.01% - 0.69%  1 (1, 0.10%)  0.01% - 0.69%  
URINARY RETENTION POSTOPERATIVE  1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
VENOUS OCCLUSION 1 (1, 0.10%)  0.01% - 0.68%  2 (2, 0.20%)  0.05% - 0.79%  
VENTRICULAR ASYSTOLE  1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
VENTRICULAR FIBRILLATION 1 (1, 0.10%)  0.01% - 0.68%  1 (1, 0.10%)  0.01% - 0.68%  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 152 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Table 28: System and/or Procedure Related AEs Associated with Transvenous ICD Systems (n=1035)  
 Within 30- days of Implant  Within 12- months of Implant  
MedDRA Preferred Term No. Events  
(No. Subjects, %)  95% CI No. Events  
(No. Subjects, %)  95% CI  
VENTRICULAR TACHYCARDIA  2 (2, 0.19%)  0.05% - 0.77%  2 (2, 0.19%)  0.05% - 0.77%  
WHEEZING  2 (2, 0.19%)  0.05% - 0.77%  2 (2, 0.19%)  0.05% - 0.77%  
 
Procedure Related Adverse Events from  Previous Clinical Studies Using a 
Similar Research System 
Limited clinical experience relevant to the EV ICD System is available from the previously co nducted 
Medtronic ASD, SPACE , ASD2, and the EV ICD Pi[INVESTIGATOR_905465].  
In the ASD study, in total ten adverse events were observed. Three adverse events were attributed to 
the ASD Procedure. The first ASD Procedure -related adverse event occurred in the patient where the 
ASD lead was observed implanted in the pleural cav ity immediately adjacent to the mediastinum. This 
patient, who underwent a planned indicated surgical procedure requiring midline sternotomy after the ASD procedure, had documented decrease in oxygen saturation levels and small bilateral effusions reported by [CONTACT_779], diagnosed as chest infection (Note: physician classified this event as not related to 
the ASD Procedure). The small bilateral effusions resolved within five days after onset, and there were no further chronic sequelae to the patient.  
The second ASD Procedure -related adverse event was associated with a patient scheduled for CABG 
surgery that had bruising along the left internal mammary artery bed following the ASD tunneling procedure, which resulted in a saphenous vein graft being used instead  of left internal mammary graft 
in the final (planned) surgical procedure. There were no further sequelae to this patient, and it was 
commented that this may not have been an adverse event, if the graft location had not been changed 
due to the bruising.  
The third ASD Procedure-related adverse event was a patient who had erythema on the back one day 
post -procedure, related to the defibrillation pad of the external defibrillation system (used as a safety 
back-up). The erythema resolved within one day after onset, and there were no further chronic 
sequelae to the patient.  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 153 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   None of the reported adverse events was classified as “related to the ASD Research System” by [CONTACT_905547].  
In the SPACE study, 14 adverse events were observed, all without chronic sequelae to the patient.  
Two of the adverse events were attributed to the SPACE Procedure. A pericardial effusion was noted in 
one patient (the first patient enrolled in the SPACE study overall) following the patient’s planned 
sternotomy procedure, with the effusion resolved the same day and without extension of the subject’s 
hospi[INVESTIGATOR_905466]; there were no further planned actions deemed necessary and no further adverse effects reported for this patient. The second SPACE Procedure-related advers e 
event occurred in a patient whose planned procedure included sternotomy and by[CONTACT_9292]. This patient reported incision site pain three days post -procedure that reduced by 16 days and required no 
further follow-up or action.  
In the ASD2 study, there wer e 20 adverse events (15 serious, 5 non -serious) experienced in 16 subjects.  
Of the 79 subjects  who underwent the ASD2 implant procedure, there were seven adverse events in 
seven subjects  adjudicated as causally (five) or possibly (two) related to the ASD2  procedure.   
Three of the five adverse events adjudicated as causally related to the ASD2 procedure were classified 
as non -serious and included bleeding at the incision site, erythema and an epi[INVESTIGATOR_905467]. The other two adverse events adjudicated as causally 
related to the ASD2 procedure were classified as serious and included one reaction to anesthesia and one pericardial effusion with tamponade.  The subject with pericardial effusion was a 62 -year-old with 
ischemic cardiomyopathy who developed cardiac t amponade and prolonged hypotension intra -
operatively. Hemodynamic stability was restored through surgical intervention, but the prolonged hypotension resulted in hypoxic  cerebral injury. With no meaningful neurologic activity after 72 hours, 
supportive care was withdrawn at the family’s request and the subject  expi[INVESTIGATOR_5697]. 
There were two adverse events adjudicated as possibly related to either t he ASD2 procedure or the 
subjec t’s final planned procedure/system: one pericarditis and one cardiac arrest. The subject with 
pericarditis received a dual -chamber ICD implant  after the ASD2 procedure, but presented with a  
pericardial effusion on echocardiography  three days later. After p ericardiocentes is the subject ’s 
complaints  resolved with no further sequelae. The subject  with cardiac arrest was an 81-year-old with 
diabetes and ischemic cardiomyopathy who  was admitted for decompensated heart failure, urosepsis 
and persistent AF.  After  medical management of these conditions,  the subject was enrolled and 
underwent the ASD2 study procedure and planned dual -chamber ICD implantation without incident.  
The subject  was then transferred in stable condition to a secondary site  where asystole wa s detected 
[ADDRESS_1270900]  expi[INVESTIGATOR_5697].  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 154 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   In the EV ICD Pi[INVESTIGATOR_799], as of 11  March 2019, among 21 subjects undergoing an implant attempt of 
the system , there were 28 adverse events in 11 subjects.  S ix reported adverse events in four subjects 
were adjudicated to be causally related to the implant procedure and/or the EV ICD System.  Five of 
the events (impaired healing, pleuritic pain (2), postoperative wound infection, implant site swelling) 
were causally related to the procedure, while one of the two pleuritic pain observations was also 
related to the EV ICD lead and the other subject with pleuritic pain eventually experienced a lead 
displacement (related to the EV ICD device and lead)  leading to an inappropriate shock and system 
removal.  Five of the six events were determined to be non-serious; the lead displacement event was 
classified as a major complication as it involved a system revision.  
Adverse events in literature  
There are limited published data available regarding the adverse events associated with the 
implantation of a subcutaneous ICD. A summary of adverse events and their published incidence of 2 
studies are listed below:  
1. Weiss R, Knight BP , Gold MR, Leon AR, Herre JM , Hood M, Rashtian M , Kremers M , Crozier I, 
Lee KL, Smith W, Burke MC. Safety and Efficacy of a Totally Subcutane ous Implantable 
Cardioverter Defibrillator. Circulation. 2013 Aug 27;128(9):944-53.  
 
This study was a prospective, nonrandomized, multicenter trial of 314 subjects  implanted with a 
subcutaneous ICD followed for 180 days. The following adverse events were reported in the 
manuscript.  
Table 29 : Safety and Efficacy of a Totally Subcutane ous Implantable Cardioverter Defibrillator, Reported 
Advers e Events   
Adverse Event  Patients  
Infections   
Total Number  18 
System Explant  4 
No System Explant  14 
Inappropriate Shocks   
Total Number  41 
Resulting from normal device function  16 
Inappropriate Sensing  25 
Cardiac Oversensing  22 
Non -Cardiac Oversensing  3 
Death   
Total Number  8 
Non -cardiac, non -sudden and unrelated to implant  5 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 155 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Adverse Event  Patients  
Unwitnessed death, device interrogation showed 
successful treatment of a singular ventricular 
arrhythmia 1 
Unwitnessed death, no interrogation available, 
diagnosed with atypi[INVESTIGATOR_905468]  1 
Unknown cause of death  1 
 
2. Maass AH , de Groot JR, van Oostrom AJ, Theuns DA, Jordaens LJ, Wilde AA, Knops RE. The 
entirely subcutaneous implantable cardioverter -defibrillator: initial clinical experience in a 
large Dutch cohort. J Am Coll Cardiol. 2012 Nov 6;60(19):1933-9.  
 
This was a retr ospective study using the files of [ADDRESS_1270901] -implant was included in the 
dataset. Adverse events observed included the following:  
Table 30 : The entirely subcutaneous implantable cardioverter-defibrillator: initial clinical experience in a large 
Dutch cohort, Reported Adverse Events  
Adverse Event  Patients  Epi[INVESTIGATOR_905469]  [ADDRESS_1270902] been reported with different terminology also include:  
Anemia , Aneurysm or pseudo -aneurysm, Angina pectoris , Aphasia , Arterio -venous fistula , Asystole , 
Atrial septal defect , Back pain , Blood or air embolism , Bruising, Cardiac dissection, Cardiogenic shock, 
Cellulitis , Constrictive pericarditis , Coronary artery constriction , Coronary artery disease , Coronary 
artery occlusion , Coronary vein occlusion , Device capture issue , Device connection issue , Device lead 
issue, Device pacing issue, Device protrusio n, Device signal detection issue , Diaphoresis , Dressler's 
syndrome, Dysplasia, Ecchymosis , Edema , Electrical conduction disorders, Electrical shock, 
Electromagnetic interference, Endocarditis, Erythema, Exit block, Extravasation, Failure to terminate a 
ventricular tachycardia/ ventricular fibrillation, Fatigue, Fever, Headache, Heart block, Heart rate 
increase, Hematuria, Hyperkalemia, Hypertension, Impedance decreased, Impedance increased, 
Implant site abscess, Implant site complication, Implant site discomfort, Implant site drainage, Implant site seroma, Implant site swelling, Inappropriate device detection, Inappropriate device programming, 
Inflammation, Insomnia, Lead insertion tool delivery problem, Local swelling, Loss of consciousness, 
Mental status c hange, Musculoskeletal discomfort, Myocardial damage, Myocardial irritability, Neck 
pain, Necrosis, Neurological symptoms, Numbness at incision site, Numbness in hand, Panic attack, Paresthesia, Pericardial rub, Phlebitis, Poor hemodynamic recovery, Presyncope, Reduced cardiac output, Reduced perfusion, Respi[INVESTIGATOR_1399], Restlessness, Retrosternal pain, Scar or scarring, Sepsis, 
Septic shock, Skin injuries, Skin reaction, Sleep apnea, Stroke, Subcutaneous emphysema, Sudden 
cardiac death, Thoracic pain, T hrombocytopenia, Thromboembolism, Thrombosis, Nerve damage, 
Transient ischemic attack, Urticaria, Valve damage, Vascular trauma, Vasovagal reaction, Venous 
insufficiency, Venous stenosis, Ventricular extrasystole, Vessel perforation or laceration, Vessel s pasm, 
Vomiting, Weakness . 
  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 157 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Appendix F: Participating Investigators and I nstitutions  
A complete list of participating investigators and institutions will be provided under separate cover.  
  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 158 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Appendix G: Ethics Committee and Competent Authority L ist 
A complete list of participating Regulatory Bodies, Competent Authorities, and Ethics Committees and 
their Chairperson(s) that will be utilized as part of the study will be dis tributed under separate cover, 
upon request.  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 159 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Appendix H: Previous Clinical Investigations 
A complete bibliography and summary of relevant literature, summary and results of preclinical testing, 
and summary of results of previous clinical investigations is provided in the Investigator’s Brochure.  
  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 160 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Appendix I: Chronic Defibrillation Testing Protocol  
Each subject will be induced  to produce up to two epi[INVESTIGATOR_905470], for up to a total of 4 potential shocks from the EV ICD  (see Figure 
11). Starting t herapy polarity i s at the discretion of the physician  (in the programmed setting) . 
 
Figure 11: Diagram outlining the process of chronic SSVA induction and defibrillation testing  
 
Epi[INVESTIGATOR_1865] 1  
Program Rx1 and Rx2 therapi[INVESTIGATOR_168167]:  
  Rx1 Rx2 
NID 30/[ADDRESS_1270903] NID  NA 9/[ADDRESS_1270904] the system implanted with no changes.  

 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 161 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Epi[INVESTIGATOR_1865] 2  
  Rx1 Rx2 
NID 9/[ADDRESS_1270905] NID  NA 9/[ADDRESS_1270906] failed chronic defibrillation testing 
criteria and the next steps are at the physician’s discretion. Medtronic recommends EV ICD device or 
lead revision (at a minimum), or system removal.  
Prior to inducing and throughout the chronic defibrillation protocol,  it is recommended to consider the 
following to improve defibrillation outcome  or troubleshooting in the event of failure of first 
epi[INVESTIGATOR_1865](s):  
• Check for /resolve  high impedance values  
• Check for/resolve  air in tunnel  (e.g., fluoroscopy)  
• Check for/resolve gastric bubbles (gas)  
• Press on device pocket during testing  
• Perform defibrillation during held end tidal expi[INVESTIGATOR_1516] (end expi[INVESTIGATOR_905390])  
  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 162 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Appendix J: Applicability to CMS Beneficiaries  
There is a high prevalence of ventricular tachycardia treatable by [CONTACT_905548]. Medicare claims data from 2017  (the most recent currently available) shows 52,967 ICD 
insertion procedures (with transvenous leads) and an additional 1,657 procedures for subcutaneous ICD insertions.
xxx As described in the background section of this CIP, subcutaneous ICD systems are 
currently the only available non-transvenous ICD systems. We anticipate that the EV  ICD system will 
provide alternative option for provider consideration in cases where non-transvenous ICD systems are necessary to provide access to potentially life -saving ICD therapy in patients where vascular access is 
challenging or compromised.   
The EV  ICD trial is designed to ensure applicability of the results to the Medicare population. O f the up 
to 60 sites worldwide, approximately  20 will be in the US. In addition, while the EV  ICD study will be 
open to patients aged 18 and older , the trial will aim to enroll approximately 30% of patients in the US 
65 years of age or older.    
                                                            
xxx Medicare Physician/Supplier Procedure Summary data. Available at: https://www.cms.gov/Research- Statistics -Data -and-
Systems/Statistics -Trends -and- Reports/Physician -Supplier -Procedure -Summary/index.html  
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 163 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Appendix K: Investigator Statement (where applicable) 
Study product Name  [CONTACT_905557] , Inc.  
[ADDRESS_1270907]  
Macquarie Park 
NSW, 2113  
Australia  
[PHONE_18768]  
 
Canada 
Medtronic of Canada, Ltd.  
[ADDRESS_1270908] Brampton  
Ontario, L6Y 0R3 Canada  
+[PHONE_2906] 
 
Europe, Middle East, Africa  
Medtronic, Bakken Research Center B.V.  
Endepolsdomein 5  
6229 GW Maastricht  
The Netherlands [PHONE_2909]-566 
 
Hong Kong  
Medtronic Hong Kong Medical Ltd.  
1104- 11, 11/F, Tower 1,  
The Gateway, Harbour City, Kowloon  
Hong Kong SAR, China  
+852 -2919 -1300 
 
 
Japan  
Medtronic Japan Co ., Ltd. 
1-2-70 Konan, Minato-ku, 
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 164 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   Tokyo Japan 108 -0075  
Shinagawa Season Terrace 22F 
 Phone: (+81) 3 -6774- 4611  
Fax: (+81) 3-[ADDRESS_1270909]  
Penrose  
Auckland 1051 New Zealand  
[PHONE_18769] -1049  
Clinical Investigation Plan Identifier  MDT1 6028  
Version Number/Date  1.0, 02-JUL-2019  
Addendum for 6 -Month Defibrillation 
Testing  Version Number/Date  To be completed  if applicable  
Addendum for Regional Reporting 
Requirements Version Number/Date  To be completed if applicable  
I have read the CIP, including all appendices  and applicable addenda , and I agree that it contains all 
necessary details for me and my staff to conduct this study as described. I will conduct this study as 
outlined herein and will make a reasonable effort to complete the study within the time designated.  
I agree to carry out all of its items in accordance with applicable regulations and in full compliance 
with  the guidelines . I agree to ensure that the confidential information contained in this document 
will not be used for any purpose other than the evaluation and conduct of the clinical investigation without the prior written consent of Medtronic.  
I will prov ide all study personnel under my supervision copi[INVESTIGATOR_905471]. I will discuss this material with them to ensure that they are fully informed about the products and the study.  
Investigator’s Signature:   
[CONTACT_10670]’s Name:   
[CONTACT_16277]:   
Date:    
 
 
EV ICD Pi[INVESTIGATOR_905340]1 6028 Version  1.0, 02- JUL -2019 Page 165 of 165   
 
Medtronic Co ntrolled Information  
  056-F275, v  A Clinical Investigation Plan Template  
  
   17. Version History  
 
Version  Summary of Changes  Author(s)/Title  
1.[ADDRESS_1270910]  
 
 